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Attention deficit hyperactivity disorder (ADHD) affects 2.6-4.5% of the worlds population, with 
affected children often performing poorly at school. The catecholamine hypothesis of ADHD 
proposes that the disorder results from a hypofunction of the fronto-striato-cerebellar 
catecholaminergic (i.e. dopaminergic and noradrenergic) system. However, abnormalities in the 
glutamatergic and GABAergic systems have also been implicated in the symptoms of ADHD. In 
addition, previous reports indicate that a deviation from the common pattern of cerebral 
lateralisation also contribute to some of the symptoms of ADHD, with under-activation of the 
right prefrontal and right parietal cortices observed in ADHD patients. The psychostimulant, 
methylphenidate (MPH) is the preferred drug for the treatment of the disorder, however the long-
term consequences of the drug are not yet established. Here, we have investigated the effects of 
acute and chronic MPH treatment on monoaminergic protein markers, genes and their 
corresponding proteins involved in synaptic plasticity, as well as the drug’s effect on metabolic 
pathways. The investigations were conducted on brain regions implicated in the symptoms of 
ADHD in adolescent rats.  
Our data shows in Chapter 3 that MPH increases whole tissue and extracellular dopamine levels 
in the frontal cortex and striatum. Interestingly, this effect was more prominent in the left sides of 
these brain areas. Chronic MPH treatment also upregulated dopamine (DAT) and noradrenaline 
(NET) transporters in the striatum and the nucleus accumbens, an effect that could limit the long-
term effectiveness of the drug, as larger doses may be required to reach a functional blockade of 
the upregulated transporters and achieve clinical efficacy. In addition, chronic MPH but not acute 
treatment increased protein expression of the: vesicular monoamine transporter (VMAT2), 
	II	
dopamine D1 receptor, and the catecholamine rate-limiting enzyme tyrosine hydroxylase (TH), in 
most of the examined brain areas. 
By using proton nuclear magnetic resonance (1H-NMR) spectroscopy, this thesis also shows that 
acute MPH enhances the levels of the large neutral amino acids (LNAAs), tyrosine and 
phenylalanine in the cerebrum (Chapter 4). In Chapter 5 the thesis further demonstrates that 
chronic but not acute MPH treatment increases the levels of tyrosine and phenylalanine in the 
frontal cortex, while also decreasing the levels of these LNAAs in the plasma, suggesting that the 
drug increases the transport of the these two LNAAs from the plasma into parts of the brain. 
Given that these two LNAAs are precursors of dopamine synthesis, their enhanced levels 
following MPH treatment in the frontal cortex but not the striatum (no significant increase of 
tyrosine or phenylalanine in striatum) this finding might contribute to the elevated cortical levels 
of dopamine as shown in Chapter 3. This novel finding has resulted in our hypothesis that MPH 
may alleviate ADHD symptoms in two ways: (1) by a blockade of DAT and NET, and (2) by 
enhancing the brain pool of tyrosine and phenylalanine. Interestingly, MPH had a similar effect 
on the energy-related metabolites, lactate and acetate, favouring their transport from the plasma 
into the frontal cortex and hippocampal areas. In addition, glutamate and GABA levels were also 
increased by MPH in the frontal cortex and hippocampus. Together, these findings provide 
support for the contribution of dopaminergic, glutamatergic and energy-related metabolites in the 
mechanism of action of the anti-ADHD drug, MPH.  
Contrasting findings were observed following acute and chronic MPH treatment in the 
cerebellum (Chapter 6), which were both dose and treatment duration-dependent. Acute treatment 
decreased cerebellar glutamate, N-acetylaspartate and VMAT2, while chronic treatment increased 
glutamate, tyrosine and VMAT2. However, the chronic MPH-induced increase of tyrosine and 
	III	
VMAT2 did not correlate with increased cerebellar dopamine, which would suggest that in the 
cerebellum, the increased tyrosine may elevate the synthesis of noradrenaline rather than 
dopamine. 
In chapter 7, the thesis shows that chronic MPH treatment increases mRNA and protein 
expression of markers mediating neuroplasticity. Here, chronic MPH increased Arc, IRSp53/58, 
Cdc42, and Arp2 levels in the: striatum, nucleus accumbens and hippocampus. The MPH-
induced increase of these synaptic plasticity-associated markers in these brain regions may 
induce changes in dendritic spine morphology, as well as in the consolidation of memory strength 
and drug-seeking behaviour. 
In conclusion, the present thesis demonstrates, by applying a wide range of bioanalytical 
techniques, that the anti-ADHD drug, MPH, has major effects on: catecholaminergic protein 
markers, metabolic markers, and proteins mediating neuronal plasticity in the adolescent brain. 
The factors influencing some of these effects were dependent on regional differences, cerebral 
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1.1 Attention deficit hyperactivity disorder 
1.1.1 Clinical features 
Attention deficit hyperactivity disorder (ADHD) is the most prevalent neurobehavioral condition 
in childhood. Based on the criteria given in the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V), ADHD is characterised by hyperactivity and impulsivity 
in motor, emotional and social responses, as well as a general lack of inhibition and deficits in 
sustained attention (American Psychiatric Association 2013). To meet the established criteria for 
clinical diagnosis, the symptoms should have manifested in at least two different environmental 
domains (home, social, educational or occupational) for not less than six months, and must have 
set in before age twelve and cause notable behavioural impairment (American Psychiatric 
Association 2013). A recent meta-analysis study estimates its global prevalence to be 2.6-4.5% 
(Polanczyk et al. 2015). Other less conservative estimates indicate a prevalence rate of 8-12% 
among school-aged children (6-12 years), which declines with age but persists into adulthood, 
affecting 2.5-5.0% of adults (Kessler et al. 2006; Valera et al. 2007). In the UK, a 6-year 
longitudinal study has shown a rise in the prevalence of ADHD and its drug prescription from 
2003 to 2008 in several age categories. The study demonstrated a rise in prevalence from 4.8% to 
9.2% in 6-12 year olds, 3.6% to 7.4% in 13-17 year olds, 0.3% to 1.1% in 18-24 year olds, 0.02% 
to 0.08% in 25-45 year olds, and 0.01% to 0.02% in adults over 45 years old (McCarthy et al. 
2012), demonstrating a higher ADHD prevalence among younger individuals than adults. ADHD 
associated impairments have been observed across lifespan in various areas such as in academic 
performance, employment, socioeconomic status, and family life (negative parent-child 
interactions) and worsened mental health status, mostly in relation to higher degree of disruptive 
behaviours and substance use disorders, as well as oppositional and conduct disorders (Valera et 
al. 2007). In particular, younger children with the disorder demonstrate more overt signs of 
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agitation, while adolescents may experience internal feeling of restlessness, inability to complete 
academic work independently, recreational drug taking, and a propensity towards risky 
behaviours culminating in high accident rates (Brookes et al. 2006).  
1.1.2 ADHD subtypes 
Three behavioural subtypes of ADHD are generally recognised, which are the inattentive 
(ADHD-I), hyperactive/impulsive (ADHD-H) and the combined (ADHD-C) subtypes (Figure 
1.1). While all three disease subtypes may be common in young and adolescent patients, the 
inattentive subtype is more prevalent in adults with the disorder. In the current categorical clinical 
view based on DSM-V, these three clinical subtypes belong to the same diagnostic entity (i.e. 
ADHD). However, there have been previous suggestions that ADHD-I should have a distinct 
diagnostic category as it shares less in common with ADHD-H and ADHD-C (Milich et al. 
2001). The subtypes may vary from each other based on inattention symptoms, demographics, 
comorbid features, and responsiveness to stimulant treatment (Carlson et al. 1999). It was also 
previously postulated that ADHD-H and ADHD-C but not ADHD-I may be associated with 
deficits in executive functions such as planning, cognition, and working memory (Barkley 1997). 
However, aspects of this theory has been challenged in some neurophysiological studies which 
demonstrated that children with ADHD-C did not differ significantly from ADHD-I patients on 
most of the listed markers of executive functioning (Geurts et al. 2005; Pasini et al. 2007). 
Moreover, despite some differences, recent genetic studies have demonstrated that these ADHD 




Figure 1.1: General ADHD subtype prevalence across all age categories.  
The combined subtype (ADHD-C, dark) remains the most common ADHD subtype 
globally, followed by the predominantly inattentive subtype (ADHD-I, blue), and the 
predominantly hyperactive subtype (ADHD-H, orange) (adapted from Miller 2014; Arthur 
and Terri 2001). 
1.1.3 Genetic aetiology 
Adoption, twin and family studies have shown the existence of a strong genetic aetiology for 
ADHD. The disorder often tends to cluster in families with genetic factors explaining up to 76-
80% of phenotypic variance (Faraone et al. 2005b; Durston et al. 2009), making ADHD one of 
the most heritable brain disorders. In one study, the heritability of the ADHD-H was found to be 
88%, with that of ADHD-I being 79% (McLoughlin et al. 2007), implying that genetic influence 
in ADHD dominates the influence of environmental factors. Other studies have observed that the 
biological relatives (siblings) of hyperactive children were more likely to have hyperactivity than 
non-biological relatives (e.g. adopted relatives) (Biederman et al. 1990; Sprich et al. 2000). The 
estimated sibling risk ratio for broadly defined ADHD (including all subtypes) is reported to be 
around three- to four-fold higher when compared with population risk (Todd et al. 2003). 
However, the sibling risk ratio for ADHD-C alone is slightly higher, with the estimate being five- 





A number of genetic linkage studies have also been performed in order to determine regions of 
certain chromosomes that may be harbouring genes for ADHD. This approach scans several 
DNA markers across the genome to detect any chromosomal regions that are shared more often 
than expected within a family that has a history of ADHD. A genome-wide scan of some families 
from a genetically isolated community in Columbia showed evidence of linkage in several 
chromosomal regions including, 8q12, 4q13, 11q23, 17p11, 8p23, and 12q23 (Arcos-Burgos et 
al. 2004). In addition, while one study involving 126 American affected pairs of siblings 
implicated four regions (logarithm of odds {LOD} scores > 1.5): 5p12, 12q23, 10q26, and 16p13 
(Fisher et al. 2002). An expanded study involving 164 Dutch affected pairs of siblings observed a 
strong linkage (LOD > 4) in the 16p13 region, which has also previously been implicated in 
another brain disorder, i.e. autism (Bakker et al. 2003). A recent study on 155 German pairs of 
siblings also reported a strong linkage for 5p17 but produced only a nominal evidence of linkage 
for chromosomes 6q, 9q, 11q, 12q, 7p and 17p (Hebebrand et al. 2006). While these data from 
genetic linkage studies are divergent and remains inconclusive, chromosomes 5p, 12q, 16p, 17p 
have often been implicated.   
In contrast to the scarcity of genetic linkage studies, several genetic association studies have been 
conducted. A major advancement in the molecular genetics of ADHD has been the IMAGE 
(International Multisite ADHD Gene) project, which evaluated 51 genes for association with 
ADHD. A total of 776 DSM-IV ADHD-C children in Europe, their siblings (n=808) and 
biological parents (n=1227) were involved in the study (Brookes et al. 2006). A high-density 
single nucleotide polymorphism (SNP) map was created for genes within monoamine 
neurotransmitter (dopamine, noradrenaline, and serotonin) pathways that are implicated in 
ADHD. Results from this study, as well as several other genetic association studies, have 
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indicated some association of ADHD with dopamine transporter (DAT1, SLC6A3) and receptors: 
D1 (D1R), D2 (D2R), D3 (D3R), D4 (D4R), and D5 (D5R), as well as dopamine β-hydroxylase, 
monoamine oxidase A, noradrenaline transporter (NET/SLC6A2), noradrenergic receptors (α2A, 
α2C, α1C), and serotonin transporter (5HTT, SLC6A4). ADHD has also been linked with 
dysfunctional tryptophan hydroxylase, insulin receptor (IRSp53), and some glutamate receptors 
such as N-methyl-D-aspartate receptor (NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-
isoxazoepropionic acid (AMPAR) (Brookes et al. 2006; Faraone and Mick 2010).  
1.2 The role of neurotransmitter systems in ADHD 
Neurons communicate via an essential process called neurotransmission. Neurotransmission 
refers to the process by which signalling molecules (i.e. neurotransmitters) are released by a 
neuron (i.e. transmitting/presynaptic neuron), which binds to and activate the receptors of another 
neuron (i.e. postsynaptic neuron). Monoaminergic neurotransmitters such as dopamine (DA), 
noradrenaline (NA) and serotonin when released from presynaptic neurons into the synapse, exert 
their actions by activating their respective receptors on the postsynaptic neurons. Monoamines 
have multiple roles in the brain including those implicated in the symptoms of ADHD, e.g. 
emotion, cognition and arousal. The termination of synaptic transmission occurs via several 
different mechanisms including: reuptake of monoamines by specific neuronal transporters, 
degradation of the released monoamine, and desensitisation of target receptors. Overall, these 
monoamine systems (i.e. DA and NA) have been implicated in ADHD  (Biederman 2005) and 
the mechanism of action of anti-ADHD medications (Del Campo et al. 2011).  
1.2.1  The dopaminergic system 
Initially, DA was only thought to be a precursor in the synthesis of NA and adrenaline, or as a 
product resulting from tyrosine degradation (Blaschko 1942). However, its prominent role as an 
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independent catecholamine neurotransmitter was later recognised (Bertler and Rosengren 1959; 
Sano et al. 1959; Hornykiewicz 2002). In neuroscience, DA is particularly important due to its 
involvement in several common disorders related to impaired brain function, including ADHD, 
schizophrenia and Parkinson’s disease, as well as drug dependence and some endocrine disorders 
(e.g. hyperprolactinemia). Further, most of the drugs used in treating these disorders target DA 
transmission (Del Campo et al. 2011). Although the distribution of DA in the CNS is more 
restricted than that of NA, DA controls a wide variety of functions, ranging from coordination of 
locomotor activity, cognition, emotion, food intake and positive reinforcement (Iversen and 
Iversen 2007). DA also plays essential roles in the periphery including kidney D1 receptor-
mediated renin secretion, pituitary D2 receptor-mediated prolactin secretion, adrenal gland D2 
receptor-mediated aldosterone secretion, sympathetic tone regulation, vasodilation, 
gastrointestinal motility, blood pressure regulation, and renal function regulation mediated by D1, 
D2 and D4 receptors (Iversen and Iversen 2007; Squire et al. 2008).  
In ADHD, one of the most robust findings remains that of upregulated DAT density in patients 
compared to healthy controls (Cheon et al. 2003; Dougherty et al. 1999; Spencer et al. 2005). In 
support of this, reports show that methylphenidate (MPH; e.g. RitalinTM), which is the main 
psychostimulant drug used in the treatment of ADHD blocks DAT upon administration, and this 
may be related to the rapid decline of the clinical symptoms of ADHD (Spencer et al. 2005; Vles 
et al. 2003). Blocking DAT has significant biological effects including an elevation of 
extracellular DA levels (Spencer et al. 2005). While moderate extracellular DA levels in the 
prefrontal cortex (PFC) and striatum may be crucial for cognition, attention and locomotor 
activity, both abnormally high or too low levels in these brain regions mediate poor cognition and 
increased locomotor activity in ADHD (Figure 1.2). 
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Figure 1.2: The inverted U (dopamine bell) curve and ADHD.  
Low levels of dopamine (DA) and noradrenaline (NA) are thought to cause decreased 
performance in ADHD. The middle of the curve signifies moderate (normal) levels of DA and 
NA, which causes peak performance by triggering D1 receptors (D1R) and α2-adrenergic 
receptors respectively. Elevation of DA and NA above normal as seen after recreational drug 
taking of cocaine and amphetamine decreases performance via excessive stimulation of D1Rs 
and α1/β1receptors respectively (Arnsten 2009).  
 
1.2.1.1 Dopaminergic pathways 
Eight individual dopaminergic nuclei have been identified and classified into individual cell 
groups designated as A8-A16 (Björklund and Dunnett 2007; Dahlström and Fuxe 1964). DA is 
synthesised in the nerve terminals originating from the retrorubral field (A8), substantia nigra 
(A9), and ventral tegmental area (VTA; A10) of the midbrain and projects into several brain 
regions including the frontal cortex, nucleus accumbens and striatum (Figure 1.3). Also 
immunoreactive for dopamine is the cell group Aaq in the rostral half of the central grey of the 
midbrain in primates, as well as the telencephalic group in the rostral forebrain structures 
including the olfactory tubercle. Dopaminergic dysregulation in these pathways have been 
associated with ADHD (Faraone et al. 2005b; Durston et al. 2009). Further, dopaminergic 
pathways are categorised into the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular 
pathways (Figure 1.3). The mesolimbic and mesocortical pathways are sometimes collectively 
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referred to as the mesocorticolimbic pathway, which regulates emotional responses, mood, and 
incentive-based behaviour.  
1.2.1.1.1 Mesocorticolimbic pathway 
Dopaminergic neurons in the VTA (A10) innervate the amygdala, prefrontal cortex (PFC), 
hippocampus, ventral pallidum and nucleus accumbens (Figure 1.3) (Björklund and Dunnett 
2007; Pierce and Kumaresan 2006). Thus, changes in dopaminergic transmission plays a crucial 
role in regulating the flow of information through this interconnected limbic circuitry. Projections 
from the VTA (A10) to the PFC constitute the mesocortical pathway and it is implicated in 
several cognitive functions including, but not limited to, memory and attention (Squire et al. 
2008). On the other hand, projections from the VTA to the limbic system via the nucleus 
accumbens are considered the mesolimbic or “reward/motivation” pathway, since these 
dopaminergic projections are primarily involved in rewarding behaviours (Squire et al. 2008). 
Therefore, this pathway is hypothesised to play a role in behavioural hyperactivity and the abuse 
potential of drugs (Pierce and Kumaresan 2006; Wise 2004). Further, the nucleus accumbens is 
rich in medium spiny (GABAergic) neurons and has a limbic and a motor area known as the shell 
and the core respectively (Pierce and Kumaresan 2006). 
1.2.1.1.2 Nigrostriatal pathway 
The nigrostriatal pathway accounts for about 75% of the dopaminergic innervations in the brain 
and consists of cell bodies located within the substantia nigra (A9) of the ventral midbrain whose 
axons terminate in the striatum (caudate and putamen), which receive only minor inputs from the 
VTA (A10), and the A8 cells located caudal to A9 (Figure 1.3). Nerve cells in this pathway send 
projections either directly to or indirectly through the globus pallidus (external globus pallidus in 
primates) to the substantia nigra and endopeduncular nucleus (internal globus pallidus in 
primates) to modulate voluntary movement and goal-oriented behaviour (Money and Stanwood 
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2013). Due to its role in motor control, this pathway has been one of the main areas of focus of 
ADHD research, as well as studies into other related disorders. Indeed, loss of DA neurons in this 
pathway is a key pathological feature of Huntington’s chorea and Parkinson’s disease (Drui et al. 
2014). 
1.2.1.1.3 Tuberoinfundibular pathway 
This pathway is made up by dopaminergic projections in the arcuate (A12) and periventricular 
(A14) nucleus of the hypothalamus to the pituitary gland (infundibular region), where it regulates 
the secretion of prolactin (Ben-Jonathan and Hnasko 2001). DA synthesised by neurons in the 
arcuate nucleus is secreted into the hypophyseal portal system of median eminence that supplies 
the pituitary gland. In this pathway, DA acts as the neuroendocrine inhibitor of prolactin (Ben-
Jonathan and Hnasko 2001). Reports indicate that the normal function of hypothalamic neurons 
in humans is often preserved in Parkinson’s disease (Ben-Jonathan and Hnasko 2001). 
              
Figure 1.3: Mesocorticolimbic and nigrostriatal dopamine pathways in rat brain.  
Dopamine neurons in the mammalian brain are localised in nine distinct cell groups, from the 
midbrain to the olfactory bulb. The numbering of the dopaminergic cell groups, from A8 to A16, 
was introduced in the classic study of Dahlström and Fuxe (1964), and is still presently valid. 
Abbreviations: VTA, ventral tegmental area; SN, substantia nigra; NAc, nucleus accumbens 
(adapted from Björklund and Dunnett 2007). 
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1.2.1.2 Dopamine synthesis, storage and release  
DA biosynthesis begins with the aromatic amino acid tyrosine. Most of the circulating tyrosine is 
derived from dietary sources and crosses the blood-brain barrier and enters DA neurons by an 
energy-dependent uptake process (Fernström 2013; Fernström and Fernström 2007). A number of 
conditions influence tyrosine transport and may diminish its availability in the brain, affecting 
DA synthesis. However, in the event of tyrosine deficiency, the enzyme phenylalanine 
hydroxylase catalyses the hydroxylation of phenylalanine into tyrosine. Tyrosine is then 
converted into L-3,4-dihydroxyphenylalanine (L-DOPA) by the rate-limiting enzyme, tyrosine 
hydroxylase (TH). L-DOPA is then converted by DOPA decarboxylase to DA (Meiser et al. 
2013). TH is the rate-limiting enzyme in DA biosynthesis and tyrosine itself is rarely a limiting 
factor, especially as TH is saturated at the normal plasma concentrations of tyrosine. Given its 
importance therefore, TH has become a key target and an endogenous mechanism for regulating 
the rate of DA synthesis in dopaminergic neurons (Melchitzky and Lewis 2000). Following 
biosynthesis, DA is transported from the cytoplasm into synaptic vesicles via vesicular 
monoamine transporter (e.g. VMAT2) for storage. The vesicles perform specific functions 
including: 1) protecting DA from enzymatic degradation by monoamine oxidase (MAO), 2) 
minimising constitutive secretion by diffusion from the presynaptic nerve cells, 3) facilitating 
regulated release, and 4) enabling rapid replenishment of depleted stores. Stored DA is released 
when action potential raises Ca2+ levels in the presynaptic neuron via the activation of voltage-
gated Ca2+ channels, which causes the vesicles to: 1) target the active zone of the presynaptic 
membrane, 2) fuse, and 3) release vesicular content (Cartier et al. 2010; Meiser et al. 2013). The 
extent of DA release appears to be a function of the rate and pattern of firing. The burst-firing 
mode causes an enhanced release of DA from dopaminergic nerve terminals. The release of DA 
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via the Ca2+-dependent exocytosis is also regulated by presynaptic D2/D3 autoreceptors (Ford et 
al. 2010; Sulzer et al. 2016).  
1.2.1.3 Dopamine receptors 
Biochemical and pharmacological studies in the late 1970s revealed that DA binds to two 
receptors, which became known as D1 and D2 receptors. Much later, it was recognised that D1 
receptor was positively coupled to GS proteins and elevated intracellular cyclic adenosine 
monophosphate (cAMP) levels, while D2 receptor was coupled to Gi proteins and inhibited 
cAMP accumulation via adenylyl cyclase (Missale et al. 1998). Owing to advancements in gene 
cloning procedures, both D1 and D2 receptors have been cloned based on sequence homology to 
known G protein-coupled receptors. At present, three additional DA receptors have been cloned 
and characterised as D3, D4 and D5 receptors (Beaulieu and Gainetdinov 2011; Butini et al. 
2016). A number of biochemical, structural and pharmacological studies have pointed out that all 
the characterised DA receptors belonged to one of the two initially identified receptor groups, and 
hence were classified into D1-like and D2-like families. The D1-like family includes D1 and D5 
receptors, whereas the D2-like family consists of D2, D3 and D4 receptors. DA receptors are 
members of the G protein coupled receptor superfamily and are made up of single polypeptide 
chains ranging in size from 387-475 residues (Butini et al. 2016). The receptors have 7 
transmembrane-spanning domains that form a ring-like hydrophobic pocket surrounded by 3 
extracellular and 3 intracellular loops (Figure 1.4). The D1 and D5 receptors are 80% 
homologous in their transmembrane domains, while D3 and D4 receptors are 75% and 53% 
homologous with D2 receptor respectively (Beaulieu and Gainetdinov 2011). Functionally, the 
initial distinction between D1 and D2 receptors also appears to apply to the new members of each 
receptor subfamily, with both D1 and D5 receptors stimulating adenylyl cyclase and increasing 
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cAMP, while D3 and D4 receptors both inhibit adenylyl cyclase and decrease cAMP in much the 
same way as D2 receptor (Sulzer et al. 2016; Wahlström et al. 2010). Presently, splice variants, 
leading to short and long forms of D2 receptor and genetic polymorphisms, especially of D4R, 
have been characterised (Shaw et al. 2007; Wang et al. 2000). 
1.2.1.3.1 D1-like receptors  
DA receptors have broad expression, with D1 receptor being expressed at a higher density than 
all the other receptor types. The D1 receptor is highly expressed on postsynaptic neurons in the 
nigrostriatal and mesocorticolimbic areas such as striatum, nucleus accumbens, prefrontal cortex, 
substantia nigra, amygdala, and olfactory bulb, with lower levels in the hippocampus, cerebellum, 
thalamic and hypothalamic areas (Beaulieu and Gainetdinov 2011; Missale et al. 1998). 
Compared to D1 receptor, D5 receptor is expressed at low levels in pyramidal neurons of the 
hippocampus, substantia nigra, hypothalamus, dentate gyrus, prefrontal cortex, and other cortical 
areas. Very low D5 receptor expressions have also been observed in the medium spiny 
(GABAergic) neurons of the striatum and nucleus accumbens (Beaulieu and Gainetdinov 2011; 
Butini et al. 2016).  
Both D1 and D5 receptors have been shown to stimulate adenylyl cyclase (Missale et al. 1998). It 
is generally thought that the activation of adenylyl cyclase by D1-like receptors is predominantly 
mediated by the GSα subunit of G-proteins. However, Golfα an isoform of GSα that also stimulate 
adenylyl cyclase is expressed at higher levels than GSα in the striatum, nucleus accumbens and 
olfactory bulb, suggesting that D1-like receptors may couple to adenylyl cyclase through multiple 
mechanisms (Hervé 2011). Indeed, in the striatum of mice lacking Golfα gene, adenylyl cyclase 
activation in response to D1-like receptor stimulation is absent, indicating that D1-like receptors 
act through the Golfα protein to stimulate the production of cAMP (Corvol et al. 2001). In 
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addition, D1 receptor stimulation can induce neuroplastic changes in the brain via the activation 
of protein kinase A and CREB (cAMP response element binding protein) leading to an increased 
activity of glutamate receptors (e.g. NMDAR), and an increased expression of plasticity related 
genes such as activity-regulated cytoskeleton-associated (Arc) gene, and the brain-derived 
neurotrophic factor (BDNF) gene (Monsma et al. 1990; Konradi et al. 1996; Dudman et al. 
2003).    
1.2.1.3.2 D2-like receptors 
D2 receptors have the highest expression in this subgroup and are mostly found in the striatum, 
nucleus accumbens, and olfactory tubercle. D2 receptors are also expressed at significant levels 
in the VTA, substantia nigra, cortical areas, hippocampus, hypothalamus, septum, and amygdala 
(Butini et al. 2016). D3 receptors have a more limited pattern of distribution, with the highest 
density being in the limbic areas, such as in the shell of nucleus accumbens, the islands of Calleja 
and the olfactory tubercle (Missale et al. 1998). Compared to D2 receptors, D3 receptors are 
detectable at lower levels in the striatum, hippocampus, VTA, substantia nigra, septum and 
various cortical areas. However, relative to D2 and D3 receptors, the D4 receptor has the lowest 
level of expression in the brain, with some level of expression in the prefrontal cortex, 
hippocampus, amygdala, hypothalamus, substantia nigra, thalamus and globus pallidus (Missale 
et al. 1998). In addition, while D1, D2, and D4 receptors have also been observed in the retina, 
all receptor subtypes have been detected at varying levels in peripheral nerves in the heart, 
kidney, adrenal glands, gastrointestinal tracts, and blood vessels (Butini et al. 2016). 
The original classification of D2 receptor was based on its ability to inhibit adenylyl cyclase in 
the CNS. Although less apparent, both D3 and D4 receptors have also been shown to inhibit 
adenylyl cyclase. Initially, D3 receptor was reported not to inhibit adenylyl cyclase in cell lines 
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and appeared not to couple to G-proteins as indicated by the lack guanine nucleotide shift in 
agonist binding curves (Sokoloff et al. 1990). Later studies, however, revealed that D3 receptor 
actually inhibit adenylyl cyclase in some cells lines, albeit less strong relative to that elicited by 
D2 receptor (Chio et al. 1994). Moreover, D4 receptors have been shown to inhibit adenylyl 
cyclase activity and cAMP accumulation in the retina via the Gi subunit of G-proteins (Cohen et 
al. 1992). Thus, confirming adenylyl cyclase inhibition as a consistent feature of D2-like 
receptors.  
In addition to postsynaptic D2 receptors, there is also presynaptic localisation of D2-
autoreceptors. Presynaptic autoreceptors exist on most dopaminergic cells including dendrites, 
soma and nerve terminals (Butini et al. 2016; Wolf and Roth 1990). Presynaptic autoreceptors 
provide important negative feedback mechanism, which adjust the rate of neuronal firing, 
synthesis and release of neurotransmitter in response to changes in synaptic levels (Wolf and 
Roth 1990). Generally, activation of presynaptic D2-autoreceptors in the somatodendritic region 
causes a decline in the firing rate of DA neurons, while the activation of autoreceptors on DA 
nerve terminals inhibit DA synthesis and release (Wolf and Roth 1990; Missale et al. 1998). 
Although the full identities of D2-autoreceptors are still somewhat unclear, evidence points 
towards distinct pharmacology of autoreceptors relative to postsynaptic D2 receptors. For 
instance, D2-autoreceptors are preferentially activated by lower concentrations of DA agonists 
(Beaulieu and Gainetdinov 2011). 
1.2.1.3.3 Function of brain dopamine receptors 
The role of DA in the nigrostriatal pathway and on locomotor activity has been studied 
extensively. The activation of D1 and D2 receptors, expressed on postsynaptic neurons, has a 
moderate stimulatory effect on locomotor activity (Tran et al. 2005). In contrast, activation of 
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D2-class autoreceptors causes a reduction in DA release, resulting in decreased locomotor 
activity (Missale et al. 1998). Since D2-autoreceptors are often activated by lower DA agonist 
concentrations than required to stimulate postsynaptic receptors, the same DA agonist can have a 
biphasic effect, resulting in reduced activity at low doses and behavioural activation at higher 
doses (Beaulieu and Gainetdinov 2011). Interestingly, the long and short D2 receptor splice 
variants (Wang et al. 2000), appear to have different neuronal localisations, with the short variant 
being predominantly presynaptic and the long being postsynaptic. Thus, the differing roles of 
presynaptic and postsynaptic D2 receptors may be determined by the varying contributions of 
these D2 receptor isoforms (De Mei et al. 2009). D3 receptors seem to have moderate inhibitory 
effect on locomotion, while D4 and D5 receptors exert minimal action on the control of 
movement, perhaps due to their limited expression pattern in the primary motor areas of the brain 
(Missale et al. 1998). At the same time, synergistic interaction between D1 and D2 receptors are 
essential for maximal locomotor activity (White et al. 1988). 
The mesocorticolimbic pathway is implicated in reward and reinforcement mechanisms, with 
stimulants and drugs of abuse eliciting an enhancement of DA release in this pathway, and their 
withdrawal causing significant reductions in dopaminergic transmission. Several pharmacological 
studies have shown that D1, D2, and to a lesser extent, D3 receptors are critically involved in 
reward and reinforcement mechanisms and play significant roles in mediating the reinforcing 
properties of drugs of abuse (Sulzer et al. 2016). Moreover, both D1 and D2 receptors appear to 
be critical for learning and memory mechanisms, particularly in the PFC (Beaulieu and 
Gainetdinov 2011; Goldman-Rakic et al. 2004). At the same time, D3, D4, and perhaps D5 
receptors, appear to have minor modulatory impact on specific aspects of cognition, mediated by 
areas in the hippocampus (Missale et al. 1998). Other functions mediated in part by the 
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dopaminergic receptor subtypes in the CNS include: attention, decision-making, impulse control, 
motor learning, reproductive behaviours, regulation of food intake and sleep (Butini et al. 2016; 
Iversen and Iversen 2007). 
1.2.1.4 Dopamine reuptake 
Reuptake is the means through which the released neurotransmitter is carried back into the 
presynaptic nerve terminals via DA transporters (high affinity neuronal uptake) or the means by 
which the released transmitter is taken up by surrounding glial cells (non-neuronal uptake). 
Reuptake represents the major mechanism through which cytosolic MAO and COMT terminate 
the action of released DA (Westerink 1985). Such tight regulation helps in limiting the duration 
and magnitude of the effect of the released DA, hence establishing a spatial and temporal 
constraint on excessive DA signalling in the brain. In addition, reuptake also permits the 
recycling of DA and saves the energy costs of biosynthesis (Sulzer et al. 2016).  
DAT plays a crucial role in regulating the intensity of DA neurotransmission in the brain by 
mediating DA reuptake. DAT transports released DA from the extracellular to the intracellular 
milieu. Inhibition or removal of DAT prolongs the lifetime of extracellular DA by several folds 
(Jones et al. 1998). Following uptake, VMAT regulates the accumulated DA in the cytoplasm. In 
particular, VMAT2 reloads the intracellular DA into presynaptic vesicles (Narendran et al. 2015). 
On the other hand, the extraneuronal monoamine transporter, belonging to a large and widely 
distributed family of organic cationic transporters, also performs extraneuronal reuptake of DA 
and other catecholamines, albeit it has a low affinity for these neurotransmitters. Overall, these 
transporter systems vary not only in structure but also in cellular localisation, substrate 
specificity, energy requirements and antagonist selectivity (Figure 1.4).  
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Figure 1.4: Structure of dopamine receptors and catecholamine transporters.  
D1 (D1R) and D2 (D2R) receptors belong to the superfamily of 7 transmembrane domains G 
protein-coupled receptors. D1Rs have a longer cytoplasmic carboxyl terminus, whereas D2Rs 
have a larger third intracellular loop. Transporters DAT (or NET) and VMAT have 12 
transmembrane domains but little primary sequence homology. In contrast to the receptors, the 
transporters have both the N- and C-termini at the cytoplasmic side of the membrane. VMAT has 
a large intraluminal loop between transmembrane domains 1 and 2, while DAT has an 
extracellular loop between transmembrane domains 3 and 4 (Ben-Jonathan and Hnasko 2001). 
 
Regardless of some structural differences, all monoamine transporters including DAT and NET 
(as well as serotonin transporter, 5HTT or SERT) are Na+/Cl− dependent and therefore act as co-
transporters of Na+/Cl− and DA (as well as NA and serotonin as is the case of NET and 5HTT), 
utilising the electrochemical gradient for Na+ as the driving force. The process of reuptake by 
DAT has a stoichiometry of 2 Na+: 1 Cl−: 1 DA (Ben-Jonathan and Hnasko 2001). VMAT, on the 
other hand, is driven by the proton gradient existing between the cytosol and the vesicle content 
(Wahlström et al. 2010). VMAT recharges the intracellular vesicles with the neurotransmitter via 
an electrochemical gradient generated by vacoular ATP-dependent H+ pump (V-ATPase), a 
pump that maintains intravesicular acidic environment and permits the uptake of the transmitter 
against its concentration gradient. DAT and NET are relatively selective for DA and NA 
respectively, with high affinity but low maximum rate of reuptake, and are important in ensuring 























the maintenance of releasable stores of DA and NA. Extraneuronal monoamine transporter, 
however, has low affinity but higher transport capacity than DAT and NET for all types of 
catecholamines (Sulzer et al. 2016). 
In situ hybridisation and immunohistochemistry studies have revealed that DAT is expressed in 
the CNS (Björklund and Dunnett 2007). The transporter co-localize with TH in the CNS and 
serves as a marker of dopaminergic neurons, especially as it is limited to these neurons and are 
not found in the locus coeruleus (the origin of NA in the CNS) or on adrenergic and 
noradrenergic nerve terminals (Björklund and Dunnett 2007). The highest expression of DAT is 
in the soma (perikarya), dendrites and axonal processes of substantia nigra and VTA. Thus, DAT 
has a significant presence in the mesocorticolimbic and nigrostriatal pathways, with limited 
expression in the hypothalamic dopaminergic neurons. However, electron microscopy has 
revealed that the DAT protein is found predominantly in the extra-synaptic area instead of the 
active zone of the synapse, indicating that DAT may have a role in limiting diffusion of DA 
following its release (Meiser et al. 2013).  
1.2.1.5 Dopamine catabolism 
Catabolism is one of the effective means of DA inactivation. DA may be enzymatically 
inactivated via different breakdown pathways: 1) oxidative deamination by MAO (isoforms A 
and B), and 2) O-methylation by catechol-O-methyltransferase (COMT). In the striatum of rats, 
DA catabolism often begins with oxidative deamination by MAO, yielding the intermediate 
product 3,4-dihydroxyphenylacetaldehyde (DHPA) (Figure 1.5). This aldehyde is inactivated 
either by rapid oxidation to the corresponding carboxylic acid, 3,4-dihydroxyphenylacetic acid 
(DOPAC), by acetyl aldehyde dehydrogenase. In the synaptic cleft, DA may be taken up by 
surrounding glial cells, which degrade DA via both MAO and COMT. 3-O-methylation of 
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DOPAC by COMT results in the formation of homovanillic acid (HVA), one of the major 
degradation products of DA (Laatikainen et al. 2013). Alternatively, DA inactivation may begin 
with COMT, giving rise to 3-methoxytyramine (3-MT), which is later converted to 3-methoxy-4-
hydroxyphenylacetaldehyde (MHPA) and HVA by MAO and aldehyde dehydrogenase 
respectively. Given that tissue levels of the extracellular metabolite, 3-MT are generally quite 
low, it is possible that this compound is deaminated quite rapidly (Laatikainen et al. 2013).  
             
Figure 1.5: Catecholamine synthesis and catabolism.  
DA is synthesised from tyrosine via L-DOPA (rate-limiting step, mediated by tyrosine 
hydroxylase). DA may either be converted to NA (catalysed by DA β-hydroxylase) or catabolised 
by the actions of monoamine oxidase (MAO), by catechol-o-methyltransferase (COMT) and 
aldehyde dehydrogenase (AD). Abbreviations: 3-MT, 3-methoxytyramine; DHPA, 3,4-
dihydroxyphenylacetaldehyde; MHPA, 3-methoxy-4-hydroxyphenylacetaldehyde; HVA, 
homovanillic acid;  (Laatikainen et al. 2013).  
 
In rodents, DOPAC and HVA are quantitatively the most prominent DA metabolites. Indeed, 
DOPAC is considered as an index of MAO mediated DA catabolism. This stems from the 
observation that reserpine, which induces neuronal catecholamine breakdown by blocking 
vesicular storage, increases striatal DOPAC levels (Fekete et al. 1980; Fornstedt and Carlsson 
1989; Westerink 1985). Reserpine also increases HVA, albeit transiently, which is to be expected 
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as most HVA is generated from DOPAC. Elevated DOPAC levels following reserpine treatment 
therefore signify a reduction in DA levels, reduction in vesicular storage and hence increased 
catabolism.  
 
1.2.2 The noradrenergic system 
Noradrenergic projections originate predominantly from neurons in the brainstem nucleus, locus 
coeruleus and project into multiple regions, including hippocampus and prefrontal cortex, which 
have critical roles in affective processes and high-level cognitive functions such as working 
memory and inhibitory response control, that are often impaired in ADHD (Robbins and Arnsten 
2009). However, noradrenergic innervations in the striatum are sparse, suggesting that its 
modulation of the striatum may be limited (Del Campo et al. 2011). In noradrenergic neurons, 
dopamine-beta-hydroxylase converts DA into NA. However, DA-beta-hydroxylase is localised to 
the vesicles rather than cytosol, implying that conversion of DA to NA only occurs after DA has 
been packaged into vesicles (Xing et al. 2016). The vesicular storage of dopamine-beta-
hydroxylase also means that it can be released into the synaptic cleft along with both DA and 
NA. By acting on presynaptic receptors, NA can regulate its own release (the so-called 
autoinhibitory feedback mechanism). This inhibitory feedback mechanism operates via α2-
adrenergic receptors, which inhibit adenylyl cyclase and prevent the opening of Ca2+ channels. At 
the post synaptic site, NA binds to two main G-protein-coupled receptor types, the α-adrenergic 
(α1 and α2) and β-adrenergic (β1, β2, and β3) receptors (Arnsten 2011). Generally, the α1 receptors 
are coupled to Gq proteins and therefore activate phospholipase C and inositol 1,4,5-triphosphate 
intracellular signalling, leading to the release of intracellular Ca2+. NA has lower affinity for α1 
receptors compared to α2 receptors. The α2 receptors stimulate Gi proteins that are negatively 
coupled to adenylyl cyclase, leading to a decrease in cAMP formation as well as inhibiting Ca2+ 
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channels. In comparison, the β-receptors have the lowest affinity to NA and are coupled to Gs 
proteins that stimulate adenylyl cyclase and activate cAMP signalling (Xing et al. 2016).   
Reuptake of released NA by NET is the main mechanism for the termination of NA transmission 
in the CNS (Seneca et al. 2006). Interestingly, most of the drugs effective in the treatment of 
ADHD such as MPH and amphetamine have important effects on NA along with DA 
transmission. In addition, the selective NA inhibitor (NET blocker), atomoxetine has shown 
clinical effectiveness and is approved for the treatment of ADHD (Faraone et al. 2005a). In 
rodents, atomoxetine increases cortical NA and DA levels by several-folds when administered 
systemically, without any significant effects on the subcortical DA system (Bymaster et al. 
2002). It is the subcortical (particularly the nucleus accumbens) DA effects that are suggested to 
underlie the abuse potential of psychostimulant treatments (Volkow 2006). The approval of NA 
modulating drugs for use in ADHD, stem from their beneficial effects on cognition (Del Campo 
et al. 2011). Some studies have shown that moderate increase of NA may improve cognition and 
impulse control mainly through effects on α2 receptors, while elevated NA levels such as during 
extreme stress, impair cognition via α1 receptors (Arnsten and Li 2005).  
Another line of evidence implicating brain noradrenergic pathways in ADHD emanates from 
findings in candidate gene and genome-wide association studies. Findings from some of these 
studies have not only indicated that some SNPs (single nucleotide polymorphisms) such as 
rs36021 (Thakur et al. 2012) within the SLC6A2 gene (this gene codes for NET) may be 
associated with ADHD, but have also shown that other SNPs (such as rs3785143) may be 
associated with improved patient responses to atomoxetine and other ADHD medications (Yang 
et al. 2013). Overall, these findings demonstrate the important role of the noradrenergic system in 
the neurobiology of ADHD. 
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1.2.3 The serotonergic system 
Evidence of the involvement of the serotonin (5-HT) system in ADHD (although not as strong as 
the evidence for DA and NA) comes from genetic and neurochemical studies investigating 5-HT, 
its transporter (5-HTT) and receptor levels, as well as pharmacological studies in ADHD patients 
and animal models of the disease (Banerjee and Nandagopal 2015; Gadow et al. 2013). 
Neuroanatomical evidence suggests that 5-HT may regulate behavioural domains of hyperactivity 
and impulsivity in ADHD through the orbitofronto-striatal circuitry (Banerjee and Nandagopal 
2015). Moreover, the prefrontal cortex, which regulates attention, emotion, motivation and 
cognitive control, contains a large density of both inhibitory and excitatory 5-HT receptors 
(Arnsten and Rubia 2012). The orbitofrontal cortex is particularly dependent on 5-HT, and a 
depletion of 5-HT from this region significantly impairs orbitofrontal cortex mediated regulation 
of emotion, inhibition and learning (Clarke et al. 2007). A chronic deficit of 5-HT at the synapse 
of these cortical areas is therefore hypothesised to trigger some of the symptoms of ADHD (Quist 
and Kennedy 2001). In line with this, deficits in blood 5-HT levels have been recorded in 
hyperactive and severely affected ADHD children (Banerjee and Nandagopal 2015; Spivak et al. 
1999).  
In addition, 5-HTT knockout rodents have increased extracellular 5-HT levels and improvements 
in performance on cognitive tasks (Brigman et al. 2010; Nonkes et al. 2012). Moreover, the 5-HT 
receptor 1B knockout mice also exhibit significant hyperactivity and are considered as models of 
motor impulsivity (Brunner and Hen 1997). Thus, these animal models provide a ‘face-validity’ 
for the involvement of the serotonergic system in ADHD. Interestingly, other reports have 
suggested that although deficits in 5-HT levels could cause hyperactivity, psychostimulants such 
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as MPH and amphetamine may act by balancing the monoaminergic tone, which includes 
balancing DA, NA, and 5-HT levels (Berger 1999; Borycz et al. 2008).  
1.2.4 Glutamatergic and GABAergic systems 
Currently existing evidence favour the ‘DA and NA hypothesis’ of ADHD, especially as drugs 
enhancing catecholamine levels such as MPH and amphetamine have displayed substantial 
efficacy in relieving the symptoms of the condition (Del Campo et al. 2011). However, although 
stimulants have shown clinical effectiveness in improving ADHD symptoms in the short term, 
they are not effective in all cases. For instance, stimulants produce complete remission in about 
30% of cases, have substantial but partial remission in another 40%, but have little or no benefit 
in 30% of cases (Steele et al. 2006). Thus, deficient DA or NA transmission seems unlikely to be 
responsible for all cases of this heterogeneous disorder. In order to fully understand the disorder 
and develop effective medications, therefore, it has become crucial to look beyond DA and NA 
(Maltezos et al. 2014). Emerging evidence points to impaired neuronal and glial energy 
metabolites, glutamate and gamma-aminobutyric acid (GABA) signalling, as well as altered 
membrane phospholipids as possible underlying abnormalities in some cases of ADHD, thus 
some of these targets are being considered as possible future therapeutic targets for ADHD 
(Adler et al. 2012; Russell et al. 2006). 
Glutamate is the principal excitatory neurotransmitter in the CNS, while GABA is a major 
inhibitory neurotransmitter. Neural activity in general is constituted, to a large extent, by 
excitatory and inhibitory balance and this must be tightly regulated to ensure proper neuronal 
signalling (Duncan et al. 2014). Preliminary evidence suggests glutamatergic involvement in the 
pathophysiology of ADHD. For example genetic studies have reported an association between 
ADHD and the genes of some glutamate receptors (e.g. NMDARs) (Dorval et al. 2007). Using 
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proton magnetic resonance spectroscopy (1H-MRS), some researchers have also recently shown 
that glutamate and glutamine are significantly altered in the corticostriatal circuitry of ADHD 
patients (i.e. increased levels in the cerebrum but decreased levels in the cerebellum) (Perlov et 
al. 2007; Perlov et al. 2010; Carrey et al. 2002; Carrey et al. 2003). In comparison with DA, 
glutamate is more widely expressed in the brain. Indeed, glutamate projections originating in the 
PFC extend into the striatum, nucleus accumbens, ventral tegmental area and the midbrain 
(Figure 1.6). Glutamate is produced in the nerve terminals of these projections via two routes: 1) 
glutamine transported from glial cells, and 2) the Krebs cycle (Rowley et al. 2012). Once 
glutamate is produced, it is transported into vesicles via vesicular glutamate transporter. 
Glutamate stored in vesicles within the presynaptic neurons are released into the synapse when a 
presynaptic action potential stimulates Ca2+-dependent exocytosis. In addition, a reversal of the 
cysteine/glutamate exchangers can sometimes cause release of non-vesicular glutamate to the 
extracellular space (Rowley et al. 2012). 
Maintenance of extracellular glutamate and GABA concentrations is facilitated via reuptake by 
high-affinity sodium dependent excitatory amino acid transporters embedded in plasma 
membranes of neurons and astrocytes (such as EAAT1/GLAST, EAAT2/GLT-1, 
EAAT3/EAAC1, EAAT4, and EAAT5 for transporting glutamate; and GATs for transporting 
GABA) (Rowley et al. 2012; Danbolt 2001). Dysfunction of glutamate transporters are known to 
cause neuronal cell death due to glutamate-induced excitotoxicity (Rowley et al. 2012). The 
glutamate taken up by the transporters (i.e. the EAATs) embedded on glial cells is converted into 
glutamine by glutamine synthetase and transported out of the glial cells by system N-transporter 
and is subsequently taken up by system A-transporter on presynaptic neurons to help restore 
glutamate levels through the mitochondrial enzyme glutaminase. Glutamate taken up by 
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presynaptic neurons may also be metabolised into GABA by glutamate decarboxylase. Glutamate 
acts on two major synaptic glutamate receptor types: 1) ionotropic [alpha-amino-3-hydroxy-5-
methyl-4-isoxazoepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA)] and kainate 
receptors, and 2) metabotropic receptors including excitatory mGluRs 1 and 5 and inhibitory 
mGluRs 2, 3, 4, 6, 7, and 8 (Danbolt 2001; Purves et al. 2001). When glutamate binds to AMPA 
and kainate receptors, a conformational change occurs making them permeable to sodium, and 
this allows Na2+ influx into the postsynaptic neuron causing depolarisation. Conversely, NMDA 
receptors require the binding of glutamate and glycine, as well as depolarisation to 
release/dislodge Mg2+ from blocking the pores of NMDA calcium channels, thereby allowing 
Ca2+ influx into the postsynaptic neuron (Danbolt 2001; Purves et al. 2001). 
On the other hand, mGluRs are G-protein coupled receptors that make use of second messenger 
systems for signal transduction and may therefore be slower in comparison with ionotropic 
receptors (Niswender and Conn 2010). Importantly, there seem to be an interaction between DA 
and glutamate systems, an aberration of which is not only implicated in ADHD but also in 
schizophrenia, Parkinson’s disease, Alzheimer’s disease, mood disorders and drug addiction 
(Rowley et al. 2012). It is hypothesised that glutamate modulate DA release in fronto-striatal 
pathways (Karreman and Moghaddam 1996).              
1.2.5 Neurotransmitter interactions  
Cortical and midbrain DA systems play crucial roles in schizophrenia, addiction, depression and 
Parkinson’s disease, as well as in ADHD (Wallace et al. 2014; Arnsten 2011). Midbrain DA 
regions such as the ventral tegmental area and substantia nigra (A10 and A9 cell groups) that 
form the origin of the nigrostriatal and mesocorticolimbic DA pathways receive glutamatergic, 
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GABAergic, serotonergic and noradrenergic innervations which influence DA activity 
(Caravaggio et al. 2016).  
Glutamate and DA interact in the prefrontal cortex and the basal ganglia (e.g. striatum), 
intimately modulating each other’s function and release (Figure 1.6). The classical basal ganglia 
model developed in the 1980s predicts that striatal DA loss would reduce extracellular glutamate 
levels in the striatum and the cortex (Albin et al. 1995; Albin et al. 1989; Jones 2011). It also 
predicts that increased striatal DA would increase striatal and cortical glutamate levels 
(Caravaggio et al. 2016). Indeed, it is now well established that glutamate influences DA release 
in the prefrontal cortex (Feenstra et al. 1995), nucleus accumbens (Del Arco and Mora 2005), and 
midbrain DA neurons, by regulating in vivo firing activity, especially burst activity (Charlety et 
al. 1991). Administration of both metabotropic and ionotropic glutamate receptor agonists have 
also been shown to produce excitatory response in midbrain DA neurons (Chergui et al. 1993; 
Shen and Johnson 1997). The hypomonoaminergic theory of ADHD suggests that decreased DA 
and/or NA levels cause the inattentive and hyperactive behaviours associated with the disorder 
(Figure 1.2). While elevated DAT may underlie the decreased DA levels in ADHD (Cheon et al. 
2003; Dougherty et al. 1999; Spencer et al. 2005), glutamate has also been shown to be decreased 
in the cerebral regions in ADHD patients, which could also contribute to the reduction of striatal 
and cortical DA levels in adult ADHD (Maltezos et al. 2014; Dramsdahl et al. 2011; Perlov et al. 
2007). However, this classical model of the basal ganglia fails to take into account the influence 
of other neurotransmitter systems such as the cholinergic system that also excite midbrain DA 
neurons via nicotinic receptors (Obeso et al. 2008).  
GABAergic inputs into midbrain DA neurons originate in the striatum and pallidum, and from 
intrinsic GABAergic interneurons of the midbrain (Mora et al. 2008). Administration of GABA 
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onto DA neurons induces hyperpolarisation, which results in an inhibitory response of DA 
neurons (Belousov and Pol 1997; Georges and Aston-Jones 2002). Moreover, extracellular 
GABA and DA levels are both increased by local infusions of both AMPA and NMDA glutamate 
receptor agonists in the basal ganglia (Cano-Cebrián et al. 2003; Hernández et al. 2003; Kendrick 
et al. 1996).  
Noradrenergic afferents originating from the locus coeruleus provide excitatory inputs onto 
midbrain DA neurons via α1-adrenergic receptors (Grenhoff et al. 1993; Grenhoff and Svensson 
1993; Williams et al. 2014). However, serotonergic afferent inputs from the raphe nuclei induce 
inhibitory response of midbrain DA neurons (Kapur and Remington 1996).  
 
 
Figure 1.6: Neurotransmitter interactions in the mesocorticolimbic and nigrostriatal 
pathways.  
Modulatory dopaminergic neurons (red) arising from the substantia nigra (SN, A9) project to the 
striatum (DS), and those arising from the ventral tegmental area (VTA, A10) also project to the 
nucleus accumbens (NAc) and prefrontal cortex (PFC). The locus coeruleus (LC) projects 
ascending noradrenergic axons (green) to the PFC and hippocampus (HIP). From the DS 
inhibitory GABAergic neurons (gold) extend to multiple sites including thalamus (Thal), with 
reciprocal glutamate connections (blue) to the DS, as well as connections to the PFC. PFC 
efferent glutamatergic neurons extend to the NAc, DS, SN, and VTA (adapted from Russo and 
Nestler 2013).  
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1.3 Neuroenergetics and ADHD 
Some researchers have suggested that some forms of brain conditions including ADHD could be 
considered as cortical energy-deficit syndromes, in addition to the hypofunctionality of 
catecholamine systems (such as DA and NA) that regulate neuronal and astrocytic glucose and 
glycogen metabolism (Todd and Botteron 2001). The brain has a high energy demand and it 
utilises approximately 25% of total glucose produced in the body (Killeen et al. 2013). 
Astrocytes carry glucose from capillaries, store it as glycogen and convert it to lactate, which 
serves as the primary fuel for rapidly firing neurons (Killeen et al. 2013). It has been 
hypothesised that some of the ADHD symptoms may arise as a result of impaired lactate 
production by astrocytes that is insufficient to meet the brain’s energy demands (Russell et al. 
2006). This subsequently impairs performance in some high-energy demanding motor and 
cognitive tasks (Killeen et al. 2013; Russell et al. 2006). This hypoenergetics theory of ADHD 
seems to be supported by several strands of emerging evidence related to ADHD. For instance, 
ADHD patients are reported to have deficiencies in enzymes associated with energy supply and 
therefore require more energy than healthy controls, possibly because they have not sufficiently 
developed energy-efficient neural networks, including limited fully myelinated axons (Fair et al. 
2010; Killeen et al. 2013; Nagel et al. 2011). 
The recent finding of decreased N-acetylaspartate (NAA) levels in ADHD lends more support to 
the energy-deficiency hypothesis in ADHD and other related brain disorders (Soliva et al. 2010; 
Yang et al. 2010; Perlov et al. 2009). Not only is NAA a marker of neuronal integrity 
(McLoughlin et al. 2007), it is also a neuron-specific storage form of acetyl coenzyme A, an 
important component of energy production in Krebs cycle (Ariyannur et al. 2010). Clinical 
treatment with MPH elicits improvements in the reduced NAA levels seen in the cortex and other 
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brain areas of ADHD patients (Wiguna et al. 2012; Kronenberg et al. 2008). In addition to energy 
metabolism, NAA plays other crucial roles in the brain including: (a) lipid biosynthesis, which is 
required for myelin sheath formation, and (b) osmoregulation – whereby NAA acts as a 
constituent of a molecular water pump, facilitating the removal of intracellular water from 
myelinated neurons (Baslow 2002). Myelin sheaths are known to make neurotransmission faster 
and more energy efficient, thus their plausible alteration in ADHD (Nagel et al. 2011). This 
implies that transmission of information along axons is more energy consuming in ADHD 
patients, possibly causing the slow and variable reaction times in energy-demanding tasks 
associated with ADHD pathology (Harris and Attwell 2012; Russell et al. 2006; Killeen et al. 
2013). 
1.4 Synaptic plasticity 
In most vertebrates, the brains communicate and store information by altering the CNS through 
an important process referred to as synaptic plasticity. This involves several mechanisms, such as 
changing existing synapses or substituting aged synapses with new ones (Kasai et al. 2003). 
These alterations involve dendritic spines, which are tiny, specialised, semi-autonomous, knob-
like structures protruding from the main dendritic shaft and are often responsible for excitatory 
postsynaptic input (Soria Fregozo and Pérez Vega 2012). Depending on stimulus, cellular 
environment and location, dendritic spines can have rapid rearrangement capabilities and undergo 
constant turnover throughout life, playing an essential role in the processing of information in the 
mammalian CNS, particularly for excitatory synaptic transmission (Maiti et al. 2015). Given that 
they are highly plastic in nature and variations in their number and morphology determines the 
strength and stability of a synapse, dendritic spines are considered the “hot spot” of synaptic 
plasticity (Maiti et al. 2015). Interestingly, while most spines are stable in mature neurons, under 
conditions such as sensory input, stress, environmental enrichment, learning, social interactions, 
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prolonged exposure to addictive drugs (e.g. psychostimulants), and other behavioural paradigms, 
spines are often remodelled to appropriately sub-serve specific functions, such as memory (Kasai 
et al. 2003). In addition, rearrangement of the structures and functions of most dendritic spines 
influences synaptic connectivity and neuronal plasticity, which could control our memory, 
learning, motor coordination and behaviour (Maiti et al. 2015; Soria Fregozo and Pérez Vega 
2012). Aberrations in spine formation and density are therefore often associated with several 
brain disorders including ADHD.  
On the basis of their functions, the main signalling proteins, hormones, and growth factors 
identified in dendritic spines are categorised as: 1) actin binding and cytoskeletal proteins, 2) 
receptor tyrosine kinases and other kinases, 3) cell surface receptor adhesion molecules, 4) small 
GTPase associated proteins, 5) microRNA such as mRNA binding proteins and transcription 
factors, and 6) postsynaptic scaffolding proteins and adaptor proteins (Sala and Segal 2014). In 
ADHD, some of these plasticity-related proteins are known to be associated with the action of 
psychostimulants (e.g. MPH), while others are actually aberrant in the disorder. Some of the 
aberrant proteins in ADHD include brain-derived neurotrophic factor (BDNF), synaptosomal-
associated protein 25 kDa (SNAP25), and activity-regulated cytoskeleton-associated protein 
(Arc) (Amiri et al. 2013; Barr et al. 2000; Corominas-Roso et al. 2013). Moreover, the 
implication of glutamatergic and GABAergic signalling in ADHD (Perlov et al. 2007; Perlov et 
al. 2010), indicates that postsynaptic scaffolding or adaptor proteins that are key regulators of 
multiple members within the glutamatergic and GABAergic pathway have become particularly 
important in ADHD (Lesch et al. 2013). Such scaffolding proteins that have attracted interest in 
ADHD include glutamate receptors (AMPA/NMDA/mGlu etc.) and GABAA receptor 
(GABAAR), which are mainly localised in the spine head and play significant roles in synaptic 
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plasticity (Lesch et al. 2013). Similarly, other kinases involved in regulating spine structure and 
dynamics, such as cyclin dependent kinase 5 (Cdk5), have also been linked with ADHD, with 
animal models lacking Cdk5 showing increased locomotor activity that is corrected by 
psychostimulants (Krapacher et al. 2010). Interestingly, recent evidence also shows an 
association of the postsynaptic scaffolding/adaptor protein IRSp53 (insulin receptor substrate 
protein 53 kDa) with ADHD (Liu et al. 2013; Ribasés et al. 2009). The IRSp53 is a key player in 
cytoskeletal dynamics (discussed in detail in Chapter 7), which may be involved in NMDA 
receptor-linked synaptic plasticity through protein kinase C signalling (Hori et al. 2005). It may 
also be involved in cerebral asymmetry and confers risk for Autism spectrum disorders, which 
share some genetic risk factors in common with ADHD (Toma et al. 2011). 
1.5 Involvement of some brain regions in the symptoms of ADHD  
The well-established role of DA and NA in the frontal cortex, striatum, nucleus accumbens, and 
hippocampus, in varying behaviours, has recently been extended by findings showing that these 
brain regions operate together with the cerebellum to execute goal-directed behaviours, although 
it is through functionally distinct neural networks (Del Campo et al. 2011).  
1.5.1 The frontal and parietal cortices 
The frontal cortex, and to an extent, the parietal cortex, regulate attention, cognitive behaviour 
and reasoning, collectively referred to as ‘executive functions’. These executive functions are 
necessary for planning and organisation. The frontal cortex regulates attention and motor 
responses through its connections with the sensory and motor cortices, the striatum and the 
cerebellum. Conversely, the frontal cortex regulates emotions through connections with the 
nucleus accumbens, amygdala and other midbrain regions mediating arousal response (Arnsten 
2009). The right frontal and right parietal cortices are particularly important for the regulation of 
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attention and motor behaviour (Arnsten 2011). Functional imaging studies in humans have shown 
that the right frontal and right parietal cortices are less-activated when patients perform poorly on 
attentional tasks (Rubia et al. 1999; Vance et al. 2007). In contrast, these regions are active when 
patients perform better on such tasks and also when they successfully inhibit or stop movements 
(Arnsten 2009). Lesions to the right frontal cortex in monkeys induce impulsivity and 
hyperactivity (Kennard et al. 1941), which are among the major symptoms associated with 
ADHD. The catecholamines DA and NA are of major importance for this network and in the 
functions of the frontal cortex. Indeed, DA and NA dysfunctions are associated deficits in 
prefrontally-mediated cognitive functions, which are associated with several brain disorders, 
including ADHD (Wallace et al. 2014; Arnsten 2011). A moderate stimulation of D1 receptors 
by DA improves frontal cortex mediated working memory and attentional functions by 
suppressing inputs to neurons that are irrelevant to current demands (i.e. it decreases ‘noise’). 
Stimulation of postsynaptic α2A-receptors by NA also enhances the functionality of the frontal 
cortex by strengthening the appropriate network connections and permitting networks to maintain 
their firing for extended periods (i.e. increasing ‘signals’) (Arnsten 2009; Arnsten 2011). 
1.5.2 The striatum and nucleus accumbens 
The human striatum is organised into the dorsal striatum (which is referred to as ‘striatum’ in this 
thesis and it is involved in cognition and motor function) and ventral striatum (also referred to as 
‘nucleus accumbens’). The interest in the striatum is related to the fact that striatal DAT is the 
main target for stimulants (e.g. MPH) that are the preferred drugs for the treatment of ADHD. In 
fact, MPH has been shown to block up to 70% of DAT in the striatum, resulting in an enhanced 
striatal DA availability (Dougherty et al. 1999; Volkow et al. 2001). There are suggestions that 
this increased extracellular DA levels following striatal DAT blockade by MPH decreases 
background firing rates (i.e. decreases ‘noise’), while increasing the signal of striatal neuronal 
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cells, which consequently improves attention and minimises distractibility (Volkow et al. 2001). 
On the other hand, the nucleus accumbens is suggested to mediate motivation, emotion and 
reward-related behaviour. It has been reported that stimulating the accumbens in rodents 
increases cocaine and amphetamine self-administration, and selective lesions to DA terminals in 
the accumbens attenuates the self-administration of these drugs (Moghaddam and Bunney 1989; 
Pettit et al. 1984). Indeed, evidence indicates that DA systems in the accumbens are particularly 
important for drug-related reinforcement behaviours such as drug self-administration and place 
preference (Moghaddam and Bunney 1989; Pettit et al. 1984).  
1.5.3 The hippocampus 
The hippocampus, which lies within the limbic system is an important structure playing crucial 
roles in the consolidation of information from short-term memory to long-term memory and 
spatial navigation (Milner and Klein 2016). Damage to the hippocampus results in memory loss 
and disorientation. Indeed, extensive bilateral hippocampal damage results in an inability to form 
and retain new memories (Milner and Klein 2016). Individuals with ADHD tend to have 
attentional and memory deficits, which may be related to abnormalities in the hippocampus. 
Indeed, a recent study found significantly reduced hippocampal volume in young medication 
naïve ADHD patients compared to matched controls (Posner et al. 2014). 
1.5.4 The cerebellum 
The cerebellum was initially only considered to play a significant role in motor control (Strick et 
al. 2009; Middleton and Strick 1994). However, it is now also suggested to be important to 
higher cognitive functions such as working memory, learning, emotion, and visuo-spatial 
processing, emphasising its importance in ADHD (Strick et al. 2009; Middleton and Strick 
1994). There appears to be a strong interconnection between the cerebellum, frontal cortex and 
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the striatal structures, with some studies also suggesting that the cerebellum is capable of 
undergoing morphological plasticity much like hippocampus and some other cerebral areas 
(Strick et al. 2009; Middleton and Strick 1994). 
With the strong interconnections displayed by multiple brain regions in the regulation of 
cognitive and motor behaviour, it is suggested that abnormalities related to the functions of 
monoamines (i.e. related to dopaminergic and noradrenergic functions), especially in the frontal 
cortex, parietal cortex, striatum, hippocampus, and cerebellum could contribute to the 
dysfunctions seen in several clinical syndromes including ADHD. Given this background, these 
brain regions were ideal targets for our investigations in the adolescent brain regarding the partly 
unknown mechanism of action of MPH, which remains the drug of choice for ADHD treatment. 
1.6 Brain lateralisation and ADHD 
Hemispheric asymmetries are evident in the anatomy, cytoarchitecture and neurochemistry of the 
vertebrate brain. Decades of research have shown that a number of cognitive abilities rely heavily 
on lateralised processing in the human brain, with the most widely investigated being language 
and visuo-spatial processing (Corballis 2009). As an example, for most right-handed individuals, 
being attentive to language-based stimuli results from an increased brain activity lateralised to the 
left hemisphere, while being attentive to visuo-spatial processing-based stimuli results from 
increased brain activity in the right hemisphere (Nielsen et al. 2013; Toga and Thompson 2003). 
Other cognitive domains relying on lateralised brain functionality include: emotional processing 
(Onal-Hartmann et al. 2012), fine motor skills (Arning et al. 2013), and memory (Habib et al. 
2003), as well as face and body perception (Thoma et al. 2014) (see Figure 1.7). Case-control 
studies have shown that anatomical and functional asymmetries underlie brain functions as well 
as several brain disorders (Altarelli et al. 2014; Toga and Thompson 2003; Wang et al. 2015). A 
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recent study on dyslexic patients and matched controls suggested that an altered pattern of 
cortical asymmetry (e.g. within the planum temporale region of the cortex), preferring the right 
hemisphere might underlie dyslexia (Altarelli et al. 2014). Abnormal structural asymmetries have 
also been reported in Parkinson’s disease, schizophrenia, and Alzheimer’s disease (Derflinger et 
al. 2011; Wang et al. 2015). Although structural and functional asymmetries in the brain were 
previously thought to be unique to humans, both structural and functional asymmetries have been 
identified in non-human primates and other species including rats (Glick and Ross 1981; Toga 
and Thompson 2003; Lister et al. 2006; Kristofiková et al. 2010). For example, Japanese 
macaques have a right-ear advantage for processing auditory stimuli, while Passerine birds 
produce songs under the control of the left-hemisphere (Petersen et al. 1978; Nottebohm 1971; 
Toga and Thompson 2003). In male Sprague Dawley rats (the rat type used in this thesis), 
significant asymmetries have been found in the hippocampus, with the right hemisphere 
containing fewer neurons compared to the left hemisphere (Lister et al. 2006).  
          
Figure 1.7: Lateralised functions of the brain.  
Structural and functional asymmetries described in the vertebrate brain.  
 
Cortical right-hemisphere dysfunctions are thought to have some roles in ADHD (Casey et al. 
1997; García-Sánchez et al. 1997). The existence of such dysfunctions leads to expectations of 
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differences in lateralisation between ADHD patients and healthy individuals. In this regard, a 
number of studies have confirmed such expectations with a higher than expected rate of non-
right-handed (ambidextrous and left-handed) individuals being observed in the ADHD population 
(Shaw and Brown 1991; Yamamoto and Hatta 1982). Converging evidence from imaging studies 
also suggest a reversed brain asymmetry in ADHD, with ADHD patients having a right-greater-
than-left cortical asymmetry compared to controls (Filipek et al. 1997; Hynd et al. 1993; Semrud-
Clikeman et al. 2000). Indeed, an abnormal pattern of brain lateralisation is suggested to 
contribute to aspects of the inattention and impulsivity symptoms of ADHD, with some patients 
showing asymmetrical performance deficits on visuospatial attention mostly for endogenous 
cuing on card sorting tasks (Semrud-Clikeman et al. 2000; Nigg et al. 1997; Carter et al. 1995). 
 
1.7 Management of ADHD 
Different treatment paradigms are available for the management of ADHD. There are both 
pharmacological and non-pharmacological treatment options. While environmental and 
behavioural psychotherapy are thought to be successful alone, in some cases, they may be more 
effective when used in conjunction with anti-ADHD drugs.  
1.7.1 Pharmacological treatment options 
Several pharmacological treatment options are available for ADHD treatment. These are 
categorised as: 1) stimulants e.g. MPH, amphetamine, 2) non-stimulants e.g. atomoxetine, 
clonidine and guanfacine, 3) tricyclic antidepressants e.g. desipramine, imipramine, 
clomipramine, amitriptyline, and nortriptyline, 4) MAO inhibitors e.g. selegiline, phenelzine, 
and, 5) Others e.g. bupropion and modafinil. Among these, the two main treatment options for 
ADHD are the stimulant and non-stimulant drugs (Biederman and Faraone 2005).  
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1.7.1.1 Stimulant drugs for ADHD treatment 
The medications of choice in ADHD treatment are stimulants, and in most cases represent the 
first-line therapeutic option. MPH and amphetamine, which are known to enhance DA and NA 
neurotransmission, are the two main stimulants prescribed for ADHD treatment. While the 
stimulants MPH and amphetamine have similar clinical efficacy, they differ in duration of action, 
dosing, and adverse effect profiles in individual patients.  
1.7.1.2 Non-stimulant drugs for ADHD treatment 
An important development in ADHD treatment has been the use of the non-stimulant, 
atomoxetine. Atomoxetine blocks NET, which then attenuates ADHD symptoms by elevating 
NA in the synapse, mostly in the prefrontal cortex (Del Campo et al. 2011). While atomoxetine 
has measurable effects on improving ADHD symptoms and even represents the first-line drug in 
patients that do not respond to stimulant medication, it could have some hepatotoxic effects and 
therefore has limited use among patients with jaundice, pruritis, dark urine, or unexplained flu-
like symptoms (Biederman and Faraone 2005). The two α2-agonists, guanfacine and clonidine, 
are also used in the treatment of ADHD but due to the sparse efficacy data and side effects, they 
are rarely prescribed. However, a meta-analysis study reported that clonidine appears to be quite 
effective against ADHD (Connor et al. 1999). There are also indications that clonidine may be 
useful as an adjunct to stimulant medications, particularly when hyperactive, impulsive and 
aggressive symptoms are not well controlled, or when tics and sleep difficulties are present 
(Biederman and Faraone 2005). Guanfacine may also be moderately effective in treating ADHD 
symptoms and may also alleviate tic disorders. Common side effects of these α2-agonists include 
sedation, depression and drowsiness (Biederman and Faraone 2005). 
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1.7.2 MPH - the main stimulant drug for ADHD treatment  
 Among the stimulant medications currently available for ADHD treatment, MPH remains the 
most commonly prescribed (Abbas et al. 2016; Lakhan and Kirchgessner 2012). MPH is sold 
under varying trade names, with RitalinTM being one of the most familiar trade names. 
1.7.2.1  Physico-chemical properties of MPH 
MPH is a benzylpiperidine and a phenethylamine derivative that shares aspects of its basic 
structure with catecholamines. Given that MPH (methyl 2-phenyl-2-(piperidin-2-yl)acetate) has 
two chiral centers, four isomers of the drug are possible, with a pair each of erythro- and threo-
isomers being distinguished. The threo-isomers are preferred, with only the d-threo-isomer 
exhibiting pharmacologically desired effects in ADHD (Figure 1.8) (Heal and Pierce 2006). 
1.7.2.2 Indications  
When taken orally, MPH has a bioavailability of ~30% (range: 11-52%), with peak plasma 
concentration attained at approximately 2-4 hours for the short-acting (e.g. Ritalin), 3-8 hours for 
intermediate (e.g. Ritalin SR), and 8-12 hours for the long-acting (e.g. Concerta) type. MPH has a 
half-life of 2-3 hours, depending on the individual. MPH is contraindicated for individuals using 
monoamine oxidase inhibitors such as phenelzine (as hypertensive crisis may result), or those 
                   
 
Figure 1.8:  Chemical stuctures of d-threo- and l-threo-methylphenidate. 
The d-threo- and l-threo isomers are mirror images of each other (enantiomers). The d-threo-





(also known as d-threo-MPH)                                    
Methyl (2S)-2-phenyl-2-[(2S)-
piperidin-2-yl]acetate  
(also known as l-threo-MPH)                                    
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with marked agitation, tension and anxiety (as the drug may aggravate these symptoms), as well 
as those with tics, glaucoma, Tourette’s syndrome or hypersensitivity to any MPH ingredient, as 
it can worsen these conditions (Lu et al. 2006). The effect of the drug on unborn babies is not 
fully understood, hence pregnant women need counselling prior to MPH intake. 
 
By increasing extracellular neurotransmitter (e.g. DA and NA) activity in the brain, MPH 
improves ADHD symptoms. The drug is reported to be effective in about 70% of users (Engert 
and Pruessner 2008; Greenhill et al. 2002). MPH medicated ADHD children generally exhibit 
improved relationships with family members and peers, and perform better at school, have longer 
attention spans and are less distractible and less impulsive (Greenhill et al. 2002). Therapeutic 
doses of MPH are known to enhance cognitive functioning, including working and episodic 
memory, as well as inhibitory control in both healthy individuals and ADHD patients (Engert and 
Pruessner 2008; Spencer et al. 2015). MPH is also known to improve task saliency and increase 
arousal (Volkow et al. 2005). The drug is a CNS stimulant and aside ADHD, it is indicated for 
the treatment of the sleep disorder, narcolepsy (Biederman and Faraone 2005). The drug’s  
effective action against narcolepsy (excessive daytime drowsiness and sudden need for sleep), is 
due to its ability to increase wakefulness, vigilance and performance (Fry 1998). 
1.7.2.3 Mechanism of action 
MPH was approved for clinical use in 1955 and has been used in treating ADHD since the 1960s. 
However, there are still uncertainties regarding its mechanism of action. Neurochemically, MPH 
is known to influence DA and NA neurotransmission, playing a crucial role in cognition and 
motor activity. MPH binds to and blocks DAT, which is responsible for the removal of DA from 
the synapse and hence the termination of DA function. MPH-induced blockade of DAT, therefore 
increases DA concentration in the synaptic cleft and extracellular space (Volkow et al. 2005). 
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Therapeutic doses (0.3-0.6 mg/kg) of oral MPH has been shown to occupy more than 50% of 
DAT (Volkow et al. 1998). The highest specific MPH binding are often detected in the terminal 
regions of the nigrostriatal and mesocorticolimbic pathways (including striatum, accumbens, and 
prefrontal cortex) (Volkow et al. 1998; Volkow et al. 2005). Following the delivery of 
therapeutic MPH doses, the moderately increased extracellular levels of DA in the prefrontal 
cortex primarily stimulates D1 receptor and improve working memory functioning by 
suppressing inputs to cells not required for improving memory (i.e. reduces ‘signal/noise’ ratio) 
(Arnsten 2011). 
Beyond the DA-specific effect, MPH also increases extracellular levels of NA by blocking its re-
uptake by NET. In line with this, a rat-based microdialysis study, has shown that MPH increases 
both NA and DA efflux in the prefrontal cortex (Berridge et al. 2006). Although both NA and 
DA have crucial influence on cognitive functions under the control of prefrontal cortex, 
compared to NET there are relatively low levels of DAT present in the prefrontal cortex, which 
emphasise the potential significance of NA in the action of MPH in the prefrontal cortex (Arnsten 
2009). Therapeutic MPH doses results in moderate increases of NA in the prefrontal cortex, 
which then engages α2 adrenergic receptors, particularly the postsynaptic α2A-receptor. The 
stimulation of the α2A-receptor improves prefrontal cortex regulation of attention, emotion and 
behaviour by strengthening network connections between neurons and allowing networks to 
maintain their firing for long periods (increasing ‘signal’) (Arnsten 2011). Indeed, blocking of 
α2A-receptors in the prefrontal cortex of non-human primates using yohimbine induces locomotor 
hyperactivity and impulsivity and impairs working memory, similar to what is seen in ADHD 
(Ma et al. 2005). Thus, currently existing data are consistent with the hypothesis that clinical 
MPH doses improve cognition, attention, and performance by increasing both DA and NA 
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availability, which in turn activate D1-like and α2-adrenergic receptors, mostly within the 
prefrontal cortex (Engert and Pruessner 2008). 
In the striatum, it is hypothesised that when DAT is blocked in the presence of a therapeutic 
MPH dose, extracellular or resting state DA level is elevated by about six-fold (moderate 
enhancement) (Engert and Pruessner 2008; Seeman and Madras 2002; Seeman and Madras 
1998). The moderately elevated DA level then acts preferentially on pre-synaptic D2-like 
autoreceptors, decreasing impulse-triggered DA release. This decreased extracellular DA level 
would therefore result in limited activation of postsynaptic D1- and D2-like receptors, leading to 
reduced psychomotor activity, hence normalising striatum-mediated hyperactive symptoms of 
ADHD (Engert and Pruessner 2008; Seeman and Madras 2002; Seeman and Madras 1998). In 
line with this hypothesis, clinically relevant MPH doses have been shown to suppress locomotor 
activity in hyperactive rats (Kuczenski and Segal 2002). Higher MPH doses, however, markedly 
raise the magnitude of DA release and extracellular DA levels, overriding the presynaptic 
inhibitory mechanism, causing widespread activation of postsynaptic DA receptors, and 
triggering a generalised CNS stimulation (see Figure 1.2) (Engert and Pruessner 2008; Seeman 
and Madras 2002; Seeman and Madras 1998).  
Emerging evidence suggests that MPH also exert significant effects on the inhibitory 
neurotransmitter GABA and the excitatory neurotansmitter, glutamate and its receptors, 
particularly NMDAR (Carrey et al. 2002; Cheng et al. 2014; Di Miceli and Gronier 2015). Other 
reports demonstrate effects of the drug on brain glucose, lactate and NAA levels, as well as other 
water-soluble brain metabolites (Tafazoli et al. 2013; Volkow et al. 2008). However, the extent 
and mechanisms by which MPH influence the glutamatergic and GABAergic systems, as well as 
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amino acids and other brain metabolites remains to be clarified, and hence addressed in this thesis 
by using proton nuclear magnetic resonance spectroscopy (1H-NMR) (see Chapters 4, 5 and 6). 
1.7.2.4 Adverse effects 
Although MPH is generally well tolerated, there are some commonly observed adverse effects 
ranging from gastrointestinal, cardiac, and opthalmologic to CNS-based effects. Predominant 
CNS adverse effects include akathisia (restlessness/agitation), lethargy (drowsiness/fatigue), and 
irritability. The opthalmologic effects may be blurred vision and dry eyes, with some sparse 
reports of mydriasis (pupil dilation) and diplopia (double vision) (Jaanus 1992). The important 
gastrointestinal side effects are abdominal pain and weight loss. Cardiac adverse effects may also 
include mild changes in blood pressure and heart rate, palpitations, and tachycardia (rapid resting 
state heart beat rate). Other adverse effects include emotional liability, confusion, bruxism 
(grinding of the teeth), depression, hypersensitivity (skin rash, fever, urticaria), and rare cases of 
chest pain. Less serious but often reported side effects include nausea, appetite loss, 
hyperhidrosis (increased sweating), anxiety or nervousness, and insomnia (Kolar et al. 2008; 
Wilens et al. 2004).  
There are some reports of mild reductions of growth rate following prolonged MPH intake, but 
causal relationships are yet to be established (Cortese et al. 2013). Importantly, MPH could 
worsen psychosis in psychotic patients, and in a few instances, it has been associated with the 
emergence of new psychotic symptoms (Kraemer et al. 2010). Additionally, in bipolar patients, 
the drug also has a potential of inducing mania (Wingo and Ghaemi 2008). Libido disorders, 
hallucinations, and disorientation are also reported, albeit rarely. 
	44	
1.7.2.5 Recreational use and abuse liability 
Although the therapeutic effects, safety, and efficacy of MPH in paediatric and adult ADHD are 
well documented, there are persisting concerns regarding its misuse, abuse and addiction 
potential. Indeed, the last few decades have seen a rapid rise in ADHD diagnoses and MPH-
prescriptions. According to the estimates by the World Health Organisation (WHO), MPH 
consumption increased rapidly (~269%), from 4.66 to 17.9 defined daily doses per 1000 
population, between 1995 and 2006 (Gahr et al. 2014). Interestingly, the number of MPH 
consumed worldwide, far exceeded the relative increase in the number of MPH prescriptions per 
year, from 15,044,359 to 30,137,136 (100%). This, has therefore fuelled debates about possible 
illicit MPH use for pharmacologic neuroenhancement or recreational purposes (Gahr et al. 2014; 
Dietz et al. 2013).  
Given that MPH can improve performance on difficult and boring tasks, it is used by some 
students’ as a study aid (Gahr et al. 2014; Dietz et al. 2013). The drug is also used by some 
athletes to enhance their performance (Lakhan and Kirchgessner 2012). Moreover, since only the 
symptoms of ADHD are treatable, young and adolescent patients rely on MPH over a prolonged 
period, raising concerns over possible drug dependence/addiction and potential long term effects 
on the developing brain (Wang et al. 2013; Zhu et al. 2011). A manifestation of these concerns is 
the Schedule II status assigned to MPH in the US Drug Enforcement Administration’s scheduling 
scheme, with the drug placed in the same schedule/class as morphine and cocaine (Zhu et al. 
2011). It is thought that the dose and duration of MPH administered is critical for eliciting 
therapeutic response and for any potential drug dependence issues. It is known that while 
therapeutic MPH doses improve working memory and learning, excessive doses beyond 
therapeutic range, could adversely affect cognitive control and working memory (see Figure 1.2) 
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(Arnsten 2009). Excessive stimulation of D1 receptor in the prefrontal cortex due to excessive 
stimulant medication or during stress, impairs cortical functioning by weakening several network 
connections and suppressing all neuronal firing (Arnsten 2009). Similarly, excessively high levels 
of extracellular NA in the prefrontal cortex following high MPH doses, engage lower affinity α1- 
and β-receptors (rather than α2- receptors), thus impairing cortical function by suppressing 
cortical cell firing (Arnsten 2009; Birnbaum et al. 2004).  
1.7.3 Non-pharmacological treatment options 
A number of non-pharmacological ADHD interventions have emerged, mostly due to concerns 
about the long-term safety of medications used in treating the disorder. Non-pharmacological 
interventions may be psychosocial or dietary in nature. The dietary interventions include: 1) 
restricted elimination diets, which involves the elimination of artificial colours or diets that 
provoke behavioural problems, and 2) free fatty acid supplementation, which involves 
supplementing diets of affected individuals with free fatty acids, particularly omega-3 and 
omega-6 supplements (Bélanger et al. 2009; Boris and Mandel 1994; Sonuga-Barke et al. 2013); 
this is vital as ADHD is thought to be secondary to essential fatty acid deficiency (Colquhoun 
and Bunday 1981). On the other hand, the psychosocial interventions include: 1) Cognitive 
training, which involves the use of computer-based systems to improve working memory, 2) 
neurofeedback (electroencephalogram), which involves teaching patients to produce brain-wave 
patterns consistent with ‘focus’, by allowing patients to see their own brain wave patterns when 
they are focused on a particular task and when they are not. Thus, patients are trained to keep 
their brain active while concentrating or performing certain tasks, and 3) parent education and 
classroom management, which involves improving parents’ and teachers’ understanding of the 
child’s behaviour and equipping them with strategies to improve functioning and communication, 
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while discouraging unwanted behaviour (Bakhshayesh et al. 2011; Sonuga-Barke et al. 2013; 
Steiner et al. 2011). 
1.8 Genetically unmodified vs. genetic models of ADHD 
Although animals cannot be used in studying complex human behaviour such as language, they 
have similar basic behavioural, genetic and developmental processes (Andersen and Navalta 
2011). Despite some obvious limitations, experimenting on rodents (non-modified) offer valuable 
data on: (a) neurobiological basis of abnormal behaviours associated with disorders like ADHD, 
(b) the normalisation of abnormal behaviour after drug treatment, and in (c) identifying 
therapeutic targets (Andersen and Navalta 2011). In general, preclinical studies on rodents offer 
the following advantages:  
• Controlled means of investigating a drug’s effect independent of drug-drug interactions 
(i.e. the medication history of animals used in experiments are known and controlled). 
• Allows the researcher to get better control over confounding factors such as environment, 
diet, and learning history.   
• Efficient and more realistic means of evaluating the chronic effects of a drug. 
• An avenue for studying a drug’s effect irrespective of the underlying disease state. 
• A good means of investigating the mechanism of action of specific medications at various 
stages of neurodevelopment. 
 
Interestingly, several animal models of ADHD have been proposed ranging from chemically-
induced and environmentally-induced models to genetically modified models. The genetic 
models include spontaneously hypertensive rat (SHR), Naples High Excitability rat, mice 
expressing human mutant thyroid hormone receptor, DAT knockout mice, SNAP-25 deficient 
mutant coloboma mouse, tachykinin-1 receptor knockout mouse, and a nicotinic receptor 
knockout mouse. The chemically induced models of ADHD include pre- or early post-natal 
animals exposed to nicotine, ethanol, polychlorinated biphenyls, or 6-hydroxydopamine. The 
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environmentally induced models available include neonatal anoxia and rat pups reared in social 
isolation. While most of these animal models have abnormalities in the monoaminergic systems, 
several of them do not satisfy the established criteria for animal models of ADHD (Russell et al. 
2005). The working list of criteria for an optimal animal model of ADHD suggests that the model 
should have; (i) face-validity – implying that it should mimic the fundamental behavioural 
characteristics of the disorder such as impulsiveness and hyperactivity (these must be absent in a 
novel non-threatening environment and should develop gradually over time), as well as sustained 
attention deficit (this must be demonstrated only when stimuli are well spaced in time), (ii) 
construct-validity – i.e. the model must conform to a theoretical rationale for ADHD, implying 
that the model should demonstrate altered reinforcement of novel behaviour, as well as deficient 
extinction of previously reinforced behaviour, (iii) predictive-validity – i.e. the model must 
predict novel aspects of ADHD-related behaviour, genetics, and neurobiology, (iv) the model 
should be neurodevelopmental, preferably a genetic model (Sagvolden et al. 2005).  
Among the existing animal models, the SHR rats and DAT-knockout mice are commonly used. 
While these animal models provide useful information regarding various aspects of ADHD, none 
of these models can truly reflect this human neurodevelopmental disorder. For instance, the 
DAT-knockout mouse model lacks the gene encoding DAT, therefore this model exhibit 
hyperactivity and shows deficiencies in learning and memory tasks (Russell et al. 2005). 
However, among other factors, the DAT-knockout mouse models have non-functional striatal D2 
autoreceptors, with postsynaptic striatal D1 and D2 receptors being down-regulated by 
approximately 50% (Gainetdinov et al. 1999). In reality, this magnitude of striatal D1 and D2 
receptor down-regulation does not appear to exist in ADHD patients, hence limiting the usage of 
this model as accurate ADHD models (Gainetdinov et al. 1999). In a similar vein, although SHR 
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rats are probably the most established ADHD models, hypertension remains a major confounding 
factor in this model. The development of hypertension in the SHR models is reported to be due to 
a repeatedly increased release of NA from the sympathetic nerve terminals (Russell et al. 2005). 
Variability in response to stimulants has also been reported in the SHR model. In this regard, 
some inter-species differences in relation to genetics, behaviour and responses to ADHD 
medications (such as amphetamine) have been reported between SHR rats and the WKY rats that 
are commonly considered as the controls for SHR. For instance, some blood group antigens and 
isozymic markers of the major histocompatibility complex in SHR and WKY rats is reported to 
be different (H’Doubler et al. 1991). Thus, such differences could introduce confounding factors 
when using this model. 
Given the variations in human ADHD and existing animal models of the disorder, and the 
difficulty associated with obtaining a model that perfectly satisfies all the criteria for an ideal 
animal model, we used genetically unmodified animals in this thesis. This ensures that an 
important foundation is laid for the development of a more radical treatment paradigm, which 
will be preventive and curative but not just symptom ameliorative (Andersen and Navalta 2011). 
Moreover, using non-genetically modified animals in this thesis ensured that only drug-specific 
changes are observed and reported independent of underlying disease state, which is something 
that remains difficult to tease apart in clinical studies (Andersen and Navalta 2011). 
1.9 Project aims 
The aim of this thesis is three-fold: 1) to examine the treatment duration and region-specific 
effects of MPH on monoaminergic targets, 2) to use the 1H-NMR approach to examine 
previously unexplored effects of MPH on water-soluble metabolites in the brain, and 3) to 
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compare the acute and chronic effects of MPH treatment on DA and neuroplasticity-related 
targets, as well as metabolic pathways in the developing brain. 
1.9.1 Specific aims 
§ To establish the treatment-duration and region-specific effects of MPH on protein targets 
in the cortico-striato-cerebellar pathways. 
§ To evaluate the acute, chronic and lateralised effects of the drug on brain neurochemistry 
and metabolic markers. 
§ To use a broad range of methodologies to examine the importance of the cerebellum in 
the mechanism of action of MPH. 
































































2.1 Animals and treatment 
2.1.1 Housing and environmental conditions 
Young (20-25 days old; 80-100 g) to adolescent (35-40 days old; 180-220 g) male Sprague-
Dawley rats were used for the experiments in this thesis and were purchased from Charles River 
(UK). All animals were housed six per cage under controlled conditions of light (12/12 h light-
dark cycle) and temperature (22-25°C, 45% humidity), with free access to food and water. After 
five days of acclimatisation, the rats were used for the experiments. All animal experiments in 
this study were carried out in strict accordance with the UK Home Office guidelines and the 
Animal Scientific Procedures Act (1986).  
2.1.2 Drug treatment 
The animals were randomly assigned to treatment (MPH) or control (saline) groups within the 
acute and chronic treatment groups, with 6, 12 or 18 animals being in a group, depending on the 
experimental design and technique used. The rats were weighed, and those in the control groups 
received either a single 1.0 ml/kg saline injection (acute group) intraperitoneally (i.p) or twice-
daily saline injections for 15 days (chronic group). The rats in the MPH groups were injected 
with either a single 2.0 mg/kg MPH dose or a 5.0 mg/kg MPH dose (acute groups) and those in 
the chronic groups received a twice-daily 2.0 mg/kg MPH dose i.p for 15 days (chronic 
treatment) at 9 am and 5 pm each day. Considering the high metabolic rate in rats compared to 
humans, doses of MPH used in this study have previously been shown to achieve clinically 
relevant therapeutic doses (8-40 ng/ml) (Balcioglu et al. 2009; Kuczenski and Segal 2005; 
Kuczenski and Segal 2002). In addition, similar doses have been reported to alter brain 
transmitters including DA and NA, as well as the expression of plasticity-related genes and 
proteins (Banerjee et al. 2009; Réus et al. 2014; Wagner et al. 2009). The rats in the acute groups 
were 35-40 days old on the day of experiment (180-220 g). However, the rats in the chronic 
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groups were 20-25 days old at the start of the experiments, while they were 35-40 days old at the 
end of the experiments (180-220 g). Overall, the weights of the animals receiving saline 
treatment (controls) and MPH treatment were not statistically different (p = 0.78; n=144 rats) on 
the day they were sacrificed (Figure 2.1). 
 
Figure 2.1: Weight of animals across experimental days 1 to 15.   
A total of 144 animals were used in this thesis, with 72 animals each receiving either saline 
(control group) or MPH treatment (MPH-treated group). In general, the animals in the control 
groups (average weight = 215.6 g) weighed slightly more than the animals receiving MPH 
treatment (average weight = 210.7 g) on experimental day 15 but this difference was not 
statistically significant (p > 0.05). 
 
2.1.3 Dissection of brain tissues 
On the day of experiment, the animals were sacrificed by rapid cervical dislocation 1 h after last 
injection for experiments on brain neurochemistry, and 24 h after the last injection for protein and 
gene expression analyses experiments (Schaefer et al. 2006). Using a fine scalpel and the Paxinos 
and Watson rat brain atlas as a guide (Paxinos and Watson 2006), the left and right brain 
hemispheres were separated by a midline cut and the brain regions corresponding to the frontal 
cortex, striatum, nucleus accumbens, hippocampus, parietal cortex, and cerebellum in the left and 
right sides of the brain were dissected out (see Figures 2.2 and 2.3). In some experiments, the left 
and right cerebral hemispheres were also dissected out for neurochemical analyses. Following 
















dissection, the brain regions were snap frozen in isopentane, before being weighed and stored at -
80ºC prior to analysis.  
                
 
 
Figure 2.2: Central neuronal pathways containing DA in the rat brain.  
There were four cut planes: 1st cut plane, was at the connection of the olfactory bulb and the 
frontal cortex (FC); 2nd cut plane, was anterior to the corpus callosum; 3rd cut plane, was anterior 
to the fornix; and 4th cut plane, was anterior to the midbrain substructures. Abbreviations: DS, 
striatum; NAc, nucleus accumbens; PCx, parietal cortex; HIP, hippocampus. 
           
Figure 2.3: Representation of the examined brain regions.  
(A) frontal cortex; (B) parietal cortex, striatum, and nucleus accumbens (NAc);  (C) 


















2.2 1H-NMR metabolomics 
Metabolomics refers to the comprehensive profiling of multiple metabolite concentrations and 
their changes in response to drugs, genetic modulations, environment, and diet, in order to 
identify the beneficial and adverse effects of such interactions (Beckonert et al. 2007). High 
resolution 1H-NMR is a quantitative technique that gives detailed information regarding the 
features (i.e. atomic nuclei properties and interactions) of solution-state molecules (Beckonert et 
al. 2007). In a typical NMR experiment, a solution of a biological sample in a 5.0 mm glass tube 
is placed between the poles of a powerful external magnet (a 400 MHz external magnet was used 
throughout this thesis) (Figure 2.4). A radiofrequency pulse is then applied, via the Fourier 
transformation method (Gallagher et al. 2008), to ‘excite’ all the proton nuclei in the samples at 
the same time. Excited nuclei resonate or flip from one energy state to another e.g. from low 
energy state to a high-energy state (Figure 2.5). As the ‘excited’ nuclei ‘relax’ back to the 
equilibrium (or low energy state), complex radio wave frequency resonances are emitted (i.e. free 
induction decays), which is analysed computationally and transformed to produce the typical 
NMR spectra. The obtained NMR spectra can then be analysed using available statistical 
packages.  
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Figure 2.4: Schematic operation of a simple NMR spectrometer. 
 
In principle, NMR is concerned with the magnetic properties of the nucleus of an atom, 
particularly the ability of the nuclei to spin i.e. nuclear spin (I). The net spin of a nucleus is 
dependent on the nucleon composition (i.e. the number of neutrons and protons). For example, if 
the number of neutrons and protons are both even, the nucleus has no spin (i.e. I = 0; e.g. 12C, 
16O, 32S) but if the number of neutrons plus protons is odd, the nucleus has a half-integer spin (i.e. 
I = 1/2, 3/2 or 5/2; e.g. 1H, 13C, 19F, 31P). Atoms with I = ½ nuclei (e.g. 1H, 13C, 31P) are 
particularly measurable in NMR spectroscopy. When a nucleus with I = ½ is placed in an 
external magnetic field, it can either align itself with the direction of the magnetic field (low 
energy state) or against it (higher energy state). If radio waves are applied it is possible for the 
nuclei in the lower energy state to absorb the applied energy and ‘flip’ to the higher energy state 
(Figure 2.5). The absorption of the energy or the subsequent release of the energy (i.e. energy 
difference between low energy and high energy states) can be observed as the nucleus ‘relaxes’ 
back to the lower energy state. The radio waves are applied by scanning each individual nucleus 
slowly through a range of radio wave frequencies (this is called continuous wave) or by using a 
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more recent method, the Fourier Transformation method, where one big broad pulse of radio 
wave is applied to excite all nuclei. The resultant ‘free induction decays’ (FIDs) or resonances are 
transformed into the NMR spectrum we know (see Chapter 4, Figure 4.2). 
 
Figure 2.5: Excitation and relaxation of a nucleus.  
When a low energy state ½ spin nuclei is excited following the absorption of a radio wave, it flips 
the magnetic moment so that its spin direction opposes the applied magnetic field (high energy 
state). When the radio wave is emitted, the ½ spin nuclei returns to equilibrium (low energy 
state). This produces resonant signals that are transformed into the typical NMR spectra. Nuclei 
in an NMR experiment are held in a sample. The sample containing the nuclei is called the 
lattice. The nuclei in the lattice are in a vibrational and rotational motion, creating a magnetic 
field called the lattice field. This lattice field has many components that can interact with the 
nuclei in the higher energy state causing them to lose energy (and returning to the low energy 
state). The average lifetime of nuclei in the higher energy state is referred to as the relaxation 
time (T1) or relaxation delay. Another relaxation mechanism called the transverse or spin-spin 
relaxation is characterised by a relaxation time T2.  
 
The description in Figure 2.5 applies to isolated nuclei (or isolated protons). However, in a real 
molecule, there are electrons surrounding the nuclei (or protons in the nuclei). These electrons 
move in response to the applied external magnetic field and ‘shield’ the protons by generating 
local magnetic fields to oppose the stronger external magnetic fields applied (i.e. nuclear 
shielding). The external magnetic fields must therefore be increased in order to achieve resonance 
or ‘flipping’ (i.e. absorption of the radio wave frequency). The increments are quite small, often 
in parts per million (ppm). The differing electronic environment around each nucleus (i.e. 
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differing nuclear shielding) means that each ½ spin nucleus would not give resonant signals at the 
same frequency values. In this regard, compounds with increased nuclear shielding produce 
resonant signals at the higher field (closer to the zero point) of the NMR spectrum and the vice 
versa, which results in a (1H-NMR) spectrum with resonant signals from individual atomic nuclei 
that are spread over a 0 ppm to 10 ppm range. It is convenient to reference the resonant signal 
frequencies to a standard (e.g. TSP, trimethylsilylpropanoic acid), which produces a resonant 
signal at the zero point and can therefore be used as a reference signal. The difference (in ppm) of 
each resonant signal from this zero point is referred to as the chemical shift (δ). 
In general, the main stages of NMR-based metabolomics include sample preparation, data 
acquisition, data processing, metabolite identification, and data analysis and interpretation 
(Figure 2.6) (Quansah and Karikari 2016).  
                      
Figure 2.6: Typical 1H-NMR metabolomics workflow. 
 
The sample preparation is an important step and requires the use of suitable solvents that have no 









signals. However, as CCl4 is a poor compound for many polar solvents, deuterium labelled 
compounds (e.g. D2O) are now preferred since deuterium has a different spin (i.e. spin 1) that is 
not visible in a spectrometer focused on protons (Quansah and Karikari 2016). At present, NMR 
spectral data is acquired using powerful external magnets (100 – 900 MHz) and Fourier 
Transformation methods. Free data processing tools such as ACD Labs 
(http://www.acdlabs.com/) are available for obtaining integral values from the obtained sample 
spectra. The spectral data can then be analysed statistically (multivariate and univariate data 
analysis) using online resources such as MetaboAnalyst (http://www.metaboanalyst.ca/). A major 
challenge associated with 1H-NMR spectroscopy has to do with overlapping/co-resonances, 
where different metabolites may have resonant signals in the same region of the spectrum. 
However, this challenge can be overcomed by performing further NMR experiments – two 
dimensional (2D) experiments, such as HSQC (Heteronuclear Single Quantum Correlation), 
COSY (COrrelation SpectroscopY), TOCSY (TOtal Correlation SpectroscopY) and STOCSY 
(Statistical TOtal Correlation SpectroscopY). These 2D experiments operate by correlating the 
chemical shifts of hydrogen nuclei with other nuclei (e.g. 13C nuclei or even another hydrogen 
nuclei). In addition, the identities of resonant signals are verified using 1H-NMR and 2D spectral 
information available from online resources such as the human metabolome database (HMDB; 
http://www.hmdb.ca/). The NMR metabolomics stages employed in this thesis are discussed in 
greater detail below. 
2.2.1 Preparation of brain extracts for NMR analysis 
The frozen brain samples were retrieved and extracted using acetonitrile. The extraction 
procedure used was based on that described by Waters et al. (2002), but with some minor 
modifications. In brief, the frozen tissue samples were weighed before being homogenised in an 
equal measure (1:1 dilution) of acetonitrile (Fisher Scientific, UK) and HPLC-grade water (4 ml 
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per gram of tissue). Homogenates were kept on ice for 30 mins, and then centrifuged at 10,000 x 
g for 10 mins at 4°C (Sorvall Legend Micro 17R, Thermo Scientific, UK). The upper aqueous 
phase of each sample was extracted and lyophilised (freeze-dried). The residue for each sample 
was reconstituted with 50 µl of 1 M sodium phosphate buffer (pH 7.0) and 550 µl of deuterium 
oxide (D2O) containing 0.9 mM of TSP (Sigma Aldrich, UK). While the D2O provided the 
deuterium lock signal for the NMR spectrometer, the TSP provided the chemical shift reference 
(δ 0.00 ppm). Following centrifugation at 10,000 x g for 5 mins, the supernatant of each sample 
was transferred into a 5.0 mm NMR tube (Norell, UK) for 1H-NMR spectroscopy.  
2.2.2 Plasma preparation for NMR analysis 
Trunk blood from MPH-treated and control animals were collected into BD Vacutainer lithium 
heparin blood collection tubes (BD, USA). Blood samples were then centrifuged at 13000 x g for 
15 mins. Following centrifugation, 500 µl of blood plasma from the blood samples were 
dispensed into fresh Eppendorf tubes. 50 µl of D2O without TSP (Fisher Scientific, UK) was then 
added to the plasma samples to provide deuterium lock signal for the NMR spectrometer. The 
mixture was centrifuged at 10000 x g at 4°C for 5 mins. The supernatants were then transferred 
into 5.0 mm NMR tubes (Norell, UK) for 1H-NMR spectroscopy. 
2.2.3 1H-NMR experiments 
All the 1H-NMR experiments were done using a Bruker Avance AM-400 spectrometer (Leicester 
School of Pharmacy facility, DMU, Leicester, UK) operating at a frequency of 399.94 MHz and a 
probe temperature of 298 K (25°C). The spectra were acquired using the noesygppr1d (TOPSPIN 
version 3.0, Bruker Biospin) pulse sequence for water suppression. The number of scans was 
128, with a relaxation delay of 3 s, a spectral width of 4,800 Hz and a time domain of 32 K 
points. An exponential line broadening of 0.3 Hz was applied to the free induction decays (FIDs) 
prior to Fourier transformation. A major consideration when acquiring 1H-NMR metabolomic 
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data is that, for some biofluids such as plasma that are not pre-treated, the samples often contain 
large molecular weight molecules such as lipoproteins and triglycerides that give rise to broad 
signals in the resultant spectra. Such broad signals may obscure the narrow signals from lower 
molecular weight molecules such as amino acids and sugars. To enable the observation of 
narrower signals, the one dimensional 1H-CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence 
was applied. The CPMG procedure employs T2 spectral editing (i.e. spin-spin relaxation) that 
attenuates the contribution of large biomolecules.  
2.2.4 Pre-processing of NMR Spectra  
The 1H-NMR spectra were corrected manually for phase and baseline using ACD/NMR processor 
(academic edition; Ontario, Canada) software before data analysis. All the 1H-NMR spectra of the 
brain tissue samples were referenced to the TSP resonance at δ = 0.00 ppm, while the 1H-NMR 
spectra of the plasma samples were referenced to the lactate resonance (1.26-1.33 ppm). An 
‘Intelligent-Bucketing’ method was employed for dividing the spectrum into integral segments, 
ranging from 0.50 to 9.00 ppm, with all the integral values for brain being normalised to the TSP 
peak (δ, 0.00 ppm). The region from 4.60 to 5.10 ppm (representing H2O/HDO peaks) in the 
brain sample was removed prior to the bucketing procedure. Generally, datasets of about 20 - 80 
rows (samples) x 110 - 150 columns (variables) were obtained after removing regions containing 
‘noise’ signals (no peak areas). 
2.2.5 Multivariate and Univariate Statistical Analysis 
Univariate and multivariate statistical analysis were performed on the TSP-normalised integral 
values. Both Principal Component Analysis (PCA) and Partial Least Squares Discriminant 
Analysis (PLS-DA) were performed using MetaboAnalyst 3.0 (Xia et al. 2015), a web based 
metabolomics data analysis resource. PCA was carried out to ascertain inherent similarities of the 
spectral profiles and to detect any potential outliers (abnormal data points) in the datasets, while 
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PLS-DA was conducted for class discrimination and biomarker identification. Spectral data were 
further analysed using Orthogonal Projection to Latent Structure Discriminant Analysis (OPLS-
DA), to remove any confounding variation and focus solely on the effect of drug treatment. Thus, 
OPLS-DA maximises the class (metabolite) selection between the control and drug-treated 
classes. The default 10-fold cross validation was applied in order to guard against model over-
fitting. Prior to any univariate and multivariate analysis, the dataset was cube root transformed 
and Pareto scaled in order to satisfy assumptions of normality and homoscedasticity (i.e. 
assumption that variance around the regression line is the same for all values of a predictor 
variable), conditions necessary for the parametric tests further performed. To explore the 
performance of the different subsets and combination of discriminatory metabolites previously 
selected by PLS-DA or OPLS-DA, ROC (Receiver Operating Characteristic) curve analysis (see 
Figure 4.3, Chapter 4) was conducted using the option available in MetaboAnalyst 3.0.  
Univariate analysis was also carried out using an ANOVA model (conducted with the 
corresponding function in R 3.1.2 statistical software) in which 2 factors and 3 primary sources of 
variation were incorporated (for samples involving the left and right hemispheres): (1) 'treatment 
status’ (MPH-treated vs. control rats) (Ti); (2) ‘brain hemisphere’ (left vs. right) (Hj) and (3) 
‘treatment status’ x ‘brain hemisphere’ (THij) combined effect. This experimental design is 
represented by equation 1, in which Yij represents the (univariate) response variable values 
observed, µ its overall population mean value in the absence of any significant sources of 
variation, and eij the unexplained error (residual) contribution. 
Yij= µ + Ti + Hj + THij + eij                                                (1) 
This univariate analysis model (equation 1) was used to further test the effect of ‘treatment status’ 
(MPH-treated vs. control samples) or ‘brain hemisphere’ (left bain vs. right brain), in order to 
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confirm the changes observed following the multivariate analysis. In addition, in samples where 
multivariate analysis was not statistically significant, the univariate analysis was performed to 
determine which individual variables (metabolites) are statistically significant. In such cases, 
Bonferroni correction [where p = (0.05/total number of buckets for each sample)] was further 
applied in order to guard against type I error (false positives). 
2.2.6 Metabolite Identification  
1H-NMR resonance signals for brain and plasma samples were assigned on the basis of literature 
values (Govindaraju et al. 2000; Gao et al. 2012; Liu et al. 2014), information available in 
databases such as the Human Metabolome Database [HMDB] (Wishart et al. 2013), and by the 
consideration of chemical shift values, coupling patterns and coupling constants. The two-
dimensional NMR techniques 13C-1H HSQC (Heteronuclear Single Quantum Correlation), 1H-1H 
COSY (COrrelation SpectroscopY), TOCSY (TOtal Correlation SpectroscopY) and STOCSY 
(Statistical TOtal Correlation SpectroscopY) were employed in order to confirm these 
assignments.  
2.2.6.1 13C-1H HSQC  
The 2D Heteronuclear Single Quantum Correlation experiment operates by correlating the 
chemical shifts of hydrogen’s with those of carbon-13 nuclei to which they are directly attached 
through one-bond 13C-1H coupling constants (1JC,H). HSQC, therefore introduces new and 
orthogonal dimension (available from the C-13 chemical shift), beyond the normal 1H-NMR, thus 
yielding more information on the structure of metabolites (Dona et al. 2016). HSQC also 
provides much more sensitive response to minor changes in metabolite structure than 1H-NMR, 
as the C-13 chemical shift has a higher range (mostly 220 ppm) than 1H-NMR chemical shift 
(mostly 10.0 ppm). The HSQC spectra were acquired on the Bruker Avance AM-400 
spectrometer (Leicester School of Pharmacy facility, DMU, Leicester, UK). The HSQC spectral 
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acquisition was done using the hsqcedetgpsp.3 pulse sequence (TOPSPIN version 3.0, Bruker 
Biospin), 128 scans for 128 increments were acquired for each spectrum. Spectra were collected 
with 2048 points in t2 and 256 points in t1 over a sweep width of 66,000 Hz and 4800 Hz and in 
F1 and F2, respectively. A 2D 13C-1H HSQC spectrum for creatine has been shown in Figure 2.7. 
                
Figure 2.7: 2D 13C-1H HSQC spectrum (correlation of a 13C spectrum and a 1H spectrum).  
Obtained from a creatine standard revealing the exact locations of the creatine resonant signals in 
a two-dimensional (x and y) plane. 
 
2.2.6.2 Two-dimensional 1H-1H COSY and TOCSY 
The 2D correlation spectroscopy (COSY) and total correlation spectroscopy (TOCSY) NMR 
experiments were performed to elucidate further structural information on the small molecules of 
interest. Both COSY and TOCSY provide similar information regarding the directly coupled 
hydrogen’s, but TOCSY provides further structural information by detecting larger, 
interconnected groups of spin-coupled hydrogen’s (Dona et al. 2016). The 2D COSY and 
TOCSY experiments were carried out at 27°C on the Bruker AV-400 MHz (DMU, UK). COSY 
spectra were acquired using the cosygpprqf pulse sequence (TOPSPIN version 3.0, Bruker 
Biospin), with presaturation during relaxation delay utilising gradient pulses for selection. The 
spectral width for the F1 and F2 axes was 4800 Hz, with 2048 data points being collected in F2. 
While the total acquisition time was 7 h, the relaxation delay was 4.5 s. A sine function was 
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applied in both time domains, prior to the Fourier transformation. Representative 2D 1H-1H 
TOCSY spectra from a creatine standard and rat cerebellum are shown in Figures 2.8 and 2.9 
respectively.  
              
Figure 2.8: 2D 1H-1H TOCSY spectra (correlation of two 1H-1H spectra). 
Obtained from a creatine standard revealing the exact locations of the creatine resonant signals in 
a two-dimensional (x and y) plane. 
      
Figure 2.9: 2D Cerebellar 1H-1H TOCSY spectra (correlation of two 1H-1H spectra).  
Obtained from rat cerebellum revealing the exact locations of the observed resonant signals in a 
two-dimensional (x and y) plane. The resonant signal labelled 1 corresponds to lactate, while 
signals 2 and 3 correspond to creatine). 
   
2.2.6.3 STOCSY  
Statistical Correlation Spectroscopy takes advantage of the inherently linear relationship existing 
between intensity variables of the same molecule in an NMR spectrum. STOCSY assess the 
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covariance of variables in a spectral set and produces a correlation matrix that reveals the degree 
of correlation between each individual variable in the spectrum. Strongly correlated variables 
may belong to the same molecule, while weakly correlated molecules may belong to the same 
pathway. STOCSY was applied for the resolution of some brain resonance signals such as inosine 
and hypoxanthine using the option available in the MUMA R package (Cloarec et al. 2005; 
Gaude et al. 2013).  
2.2.7 Metabolite set enrichment and metabolic pathway analysis  
Detailed analysis of the most relevant cerebral metabolic pathways and networks invoked as 
respondents to MPH treatment was performed by the MetaboAnalyst 3.0 tool (Xia et al. 2015). 
This web-based facility employs high-quality Kyoto Encyclopedia of Genes and Genomes 
(KEGG) metabolic pathways as the structured back-end knowledge base, and integrates a series 
of now well-established methods (i.e., univariate and over-representation analyses), together with 
novel algorithms and concepts (i.e., Global Test, Global-ANCOVA and Network Topology 
Analysis) with pathway analysis. For all datasets, the Global ANCOVA and Relative-Betweeness 
Centrality algorithm for metabolic pathway and topological analyses were employed, the latter 
serving as a key measure indicating the importance of a graph node when expressed relative to 
that of the others (Aittokallio and Schwikowski 2006). For the pathway topology analysis 
performed, the Rattus norvegicus (rat) mammalian pathway library was selected. This approach 







2.3 In vivo microdialysis 
In vivo microdialysis is a technique widely used in neuropharmacology research for the sampling 
and quantitation of extracellular transmitter levels, which serves as an index of transmitter release 
(albeit not always the case). The microdialysis technique was established by Ungerstedt and 
colleagues during the late 1970s and early 1980s at the Karolinska Institute in Sweden 
(Ungerstedt et al. 1982; Zetterström et al. 1988). In this thesis, the microdialysis technique was 
employed to investigate the extracellular levels of striatal DA and its main metabolite, DOPAC. 
The technique involves the implantation of a probe that contains a semi-permeable membrane. 
The implanted probe is perfused with a medium having ionic composition similar to that found in 
endogenous cerebrospinal fluid, hence referred to as artificial cerebrospinal fluid (aCSF). A 
perfusion pump at an optimum rate, usually 1.0 – 5.0 µl/min, pumps the aCSF medium into the 
probe. The perfusion pump is connected to the probe’s inlet tubing (see Figure 2.10). Once the 
probe is inserted (e.g. into the brain) and the perfusion medium (aCSF) is pumped into the probe, 
molecules (e.g. neurotransmitters) on the outside of the microdialysis membrane (i.e. in the 
extracellular space) diffuse through the semi-permeable membrane along their concentration 
gradient into the probe and are collected at the probe’s outlet either manually or by using a 
fraction collector (Chefer et al. 2009). The dialysates (dialysis samples) can be collected at 
regular time intervals (e.g. every 20 min) and the neurotransmitter contents can then be analysed 
using an analytical technique such as high performance liquid chromatography coupled with 
electrochemical detection (HPLC-EC). Given the large number of neuroactive substances (e.g. 
transmitters, amino acids, proteins, peptides etc.) present in the brain and other tissues, probes 
with different pore sizes have been developed to screen the substances entering the probe’s semi-
permeable membrane. In this thesis, a probe of 6 kDa was used, hence only molecules smaller 
than this size could cross the membrane. 
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A key benefit to the use of the microdialysis technique is that the semi-permeable membrane is 
only present at the tip of the probe (see Figure 2.10), thus dialysis occurs only at the desired 
discrete brain area. Crucially, probes with different membrane sizes are currently available to suit 
different research purposes. In general, the small size of the dialysis probe (smaller than devices 
used for push-pull or cortical cup perfusion) means that it displaces a smaller area of tissue and 
therefore does less damage to tissues when compared to the push-pull technique (Chefer et al. 
2009; Darvesh et al. 2011). A major disadvantage of the technique, however, is that the sample 
collection stage takes a longer time (typically 20 min collection periods are employed), as 
opposed to other techniques such as in vivo voltammetry (Chefer et al. 2009). However, 
continuous improvements in the detection limits of analytical devices coupled to the 
microdialysis technique may help in reducing this time limitation. In addition, the dialysis 
process can create an area around the probe in which solutes capable of crossing the probe’s 
membrane are all depleted. Such changes in the neurochemical milieu could affect basal levels 
and perhaps pharmacological responsiveness. However, reports indicate that basal levels of DA 
in the striatum is relatively unaffected by variations in the amount of non-DA solutes depleted 
around the probe (Sam and Justice, 1996). 
2.3.1 Probe design 
The microdialysis experiments were conducted using AT 9 probes (AGNTHOS, Sweden), having 
3.0 mm polyethersulphone (PES) membranes with a 6 kDa cut-off. The probes had the typical Y-
like skeleton, with the inlet/outlet made with thermoplastic polyimide polyetheretherketone 
(Figure 2.10) tubing (non-metallic), while the shafts were made from polyimide tubing and fused 
silica and was 14 mm long.  
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Figure 2.10: A schematic diagram of a microdialysis probe used in extracting dialysates 
from the striatum of the adolescent rats. 
 
2.3.2 Surgical Procedure and probe implantation 
Male Sprague Dawley rats (weight: 180 - 220 g) were anaesthetised with urethane (10.0 mg/kg, 
i.p. over the entire duration of the procedure) and placed in a stereotaxic frame (David Kopf 
Instruments, USA). The incisor bar was set at 3.3 mm below the interaural line (flat skull 
position) and the animals body temperature maintained at ~37°C via a thermostatically controlled 
heating blanket coupled with a rectal probe (Havard Apparatus Ltd, UK). A longitudinal incision 
made in the scalp exposing the surface of the skull and the bregma position was marked with a 
small pencil dot. A trephine hole was drilled in the skull in one hemisphere of the striatum (2.5 
mm anterior and 1.5 mm lateral) with the duramater (dura) remaining intact.  
The microdialysis probe mounted on a probe holder was connected to a UNIVENTOR 801 
perfusion pump (AGNTHOS, Sweden) using polyethylene portex tubing (1.09 mm OD, 0.38 mm 
ID; Sims Portex Ltd, UK), and perfused at 2 µl/min flow rate with artificial cerebrospinal fluid 
(aCSF). The microdialysis probes were attached to a stereotaxic manipulator and positioned at 
the desired anterior and medio-lateral stereotaxic coordinates relative to bregma (2.5 mm anterior 








a sterile needle had been used to pierce the exposed dura. Throughout the duration of the 
experiment, the anaesthesia levels were checked every hour and maintained using additional i.p 
injections of 0.5 ml of 100% (w/v) urethane as a top up.  
2.3.3 Sample collection 
To collect the dialysis samples, 0.2 ml microtubes (Sigma Aldrich, UK) containing 10 µl of 0.2 
M perchloric acid were placed upside down on the outlet of the dialysis probe. Perchloric acid 
was added to protect the dialysates, particularly DA from degradation (i.e. from rapid oxidation). 
The dialysates were collected every 20 min (2 µl/min), yielding 50 µl samples. The collected 
samples were immediately placed on ice and then quickly analysed using high performance liquid 
chromatography coupled with electrochemical detection (HPLC-EC), as described below. 
2.3.4 Perfusion medium 
The microdialysis probes were perfused using artificial cerebrospinal fluid (aCSF) containing: 
• NaCl   140 mM 
• KCl   3.0 mM 
• MgCl2   1.0 mM 
• NaH2PO4  0.27 mM 
• Na2HPO4  1.20 mM 
• Glucose  7.2 mM 
• CaCl2   2.4 mM 
• pH adjusted to  7.4 
A fresh aCSF stock solution was prepared each week and filtered using Whatman filter discs 
(Whatman, UK) before use in any experiment.  
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2.3.5 Location of implanted probe 
At the end of the experiment, the animals were given an overdose of urethane i.p. and the brains 
were removed, snap frozen and stored in -20°C for probe placement analysis. Probe placement 
was verified by examination of the striatal brain sections. Striatal brain sections were cut on a 
cryostat to a thickness of 30 µm (Bright Instruments Ltd, UK) and then mounted on chromalum 
gelatin subbed microscope slides. The brain sections were examined using a microscope and then 
compared to the brain atlas (Paxinos and Watson 2006). To further aid identification, the slides 
were hydrated in decreasing solutions of isopropanol and subsequently stained with haematoxylin 
(Mayer’s) and 1% eosin stain, and then a DPX mountant (Sigma Aldrich, UK) added following 
dehydration to aid microscopy. Figure 2.11 gives the typical positions of the microdialysis probes 
inserted into the striatum.  
                       
Figure 2.11: Typical position of the microdialysis probes inserted into the striatum of rats. 
(A) Shows the site of probe placement in the striatum, (B) Probe inserted in the rat striatum, the 







2.4 High performance liquid chromatography-electrochemical detection 
HPLC coupled with electrochemical detection (HPLC-EC) is an important method for the 
analysis of brain monoamine levels. HPLC and carbon-based electrochemical detection offers a 
highly selective and sensitive means for the detection of compounds having a catechol or indole 
core. In this thesis, HPLC was employed to analyse DA and its metabolite (DOPAC and HVA) 
levels in whole tissues (from the frontal cortex, striatum, and cerebellum) and in the striatal 
dialysates obtained from the microdialysis experiment. A typical setup of the HPLC-EC system is 
shown in Figure 2.12. The HPLC-EC system (Waters Ltd, UK) used in the present study 
consisted of:  
• HPLC pump – Waters 1515 Isocratic HPLC pump 
• Injector – Rheodyne model 7725i (manual injector), fitted with 50 µL loop. 
• HPLC Column - C18 column (5 µm Spherisorb ODS2, 4.6 x 250 mm; Waters Ltd, UK) 
• Detector – Waters 2465 electrochemical detector (Waters Ltd, UK). 
• Flow cell (working, reference and auxillary electrodes) – Waters model 282065 
• Recorder/Integration software – Breeze 2 software (Waters Ltd, UK). 
                           
Figure 2.12: Isocratic HPLC system and electrochemical detection setup. 
In an HPLC-EC system, a high-pressure pump is used to generate and circulate a specified flow 
rate of solvent (i.e. mobile phase) typically in millilitres per minute. A sample (in a Hamilton 
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syringe) to be analysed can be introduced by manually injecting it into the injection valve 
(injector), which introduces the sample into the continuously flowing stream of mobile phase 
(polar mobile phase used in this thesis) that carries the sample into the HPLC column. The 
column has chromatographic packing material (called stationary phase) required to effect the 
separation. In this thesis, the Spherisorb ODS2 (reverse phase C18 column, 5 µm particle size 
and 25 mm long; Waters, UK) was used. This column has a silica-based packing material that has 
18 carbons added to make it non-polar (non-polar stationary phase) and this interacts with non-
polar compounds in the injected sample making them pass through the column slowly (greater 
attraction), while the polar compounds pass through the C18 column more rapidly (less 
attraction). This means that some compounds in the injected sample (or analyte) exit the column 
faster than others (chromatographic separation).  
As the separated analyte exit the column, it passes through the electrochemical cell, where it 
undergoes either oxidation or reduction. The electrochemical cell has three electrodes: (1) 
working electrode – where oxidation and reduction occur, (2) auxillary electrode – which acts as 
a counter electrode, (3) reference electrode – for stabilisation of the set-up. For oxidation or 
reduction to occur in the working electrode, a controller (potentiostat) maintains the potential of 
the working electrode (relative to the reference electrode) at value (set at 0.65V in this thesis) that 
causes the analyte to eletrolyse (i.e. oxidise or reduce). As an example, the oxidation/reduction 
reaction of DA is shown in Figure 2.13.  
            
Figure 2.13: Oxidation and reduction of dopamine.  
When the cell potential increases, dopamine is oxidised to dopamine-o-quinone but when the 
potential decreases, the dopamine-o-quinone is reduced back to dopamine. 
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The electrolysis current (electrical signal) resulting from the oxidation (or reduction) of the 
analyte is then measured by the cell and then transmitted to a computer data station. The electric 
signal arising from the analyte (injected sample) is then plotted as electric signal (y-axis) with 
respect to time (x-axis), producing peaks corresponding to the compounds in the injected sample 
(see Figures 2.14, 2.15 and 2.16). The area of resultant peaks from the injected analyte have a 
linear correlation with the concentration of the compounds in that sample (Schaefer et al. 2006). 
Each chromatographic peak is then identified and the area under each signal (integral data) 
analysed using statistical packages.  
2.4.1 Mobile phase 
In HPLC-EC analysis, the composition of the mobile phase depends on the sort of compounds the 
system is set-up to measure. In this thesis, the mobile phase prepared for detecting DA, DOPAC 
and HVA consisted of: 
• Sodium dihydrogen orthophosphate dihydrate 1.2 M 
• Disodium ethylenediamine tetracetate  10% (v/v) 
• Octanesulfonic acid sodium salt   0.5 mM 
• Methanol      15% (v/v) 
• pH       4.0  
The mobile phase was filtered using Whatman filter discs (Whatman, UK) and degassed for 20 
mins before use. The mobile phase was pumped at a flow rate of 1.0 ml/min. 
2.4.2 Extraction procedure for whole tissue experiments 
The extraction procedure for the brain tissues used is similar to that described by Schaefer et al. 
(2006) but with some minor modifications. In brief, the tissues from striatum, frontal cortex, and 
cerebellum were homogenised in 0.2 M perchloric acid (4 ml per gram of tissue) and centrifuged 
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for 5 min at 10,000 g. 50 µl aliquots were injected using the Rheodyne manual injection valve 
into a 50 µl loop and then pumped onto the C18 column (5 µm Spherisorb ODS2, 4.6 x 250 mm; 
Waters Ltd, UK) placed in a column oven maintained at a 35°C (Waters Ltd, UK). The column 
was protected from any possible contaminants by a pre-column filter of pore size 0.5 µm (Waters 
Ltd, UK).  
2.4.3 Analysis of microdialysates 
The microdialysates were analysed similar to the whole tissue samples. Here, 50 µl dialysates 
were injected manually into the 50 µl loop and then pumped onto the C18 column (5 µm 
Spherisorb ODS2, 4.6 x 250 mm; Waters Ltd, UK), as already described (see section 2.4.2). 
2.4.4 Determination of concentrations  
The concentrations of the analytes [DA; 3,4-dihydroxyphenylacetic acid (DOPAC); and 
homovanillic acid (HVA)] were determined using their peak area with reference to external 
standards (see Figure 2.14) assayed daily in 0.2 M perchloric acid from stock solutions of each 
compound.  
 
Figure 2.14: Typical standard (calibration) curve used in the determining the concentration 





















The identity of each peak was confirmed by running the individual standard compounds and also 
by spiking brain samples with each standard compound in trial experiments. The standard 
measurements of the peak area have been previously reported to be linear to the concentration of 
compounds (Schaefer et al. 2006). Typically, the retention times for DA, DOPAC and HVA 
standards were approximately 5.5, 7.5, and 19 min respectively (see Figure 2.15). Figure 2.16 
also shows the retention times within the rat brain samples. 
 
Figure 2.15: Chromatogram of DA, DOPAC and HVA standards of 0.2 µg/g concentration 
(i.e. 10-6 M dilution). 
 
 
Figure 2.16: Chromatogram of DA, DOPAC and HVA peaks in a rat striatal sample (i.e. 
whole tissue levels). 
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2.5 Western blotting 
The Western blot technique is used for the detection of specific protein molecules from among a 
complex mixture of proteins. This mixture may include all the proteins associated with a 
particular cell type or tissue. Western blots are used in evaluating protein expression or for 
assessing the size of a protein of interest (Kurien and Scofield 2006; Mahmood and Yang 2012). 
In this thesis, the Western blot technique was employed to evaluate the expression of proteins 
involved in the monoaminergic system and those associated with synaptic plasticity following 
MPH treatment relative to non-drug treated controls.  
The first major step in a Western blot is sample preparation, where samples are mixed with a 
detergent, usually sodium dodecyl sulphate (SDS), which unfolds the proteins in the sample into 
linear strands and then coats them with a net negative charge (Kurien and Scofield 2006; 
Mahmood and Yang 2012). The protein molecules are then separated according to their sizes via 
gel electrophoresis. After separation, the proteins on the gel are transferred onto a blotting 
membrane (e.g. nitrocellulose membrane). Following a successful protein transfer, the 
nitrocellulose membrane would carry all of the protein bands originally seen on the gels. The 
membrane then goes through a treatment process called ‘blocking’ (carried out using non-fat dry 
milk or bovine serum albumin), which prevents the occurrence of any non-specific reactions. To 
detect a specific protein from the protein mixture on the membrane, the membrane is incubated 
with a primary antibody that specifically binds to the target protein. After primary antibody 
incubation, any unbound antibody is washed off with a buffer (e.g. using a tris buffered saline 
with tween i.e. TBST buffer). The membrane is incubated again but this time with a secondary 
antibody that recognises and binds specifically to the primary antibody (Figure 2.17). The 
secondary antibody used in this thesis was linked with a reporter enzyme (e.g. HRP i.e. horse 
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radish peroxidase) that produces colour or light, permitting it to be detected, imaged and 
quantified (Kurien and Scofield 2006; Mahmood and Yang 2012). Through these processes, 
therefore, the Western blot technique allows the detection and quantification of target proteins 
from among a complex mixture of proteins.  
                       
Figure 2.17: The primary and secondary antibody complex in Western blotting.  
The primary antibody binds to the target protein and then a secondary antibody linked with a 
reporter enzyme (e.g. HRP – horse radish peroxidase) then binds to the primary antibody. This 
enzymatic complex can then be detected upon addition of chemiluminescence substrates. 
 
Regardless of the great utility of Western blots, there are several known limitations. Western 
blots are manually intensive and time consuming, requiring long hours when taking into account 
the gel preparation, sample separation, electro-blotting, and the multiple incubation periods. 
Sensitivity is often in the nanogram and microgram range making them incompatible with 
sample-limited analysis. In addition, analysis of large proteins is hindered by difficulties in 
transferring them from slab gels. However, the ability to refine protein separation by altering a 
number of important components, including buffer constituents, pH, gel concentration, and 
effective pore sizes of gels, means that the SDS-PAGE stage can be highly specialised to suit 












widely used detection technique for chemiluminescent blots. However, oversaturation is a major 
challenge associated with this detection technique, as blots can get easily saturated (Kurien and 
Scofield 2006; Mahmood and Yang 2012). Moreover, it is sometimes not obvious when 
oversaturation has occurred. To prevent effects of saturation, the films can be characterised to 
identify its linear dynamic range for detection of a specific antibody under relevant testing 
conditions (as performed in this thesis by first exploring and deciding on the best exposure time). 
Despite the outlined limitations, the selective protein detection ability of the technique following 
antibody binding coupled with the ability to tailor experimental procedures to maximise protein 
signals, makes Western blot a suitable technique for examining the effect of MPH on the 
monoaminergic and plasticity-related proteins. The steps used in this thesis are detailed below.  
2.5.1 Preparation of brain samples 
A 1:1000 dilution of protease inhibitor and RIPA lysis buffer (Cocktail SIGMA) mixture was 
prepared. 500 µl of this mixture was added to each of the dissected brain regions: nucleus 
accumbens, frontal cortex, parietal cortex, striatum, hippocampus and cerebellum for the left and 
right sides. The tissue samples were then homogenised using Polytron PT318 (Kinematica, 
Switzerland) and then centrifuged for 10 mins at 13,000 g and 4ºC using a bench top temperature-
regulated centrifuge (Sorvall Legend Micro 17R, Thermo Scientific, UK). The supernatant was 
extracted and 100 µl of the extract added to 100 µl of 2x electrophoresis buffer (5% β-2-
mercaptoethanol, 20% glycerol, 0.5 M Tris-HCl of pH 6.8, 0.006% w/v bromophenol blue and 
10% sodium dodecyl sulphate). The resultant mixture was heated at 90ºC for about 3 mins and 
then stored at -80ºC for later use. The remaining supernatants were used in estimating the 
concentrations of the total proteins using Bradford assay kit (Sigma Aldrich, UK), which allowed 
for equal protein concentrations (20 µg/µl) of the brain samples to be loaded. 
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2.5.2 Estimation of brain tissue protein concentration 
A standard protein curve was generated from the Bradford assay by diluting 1.0 mg/ml of bovine 
serum albumin (BSA) in distilled water to yield a range of concentrations from 0 - 1 mg/ml at 
intervals of 0.1 mg/ml. The protein standards were made in duplicate. From the 1.0 mg/ml BSA 
stock, the standards were prepared as shown below: 
• BSA stock (100 µl)  1.0 mg/ml 
• 90 µl stock + 10 µl diluent 0.9 mg/ml   
• 80 µl stock + 20 µl diluent 0.8 mg/ml   
• 70 µl stock + 30 µl diluent 0.7 mg/ml   
• 60 µl stock + 40 µl diluent 0.6 mg/ml   
• 50 µl stock + 50 µl diluent 0.5 mg/ml   
• 40 µl stock + 60 µl diluent 0.4 mg/ml   
• 30 µl stock + 70 µl diluent 0.3 mg/ml   
• 20 µl stock + 80 µl diluent 0.2 mg/ml 
• 10 µl stock + 90 µl diluent 0.1 mg/ml 
• 0 µl stock + 100 µl diluent 0.0 mg/ml 
Along with the protein standards, tissue homogenates were also diluted 1 in 8 in distilled water 
and loaded into a 96-well plate (Multiwell plate, polystyrene 96-well, Fisher Scientific, UK). 200 
µl of Bradford reagent (Sigma Aldrich, UK) was then added to each well. The 96-well plate was 
mixed gently, covered with a foil and incubated at 37°C for 30 mins. Following incubation, the 
plate was allowed to cool for 10 mins, mixed gently and the foil removed before being placed in a 
micro-plate reader (uQuantTM, BioTek, USA) set at 595 nm. Prior to the calculation of the 
concentration (µg/µl) of protein in each sample, the standard curves were checked for outliers.  
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2.5.3 SDS-PAGE electrophoresis 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using the BIO-RAD Mini-Protean system. Glass plates (0.75 mm) along with its spacer plates 
(BIO-RAD, UK) were mounted in support cassettes. Before sealing the cassettes, the lower 
borders of both the glass plates and their spacers were checked to ensure correct alignment. The 
gel cassettes were then clamped against a casting frame, which allowed a level pouring of gels. 
To maximise the resolution of protein molecules, a discontinuous SDS-PAGE system was 
employed. Both the stacking and the separation (resolving) gels were prepared with standard 
acrylamide gel reagents using concentrations estimated from the Chang Bioscience website 
(http://www.changbioscience.com/calculator/sdspage.html). A 10 ml of 12% separation gel (for 
10 – 200 kDa proteins) was prepared as follows: 
• 30% Polyacrylamide    4.0 ml 
• 1.5 M Tris-base (pH 8.8)   2.5 ml 
• 10% Ammonium persulphate   0.1 ml 
• 10% SDS     0.1 ml 
• TEMED (tetramethylethylenediamine) 0.004 ml 
• Distilled water     3.3 ml 
A 5 ml of 5% stacking gel was also prepared as follows: 
• 30% Polyacrylamide    0.85 ml 
• 1.0 M Tris-base (pH 6.8)   0.63 ml 
• 10% Ammonium persulphate   0.05 ml 
• 10% SDS     0.05 ml 
• TEMED     0.005 ml 
• Distilled water     3.4 ml 
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The prepared separating gel solution were gently inverted two or three times and then dispensed 
into the space between the mounted glass plate and the spacer plate of the gel cassettes. To ensure 
a smooth surface, a small layer of isopropanol was placed at the top of the separating gel and left 
for 30 mins to polymerise. After polymerisation, the isopropanol was decanted and the stacking 
gel solution was prepared and poured on top of the separating gel. A 15 well comb (3 mm x 10 
mm, BIO-RAD, UK) was then inserted gently in the gel, refilled and left for an hour to 
polymerise. Subsequently, the wells were thoroughly rinsed with distilled water to remove excess 
polymerised acrylamide. The gels were then connected to the electrophoresis tank and then filled 
with 1x running buffer prepared from a 10x stock. A litre of the 10x running buffer stock was 
prepared as follows: 
• Tris-base   30.3 g    25 mM 
• Glycine   144 g    250 mM 
• SDS    10 g    1% 
• Distilled water   up to 1000 ml 
Equal concentrations (20 µg/µl) of each tissue sample were loaded into the wells. The first and 
the last wells contained 2 µl of all blue precision protein standard (BIO-RAD, UK) and 2 µl of 2x 
electrophoresis buffer (negative control), respectively. The standard protein aided in the later 
estimation of the molecular weight range of the proteins of interest. Prior to loading, all the 
samples were denatured at 90°C for 3 mins. The samples were initially run at 120 V for 15 mins 
to allow sample passage through the stacking gel followed by 100 V for 45 mins. The 
bromophenol blue tracking dye present in the electrophoresis (loading) buffer and/or the all blue 
standard protein marker allowed the visualisation of protein movement in the gel.  
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2.5.4 Protein transfer 
The separated proteins were transferred from the gels onto a ProtranTM nitrocellulose membrane 
(GE Healthcare, UK) via a transfer sandwich and an electroblotter. The transfer sandwich 
consisted of two pieces of white scotchbrite pads (200 mm x 160 mm, BIO-RAD, UK), two 
pieces of 3 mm Whatman filter papers (Fisher Scientific, UK) and a piece of nitrocellulose 
membrane. The transfer sandwich was arranged as follows:  
•  Scotchbrite pad 
• Whatman filter paper 
• Gel 
• Nitrocellulose membrane 
• Whatman filter paper 
• Scotchbrite pad 
The black side of the transfer cassette was placed on the workbench and each element in the 
transfer sandwich was soaked in a transfer buffer, and then stacked on the cassette with air 
bubbles being dispelled at each stage by rolling sterile glass pipette over the sandwich. The 
cassette was then sealed and inserted into a Mini trans-blot tank (BIO-RAD, UK), while taking 
note of the colour codes (red for red). The transfer tank was filled with cold (4°C) transfer buffer. 
One litre of 1x transfer buffer (pH 9.2) was prepared as follows: 
• Tris-base   5.82 g    48 mM 
• Glycine   2.93 g    39 mM 
• Methanol   200 ml    20% 
• Distilled water   up to 1000 ml 
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The transfer set up was then run at 100 V for 1 h. Following the transfer procedure, the 
nitrocellulose membranes were stained a Ponceau S dye to allow an estimation of transfer 
efficiency. The nitrocellulose membranes were immersed in the Ponceau S dye and left on a 
shaker for 5 mins. After staining, the nitrocellulose membranes were placed in a destaining 
solution (5% glacial acetic acid) and left on the shaker for 5 mins. The destaining solution was 
changed 3-5 times until clear bands with almost no pink background were obtained. A 0.1% (x/v) 
Ponceau S dye in 1% (v/v) acetic acid was made as follows:  
• Ponceau S dye    0.033 g 
• Glacial acetic acid   0.3 ml 
• Distilled water    up to 30 ml 
Dissolving 5 ml of the 100% glacial ascetic acid in 95 ml distilled water also yielded a 100 ml of 
5% glacial ascetic acid.  
2.5.5 Immunoblotting  
Following Ponceau staining, a 10x TBS stock was (24 g Tris-base, 88 g NaCl, distilled water up 
to 1000 ml, pH 7.6) prepared. The membranes were blocked with 3% (w/v) non-fat dried milk in 
1x TBST (0.1% Tween 20 in 1x TBST; blocking buffer) for 30 mins at room temperature to 
prevent non-specific antibody binding. The 3% non-fat dried milk blocking buffer was observed 
to produce better quality bands with less background compared to 5% non-fat dried milk buffer. 
Primary antibodies were incubated overnight at 4°C in blocking buffer. While 1:2000 dilutions 





Table 2.1: Primary antibody dilutions for Western blotting 
Primary antibody (source) Dilution Final concentration 
(µg/ml) 
Secondary antibody 
Goat anti-DAT polyclonal IgG 1:1000 0.2 Anti-goat IgG-HRP 
Anti-DA D1R rabbit pAb 1:1000 0.2 Anti-rabbit IgG-HRP 
Anti-SLC18A2 rabbit polyclonal IgG 
(VMAT2) 
1:1000 0.2 Anti-rabbit IgG-HRP 
Rabbit polyclonal anti-NA transporter 
(NET) 
1:1000 0.2 Anti-rabbit IgG-HRP 
Rabbit polyclonal anti-Tyrosine 
Hydroxylase IgG (TH) 
1:1000 1.0 Anti-rabbit IgG-HRP 
Goat anti-BAIAP2 polyclonal IgG 
(IRSp53/58) 
1:2000 0.25 Anti-goat IgG-HRP 
Rabbit polyclonal anti-Arc IgG) 1:1000 0.2 Anti-rabbit IgG-HRP 
Mouse monoclonal anti-Cdc42 IgG3 1:1000 0.2 Anti-mouse IgG-HRP  
Rabbit polyclonal anti-Arp2 IgG 1:1000 0.2 Anti-rabbit IgG-HRP 
Mouse anti-β-actin monoclonal IgG1 1:2000 0.1 Anti-mouse IgG-HRP 
DAT, Cdc42, Arp2, Arc, β-actin and the secondary antibodies (anti-mouse IgG, anti-rabbit IgG 
and anti-goat IgG) were purchased from Santa Cruz Biotechnology, while D1R was from 
Millipore. VMAT2, NET and IRSp53 were also from Origene, with TH being purchased from 
Abcam (Cambridge, UK).   
 
Following overnight exposure to the appropriate primary antibodies, the membranes were washed 
three times with 1x TBST for 5 mins each time, in order to wash off unbound antibody. The 
membranes were then incubated with the relevant secondary antibody in blocking buffer. In 
accordance with the enhanced chemiluminescence (ECL) system (Amersham Biosciences, UK), 
all secondary antibodies used were linked to the detection enzyme, horseradish peroxidase 
(HRP). After secondary antibody binding, the membranes were again washed three times with 1x 
TBST for 5 mins each. Following the last wash, the membranes were developed via the ECL plus 
detection kit (Amersham Biosciences, UK), which allows the emission of light produced in a 
multistep reaction in which peroxidase catalyses the oxidation of luminol. In this procedure, the 
nitrocellulose membranes were incubated with ECL reagent A (luminol) and reagent B 
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(peroxide) for 5 mins (1:1 dilution). After the 5 mins exposure, excess ECL reagents were poured 
off and the membrane was sealed in a plastic wrap (Saran™ film). In a dark room, the wrapped 
membranes were gently smoothened to remove air bubbles and then placed in a film cassette. 
Subsequently, a sheet of autoradiography film (KodakTM, UK) was placed on top and the cassette 
was closed for 40 s (exposure time). The sheets were then dipped in a developer solution (135 ml 
water, 50 ml developer) followed by a fixer solution (135 ml water, 50 ml fixer) and then dried 
under red light. 
2.5.6 Image analysis 
Membrane images were captured using MCIDTM
 
core digital imaging system (MCID, UK), 
consisting of a video camera coupled to a computer. MCIDTM
 
image analysis software (version 
7.0) was used for post image acquisition analysis and quantification of immunoreactive bands. 
The MCIDTM
 
software assigns each protein band with an optical density value, which is the sum 
of the pixel values for each individual band. The background values were also obtained by 
calculating the fringe pixel density around each band of interest and then deducted from the 
corresponding protein band. 
2.5.7 Membrane stripping and reprobing 
For all experiments, the nitrocellulose membranes were stripped following film development. 
Stripping allowed for the removal of the primary and secondary antibodies from the membranes. 
The membranes were then re-probed with the mouse anti-β-actin monoclonal IgG1 primary 
antibody. The β-actin protein was used as a control for the amount of protein loaded into each 
well. A mild stripping buffer (containing 15 g glycine, 1 g SDS, 10 ml Tween20, distilled water 
up to 1000 ml, pH 2.2) was prepared. The membranes were washed twice with stripping buffer 
for 10 mins each at room temperature. The membranes were then washed twice with 1x PBS for 
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10 mins each, followed by a 5 mins wash with TBST. A 10x PBS stock solution was prepared as 
follows: 
• NaCl     80.0 g 
• KCl     2.0 g 
• KH2PO4    2.4 g 
• Na2HPO4    14.4 g 
• Distilled water    up to 1 L 
• pH     7.4 
The membranes were then blocked for 1 h with 3% non-fat dried milk blocking buffer, after 
which the immunoblotting protocol was repeated with anti-β-actin primary antibody and an anti-









2.6 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a molecular/genomic technique used to make multiple copies 
of a section of a gene (or DNA), which allows for the detection and/or identification of gene 
sequences. The PCR technology was developed by Kary Mullis in the 1980s (Mullis 1990). PCR 
can be performed using DNA from a variety of biological samples including tissues (e.g. from 
brain, skin, etc.), fluids (e.g. blood, saliva), and hair.  
Each PCR reaction is facilitated by polymerase enzymes. DNA polymerase is a crucial enzyme in 
the PCR process as this enzyme links complimentary deoxynucleotides (adenine, thymine, 
guanine, and cytosine i.e. A, T, G, C) to an existing DNA template (i.e. a short DNA strand). 
Smaller pieces of DNA, usually between 20-30 nucleotides long, called primers are used as 
starting points for the DNA polymerase enzyme to add nucleotides (VanGuilder et al. 2008; 
Garibyan and Avashia 2013). For a PCR reaction to occur, therefore, the following are required: 
template DNA or complementary DNA (cDNA), DNA polymerase, deoxynucleotides, and 
primers. These components, together with an appropriate Buffer and Magnesium source, is 
placed in a thermal cycler that allows repeated cycles of DNA amplification to occur through 
three steps: denaturation, hybridisation/annealing, and elongation (VanGuilder et al. 2008; 
Garibyan and Avashia 2013). The thermal cycler is programmed to heat up at a high temperature 
of 90-95°C, to allow the double stranded DNA to split into two single stranded DNAs 
(denaturation). The temperature is then reduced to a primer specific temperature (approximately 
between 50-60°C) for the primers to bind to the complementary sequence of the single stranded 
DNA (annealing). Following primer annealing, the temperature is increased (to usually 72°C), 
permitting the DNA polymerase enzyme to add the deoxynucleotides to the primer, thereby 
extending the DNA (Garibyan and Avashia 2013). By repeating these steps, the number of 
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amplified DNA molecules doubles. To obtain enough copies of the target gene for analysis, these 
three steps are typically repeated 30-40 times.     
For verification of the integrity of the amplified DNA and for visualisation and analyses of the 
PCR products, agarose gel electrophoresis is often conducted. Agarose gel electrophoresis 
separates the DNA products according to their size. This allows for the determination of the 
presence and size of the amplified PCR products. Figure 2.18 shows the PCR products of the 
target genes investigated in this thesis.  
                
Figure 2.18: Visualisation of the PCR products via agarose gel electrophoresis.  
The first lane corresponds to a ladder (standard marker), followed by the PCR products of the 
housekeeping gene and genes of interest (i.e. IRSp53, GAPDH, Arp2, Cdc42, and Arc). In the 
lane preceding each cDNA of interest was loaded the RNA product of that gene (which produced 
no visible bands).  
 
Standard PCR is used for quality control. To quantify a product, real time quantitative PCR (RT-
qPCR) is usually used. RT-qPCR can be used for both the detection and the quantification of the 
target DNA in real time, while it is being synthesised. The steps and necessary components in 
RT-qPCR are the same as already described for the standard PCR. However, in addition, each 
RT-qPCR reaction has a fluorescence reporter molecule. The fluorescence reporter molecule 
produces increased fluorescence with an increasing amount of amplicon product (VanGuilder et 
al. 2008; Garibyan and Avashia 2013). Either double stranded DNA binding dyes or 
fluorescently-labelled sequence specific probes may be used as the fluorescence-labelling 
method. A light source in the RT-qPCR instrument excites the fluorescence and a camera 
captures the fluorescent signals. As the amplification proceeds, the fluorescence accumulated is 
Ladder								IRSp53															GAPDH	 																	Arp2																			Cdc42																					Arc	
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captured by the instrument after every cycle and translated into an RT-qPCR graph (see Figure 
2.19). 
                  
Figure 2.19: Typical real-time PCR amplification curve.  
This displays the three phases of real-time PCR amplification including exponential, linear, and 
plateau phases. The cycle threshold (Ct) value, which represents the cycle at which the sample 
reaches the threshold line, can be compared to that of a standard curve to estimate the 
concentration of the sample. 
 
Real-time PCR amplification curves can be divided in three phases: the exponential phase where 
the reagents are in abundance and PCR product doubles in every cycle, the linear phase where the 
reagents begin to run out and the PCR reaction slows down, and the plateau phase where the 
reagents are depleted and the reaction stops. Real-time PCR amplification results focus on the 
exponential phase as this phase provides the most precise data for quantitation. Within the 
exponential phase two values are calculated: (a) the threshold line which is the point at which a 
reaction reaches a fluorescent intensity above background, and (b) Cycle threshold (Ct) which is 
the PCR cycle at which the sample reaches the threshold line (this Ct value is used in 
quantitation; see Figures 2.19 and 2.20). By comparing the Ct value of samples to that of a 







                 
Figure 2.20: Amplification curve from the PCR products of the IRSp53/58 gene in all the 
analysed brain samples. 
 
In general, RT-qPCR can be combined with reverse transcription, which permits messenger RNA 
to be converted into cDNA (complementary DNA), after which quantification of the cDNA may 
be performed with RT-qPCR. In this thesis, RNA was extracted from rat brain regions (such as 
frontal cortex, parietal cortex, striatum, and cerebellum) and reverse transcribed into cDNA. Prior 
to RT-qPCR, regular PCR was performed followed by agarose gel electrophoresis to ensure the 
integrity of the amplified genes of interest. The genes of interest investigated here included the 
insulin receptor substrate protein (IRSp53/58; BAIAP2), activity-regulated cytoskeleton-
associated protein (Arc), cell division control protein 42 (Cdc42), and actin-related protein 2 
(Arp2) that are associated with synaptic plasticity and actin dynamics. 
Despite the numerous advantages associated with PCR, in practice the technique can fail for 
various reasons. Indeed, due to the high sensitivity of the technique, it is prone to contamination 
from extraneous DNA, resulting in the amplification of spurious DNA products. Contamination 
with extraneous DNA can, however, be addressed with laboratory procedures that separate pre-
PCR mixtures from any potential source of DNA contaminants. Such laboratory measures may 
involve spatial separation of PCR set-up areas from areas used for purification or analysis of PCR 







design techniques are also essential in improving the yield of PCR products and in avoiding the 
formation of spurious PCR products. Other critical issues defining the reliability of real time 
quantitative PCR data are the choice of housekeeping (reference) genes and the sample 
preparation methods. An ideal housekeeping gene should always have the same level of 
expression. However, not all currently available housekeeping genes fulfil this prerequisite. As 
such, the constant expression of the chosen reference gene must be tested and verified for reliable 
data to be obtained. Alternatively, as done in this thesis, two or more reference genes can be used 
in the experimental setup for data analysis.  
2.6.1 Primer selection, design, and verification 
A total of four actin-binding genes of interest and two reference genes were selected based on 
previously published papers associating these genes with ADHD (Liu et al. 2013; Ribasés et al. 
2009; Banerjee et al. 2009). The actin-binding genes of interest selected were, IRSp53/58 (also 
known as BAIAP2), Arc, Cdc42, and Arp2. The two selected reference genes commonly used in 
previous studies were glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta-actin (β-
actin) (Miao et al. 2009; Ning et al. 2011). The nucleotide sequence of each of the targeted genes 
specific for rattus norvegicus was retrieved from GenBank (https://www.ncbi.nlm.nih.gov/gen-
bank/) (Table 2.2) and a blast search conducted for verification. The coding sequence of the 
matching contigs for each gene of interest was used in designing the primers using Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) (Sgamma et al. 2016). To 
select the ideal primer pair, different factors were taken in consideration and set as parameters 
e.g. annealing temperature (60-67°C), GC content (40-60%), an optimum primer length of 20-24 
base pairs and a maximum product size of 230 base pairs (see Table 2.2). Secondary structures of 
each amplicon were examined via Mfold (http://unafold.rna.albany.edu/?q=mfold/rna-folding-
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form). Primer dimers and non-specific amplifications were observed post-PCR, if any, by 
analysing the melting curve data.  
Table 2.2: Target primers and their annealing temperatures 
Gene (GenBank 
accession number) 






F: GGGAGTTCAAACAGGGCTCGGT 65 65 199 
 R: TCCTCCTCCTCAGCGTCCACAT 65   
     
IRSp53* 
(AY037934) 
F: GACCAAGATGCGGGGCTGGT 61 62 152 
 R: AGTCAGGAGGAGGGAGGGCC 63   





65 64 179 
 R: TCAATTTGGGTCCCGACAAGCAA 63   
     
Arp2* (FQ219838.1) F: GTGGCGCAGTCCTAGCAGACAT 65 68 147 
 R: TTAGAGGCGTGATGGGGACAAGCC 71   
     
Beta-actin+ 
(NM_031144.3) 
F: TCCGTAAAGACCTCTATGCC 55 57 230 
 R: GGACTCATCGTACTCCTGCTT 59   
     
GAPDH+ 
(NG_028301.2) 
F: AAACCCATCACCATCTTCCA 53 55 156 
 R: GGCGGAGATGATGACCCTTT 57   
F, Forward primer; R, Reverse primer; Ta, Annealing temperature; (*), Gene of interest; (+), 
Control. 
 
2.6.2 RNA extraction  
Twenty milligram of the frozen tissue samples corresponding to nucleus accumbens, frontal 
cortex, striatum, and cerebellum were dissected out on ice for total RNA extraction using 
RNeasy® Mini Kit (Qiagen, UK). Each 20 mg tissue was homogenised using 350 µl buffer RLT 
(lysis buffer) and the supernatant was carefully removed. 350 µl of 70% ethanol was added to the 
lysate and thoroughly mixed by pipetting. 700 µl from each sample, including precipitate, was 
transferred into an RNA mini spin column placed in a 2 ml collection tube and centrifuged for 15 
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s at 10,000 g, with the flow through subsequently discarded. Then 700 µl of Buffer RW1 
(washing buffer) was added to the RNeasy spin column and centrifuged for 15 s at 10,000 g, with 
the flow through subsequently discarded. The samples were then mildly washed by adding 500 µl 
of buffer RPE (mild washing buffer) to the RNeasy spin column and centrifuging for 15 s at 
10,000 g, and the flow through discarded. Further, the samples were mildly washed twice by 
adding 500 µl of Buffer RPE to the RNeasy spin column and centrifuging for 2 min at 10,000 g. 
The RNeasy spin column was then changed and centrifuged for 1 min at 10,000 g in order to dry 
the membrane. Finally, the RNeasy spin column was placed in a new 2 ml collection tube and 30 
µl of RNase-free water was added directly to the spin column membrane and centrifuged for 2 
min at 10,000 g. In order to obtain a high RNA yield (> 30 µg), the final step was repeated. The 
sample was then transferred into an Eppendorf tube and kept on ice.  
2.6.3 DNA digestion 
The TURBO DNA-free™ DNase treatment kit (Ambion Inc, USA) was used to remove genomic 
DNA contamination following the manufacturer’s guidelines. The concentration and quality of 
the RNA sample was then verified by spectrometry using A260/280 ratios, with a Nanodrop Lite 
Spectrophotometer (Thermo Scientific, UK). This was achieved by placing 1 µl of the RNA 
sample on the Nanodrop Lite Spectrophotometer. PCR was performed, as described in section 
2.6.5 (see below), to prove the lack of DNA contamination using the primers listed in Table 2.2. 
The integrity of the RNA sample was also evaluated by running 2 µg of total RNA (PCR product) 
on 2% agarose gels.  
2.6.4 cDNA synthesis 
cDNA was synthesised using 1.0 µg of the cleaned total RNA from each brain sample using 
iScript™ cDNA synthesis kit (Bio-Rad, UK) following the manufacturers instructions. In brief, a 
reaction mix was prepared comprising: 4 µl 5x iScript mix, 1 µl iScript reverse transcriptase, 1.0 
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µg RNA template, and nuclease-free water adjusted to give a total volume of 20 µl. The reaction 
mix was then incubated in a thermal cycler (PTC-200 Peltier Thermal Cycler) with the following 
parameters: priming for 5 min at 25°C, reverse transcription for 20 min at 46°C, reverse 
transcription inactivation for 1 min at 95°C, and a final incubation step for 5 min at 4°C. The 
samples were subsequently treated with 1 µl RNAse H (ThermoFisher Scientific, UK) for 20 min 
at 37°C in order to digest any remaining RNA. The cDNA samples were then kept at -20°C.  
2.6.5 PCR amplification and gel electrophoresis 
To verify the integrity of the synthesised cDNA and to test the primer conditions prior to real-
time quantitative PCR (RT-qPCR), regular PCR amplifications were run and the products 
analysed via gel electrophoresis. MyTaq red master mix (Bioline, UK) was prepared as follows: 5 
µl of MyTaq red (containing Taq polymerase), 0.5 µM of each forward and reverse primer, 4.1 µl 
nuclease-free water, and then either 1 µl cDNA  or 1 µl RNA, or 1 µl nuclease-free water. The 
PCR reactions were run at an initial denaturation temperature of 95°C for 15 s, primer specific 
annealing temperature (see Table 2.2) for 15 s, extension/elongation 72°C for 10 s for 35 cycles.  
The PCR products (including the test sample/PCR products, RNA and negative control/blank) 
were run on a 2% agarose (ThermoFisher Scientific, UK) gel prepared with 1x 
Tris/Borate/EDTA buffer (TBE buffer) and 0.2 µg/ml of SYBR™ Safe DNA Gel Stain 
(Invitrogen Ltd, USA). Electrophoresis was carried out in tanks filled with 1x TBE buffer at 90 V 
for 30 min and visualised on a Gel Doc™ EZ Imager (Bio-Rad, UK). HyperLadderTM 100 bp 
DNA ladder (Bioline, UK) was run alongside the samples in gels. 
2.6.6 Real-time quantitative polymerase chain reaction 
The RT-qPCR analysis was carried out using StepOnePlus™ Real-Time PCR system (AB 
Applied Biosystems, UK). Each reaction contained 5 µl SensiFAST™ SYBR Hi-ROX Mix 
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(Bioline, UK), 0.5 µl cDNA, 0.5 µM of each of the forward and reverse primers, in a total volume 
of 10 µl made up with sterile distilled water. The amplification conditions were as follows: 95°C 
for 2 min followed by 40 cycles of 5 s at 95°C and 30 s at the primers specific annealing 
temperature (see Table 2.2). To obtain the melting curve, the amplified template was melted from 
65°C to 95°C increasing the temperature by 0.5°C per cycle. Three technical replicates were used 
for each sample. The amplification efficiencies for all pairs of primers were evaluated via tenfold 
serial dilutions of pooled cDNA. 
2.6.7 Relative quantification and statistical analysis 
Relative quantification, which is based on internal reference genes to determine fold differences 
in the expression of the target genes, was performed in this study. To do this, the qBASE+ 
software (Qbase, UK) was used for preprocessing of the data. The qBASE+ relative 
quantification takes into consideration the Ct values obtained from the RT-qPCR experiments, 
along with the PCR efficiencies in each experiment. The data was then normalised to two genes, 
GAPDH and β-actin. Also, to control for differences arising from running samples in the 
different 96-well plates, an inter-run calibration was performed using standard samples that were 
included in all plates. After performing the relative quantification, the two treatment groups 
(chronic MPH-treated vs. saline control) were tested for their statistical significance. The data 
was entered into GraphPad Prism (version 5.0, GraphPad software Inc., La Jolla, CA) and a 




















































The monoamine (e.g. DA, NA and 5HT) hypothesis of ADHD proposes that hypofunction of the 
fronto-striatal monoamine circuit result in the inattention, hyperactivity and impulsivity 
symptoms associated with the disorder (Del Campo et al. 2011). Administration of MPH, which 
is the first-line drug for ADHD reduces the symptoms of the disorder in about 70% of affected 
children (Fusar-Poli et al. 2012; Vles et al. 2003). MPH blocks both DAT and NET, increasing 
extracellular DA and NA levels in both rodents and humans (Berridge et al. 2006; Moghaddam et 
al. 1993; Volkow et al. 2005; Kuczenski and Segal 2005). However, despite decades of clinical, 
biochemical, genetic, and neuroimaging research, the exact neurobiological mechanism 
underlying ADHD and its psychostimulant drug treatment is not fully understood. 
The hypo-functional DA hypothesis in ADHD emerged from initial molecular imaging studies 
that focused on the role of DAT and found increased DAT density in ADHD patients (Cheon et 
al. 2003; Dougherty et al. 1999; Spencer et al. 2005). An overexpressed DAT implies that 
extracellular DA may be quickly taken up by the transporter into the presynaptic neuron, thus 
limiting the synaptic availability and activity of DA (Del Campo et al. 2011). However, this idea 
of an overexpressed DAT in ADHD has been challenged recently by a series of case-control PET 
studies in adult never medicated ADHD patients, which found ADHD to be associated with a 
decrease of DAT and D2/D3 receptor availability in the left striatum, accumbens and the 
midbrain (Volkow et al. 2009; Volkow et al. 2007b; Volkow et al. 2007a). Possible reasons that 
may be underlying these discrepancies in findings on DAT could be the medication history and 
the different ages of the patients used in these studies. This may emphasise the importance of 
prior drug treatment and its influence on DAT expression. It also underscore the need to delineate 
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the effect of drugs (e.g. MPH) from the underlying disease pathology by examining the effect of 
the drug on normal drug naïve rodents.  
Altered DA activity in ADHD could be due to a direct defect in the function of dopaminergic 
cells (i.e. regarding DA synthesis, cell firing, DA autoreceptors, DAT, TH, and VMAT2) or it 
could be as a result of indirect effects (i.e. dysregulation of glutamatergic cortical inputs to 
dopaminergic cells) (Volkow et al. 2009; Volkow et al. 2007b; Volkow et al. 2007a). DA is 
synthesised from tyrosine and subsequently serve as a precursor for the synthesis of NA. The 
rate-limiting enzyme, TH is responsible for catalysing the conversion of L-tyrosine to L-DOPA, 
which is then converted into DA. The synthesised DA is sequestered into vesicles by the integral 
membrane transporter, VMAT2 (Calipari et al. 2014). The vesicles fuse with the plasma 
membrane in an action potential dependent manner, releasing DA into the synaptic cleft (i.e. 
exocytosis). DA released from dopaminergic neurons regulate cortical, striatal, and hippocampal 
pathways through the activation of two distinct families of receptors, the D1-like (D1 and D5 
receptors) and the D2-like (D2, D3 and D4 receptors) families (Missale et al. 1998). On the other 
hand, the action of DA at the synapse is terminated by its uptake back into the nerve terminal via 
DAT. If DAT is impaired it has significant effect on synaptic DA levels, making DAT a crucial 
regulator of synaptic DA action. Similarly, NET functions as a key regulator of synaptic NA 
levels. The deficits in DA and NA activity reported in ADHD (Volkow et al. 2007b), highlights 
the focus on the expression of proteins such as DAT, NET, TH, VMAT2, and D1 receptor within 
the dopaminergic circuitry of ADHD patients and in the mechanism of action of MPH and other 
anti-ADHD medications (Calipari et al. 2014; Del Campo et al. 2011; Narendran et al. 2015).  
The human brain is well-known to show cerebral lateralisation (see Chapter 1, section, 1.6), 
similarly lateralisation of cerebral function has been documented in the brain of several animals 
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species, including rats (Glick and Ross 1981; Toga and Thompson 2003; Lister et al. 2006; 
Kristofiková et al. 2010). A deviation from the common pattern of cerebral lateralisation is 
suggested to be involved in the various impairments observed in ADHD patients, including the 
core symptoms of impulsivity, inattention and executive function deficits (Liu et al. 2013; 
Ribasés et al. 2009). Indeed, the development of human cerebral asymmetry is reported to have a 
key importance in cognition, handedness and language (Liu et al. 2013). Non-right-handedness, 
particularly mixed-handedness is suggested to be a potential risk factor for the symptom severity 
of inattention in ADHD (Liu et al. 2013; Rodriguez et al. 2010). Brain asymmetry has also been 
reported in several brain disorders including Alzheimer’s disease, schizophrenia, autism and 
Parkinson’s disease (Morris et al. 1994; Ricciardi et al. 2015). The dysfunctional right 
hemisphere hypothesis of ADHD is based mainly on abnormal right-sided frontostriatal activity 
in patients (Castellanos et al. 1996; Heilman et al. 1986; Heilman and Van Den Abell 1980; 
Vance et al. 2007). In support of this, a number of structural magnetic resonance imaging (MRI) 
studies have shown that ADHD patients have reductions in right caudate and right cerebral cortex 
(Valera et al. 2007), and thinner right frontal and parietal cortices (Makris et al. 2007). Further, 
delayed maturation of the cortical thickness and cortical surface area, also more prominent in the 
right hemisphere, have also been reported (Shaw et al. 2007; Shaw et al. 2009). In fact, some 
researchers have suggested that the level of rightward volumetric asymmetry might be an 
indicator of the severity of the inattentive symptom of ADHD (Schrimsher et al. 2002). In 
addition, hemisphere-specific findings have also been observed in functional MRI studies on 
ADHD patients, including an under-activation of the right parietal cortex (Vance et al. 2007), and 
right PFC (Rubia et al. 1999) during motor and attentional tasks.  
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Despite the growing evidence suggesting an abnormal right-sided frontostriatal activity in 
ADHD, information is still lacking regarding any lateralised action of drugs used in the treatment 
of ADHD, including MPH. 
3.1.1 Aims 
The aim of this study was to investigate the effects of MPH on protein markers associated with 
dopaminergic and noradrenergic function after acute and chronic treatment. In addition, the study 
evaluates the hemisphere-specific effects of acute and chronic MPH treatment on whole tissue 
and in vivo extracellular levels of DA, and its metabolites DOPAC and HVA. Specifically the 
effects of MPH on the following were examined: 
§ Proteins associated with pre- and post-synaptic dopaminergic and noradrenergic function in 
the frontal cortex, parietal cortex, striatum, nucleus accumbens, and hippocampus using 
Western blotting.  
§ Ex vivo whole tissue DA and its metabolite levels in the left and right frontal cortex and 
striatum following acute and chronic MPH treatment, using HPLC-EC. 
§ Extracellular DA and DOPAC levels in the left and right striatum following acute MPH 




3.2.1 MPH Treatment 
For a detailed description of the MPH treatment procedures see Chapter 2, section 2.1. In brief, 
the animals were assigned to two treatment groups i.e. acute and chronic groups. The adolescent 
animals in the acute groups (35-40 days old) received either a single i.p injection of 1.0 ml/kg 
saline (controls) or a 2.0 mg/kg MPH dose (drug-treated group). On the other hand, the animals 
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in the chronic groups either received a twice daily 1.0 ml/kg saline injection (control group) or 
2.0 mg/kg MPH injection (treatment group) for 15 days (from post natal day 25 to post natal day 
40) at 9 am and 5 pm each day. For the in vivo microdialysis study, to ensure an effect 
sufficiently strong for the occurrence of a lateralised action, adolescent animals (35-40 days old) 
were given a single i.p. injection of 5.0 mg/kg MPH dose. For all treatment groups, MPH was 
freshly prepared in saline on the day of the experiment.   
3.2.2  Acute and chronic effects of MPH on monoaminergic markers  
The Western blot technique was employed to examine the acute and chronic effects of MPH 
treatment on DAT (1:1000 dilution; Santa Cruz, USA), NET (1:1000 dilution; OriGene, USA), 
TH (1:1000 dilution; Abcam, UK), VMAT2 (SLC18A2; 1:1000 dilution; OriGene, USA), and 
D1R (1:1000 dilution, Millipore, UK) protein expression in the frontal cortex, parietal cortex, 
striatum, nucleus accumbens, and hippocampus (as previously described in Chapter 2, section 
2.5). In these experiments, β-actin (1:2000 dilution; Santa Cruz, USA) was used as the reference 
protein. There were six animals in each treatment group (treatment and controls). The animals 
were sacrificed 24 h after the last drug treatment and the brains removed, snap-frozen and then 
stored at -80°C until analysis (as previously described in Chapter 2, section 2.1).  
3.2.3 In vivo microdialysis and whole tissue DA analysis 
A 10-3 M stock solution of DA, DOPAC and HVA standards (Sigma, UK) were prepared weekly 
in 1.0 M perchloric acid and stored at 4°C in the dark. From these stock solutions, serial dilutions 
of the standards were prepared daily using 0.2 M perchloric acid to obtain 10-5 - 10-9 M dilutions 
for the microdialysis and whole tissue experiments. For the in vivo microdialysis technique, 1.5 
mg/ml solutions of urethane were prepared daily and stored at 4°C for use in anaesthetising the 
animals.  
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3.2.4 Probe implantation 
Microdialysis probes were implanted into the striatum using stereotaxic coordinates relative to 
bregma (2.5 mm anterior, 1.5 mm lateral and 6.5 mm below the dura) (Paxinos and Watson 
2006), and then perfused with artificial CSF (see Chapter 2, section 2.3.4). DA and its main 
metabolite (i.e. DOPAC) were then measured using HPLC-EC, with perfusates being collected 
every 20 mins (2 µl/min) over a 2 h period or until the dialysate DA levels had reached a steady 
state (see Chapter 2, section 2.3).  
3.2.5 Acute MPH effects on extracellular DA and its metabolites 
The in vivo microdialysis technique was employed on the urethane anaesthetised rats to measure 
the effects of acute MPH treatment on extracellular levels of DA and its main metabolite (i.e. 
DOPAC) in the striatum of adolescent male Sprague Dawley rats (approximately 35-40 days old, 
180 - 220 g; n=6 rats/group). To investigate the effect of drug treatment in the left and right 
striatum, dialysates were taken from the left (n=3 rats/group) and right (n=3 rats/group) sides of 
the MPH-treated animals and their corresponding controls. The animals were anaesthetised with 
urethane (10.0 mg/kg, i.p.) over the entire duration of the procedure.  
3.2.6  Effects of MPH treatment on whole tissue levels of dopamine and its metabolites 
The effects of both acute and chronic MPH treatment on the whole tissue levels of DA, DOPAC 
and HVA levels were examined using HPLC-EC (Chapter 2, section 2.4). Following MPH 
treatment (2.0 mg/kg MPH dose) or 1.0 ml/kg saline injection (controls), brain regions 
corresponding to the frontal cortex and striatum (left and right sides) were quickly dissected out 
and homogenised in 0.2 M perchloric acid. Following HPLC-EC analysis, whole tissue levels of 
DA, DOPAC, HVA, and the turnover ratios, DOPAC/DA were calculated for each sample.  
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3.2.7 Statistical analysis 
Data from the whole tissue DA, DOPAC, and HVA study were calculated as µg/g for each 
treatment group. These datasets were analysed using SPSS (version 22, IBM Statistics, Illinois, 
USA) and GraphPad Prism (version 5.30, GraphPad Software Inc., La Jolla, CA). Separate two- 
and three-way ANOVAs [with the factors, ‘drug’ (MPH, saline), ‘hemisphere’ (left, right), and 
‘duration’ (acute, chronic)] and all interactions were carried out on the concentration levels of 
DA, DOPAC, and HVA, and the two ratios DOPAC/DA and HVA/DA. On the other hand, 
significant effects of ‘drug’ and ‘duration’ on the monoaminergic protein markers (DAT, NET, 
TH, VMAT2, and D1 receptor) were tested using two-way ANOVA. The data on the 
monoaminergic protein markers represent percentage of controls ± S.E.M. All significant main 
effects or interactions were further analysed using multiple comparison Bonferroni post-hoc 
analyses, with a p < 0.05 considered statistically significant. 
Data from the in vivo microdialysis study were plotted as mean ± S.E.M for each treatment 
group. Data analysis was performed using GraphPad Prism (version 5.30). Striatal DA and 
DOPAC (% of baseline levels at time 0 min) were analysed among treatment groups using two-
way mixed design ANOVA with ‘time’ as a repeated measure. Two-way repeated ANOVA was 
used to determine the significant effect of ‘time’ on the MPH-treated and saline-treated groups, 
with Bonferroni post-hoc tests for multiple comparisons against the baseline (0 min) used to 
detect, which time points differed significantly. Significant effects and interactions between 
‘drug’ (MPH vs. control) and ‘time’ were also followed up with Bonferroni post-hoc tests.  
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3.3 Results 
3.3.1 MPH induces an overexpression of DAT and NET  
The present study shows that MPH alters the expression of DAT and NET transporters in several 
brain regions in a ‘treatment duration’ dependent manner. In this experiment, DAT was reliably 
detected and measured in the striatum and nucleus accumbens. Here, the influence of two 
variables (factors) were tested i.e. ‘drug’ (MPH vs. saline) and ‘duration’ (acute vs. chronic). The 
two-way ANOVA (drug x duration) indicated no significant interaction between these two 
variables and no significant effect of ‘duration’ but a statistically significant effect of ‘drug’ on 
DAT levels in the nucleus accumbens (F(1,44) = 19.1, p < 0.00001). The Bonferroni post-hoc 
analysis showed that both acute (p < 0.05) and chronic (p < 0.01) MPH treatment significantly 
enhanced DAT density in the accumbens (Figure 3.1). In contrast, there was a significant effect 
of both ‘drug’ (F(1,44) = 14.8, p = 0.0002) and ‘duration’ (F(1,44) = 22.5, p = 0.00004) influencing 
DAT levels in the striatum. In this region, there was a contrasting effect of MPH on DAT, 
whereby acute MPH treatment had no significant effect on DAT (marginal decrease) but chronic 
treatment significantly up-regulated DAT (p < 0.05) (Figure 3.1). 
          
Figure 3.1: Effect of (A) acute, and (B) chronic MPH treatment on DAT protein density. 
DAT density was reliably measured in the nucleus accumbens (NAc) and striatum (DS) of 
adolescent rats. Values represent percentage ± S.E.M (n=6 rats/group but two data points from 





































Unlike DAT, which was only reliably detected and measured in the accumbens and striatum, the 
expression of NET was reliably measured in the frontal cortex, parietal cortex, striatum, nucleus 
accumbens, and hippocampus. The two-way ANOVA revealed significant interaction effect 
between ‘drug’ x ‘duration’ (F(1,44) = 14.4, p = 0.0008) and a significant effect of both ‘drug’ 
(F(1,44) = 10.1, p = 0.006) and ‘duration’ (F(1,44) = 16.9, p = 0.0007) in the nucleus accumbens and 
parietal cortex (main effect of drug: F(1,44) = 18.4, p = 0.0006; main effect of duration: p = 0.003; 
duration x drug interaction: p < 0.00001). The post-hoc analysis indicated that chronic MPH 
treatment (but not acute) significantly increased NET density in the accumbens (p < 0.05) and 
parietal cortex (p < 0.05) (Figure 3.2). 
 
Figure 3.2: Effect of (A) acute, and (B) chronic MPH treatment on NET protein density.  
NET density was measured in the nucleus accumbens (NAc), frontal cortex (FC), parietal cortex 
(PCx), striatum (DS), and hippocampus (HIP) of adolescent rats. Values represent percentage ± 
S.E.M (n=6 rats/group but two data points from the left and right sides of each brain region). *p < 
0.05 (two-way ANOVA).    
 
3.3.2 MPH elevates TH and VMAT2 densities 
TH and VMAT2 play key roles in the synthesis and vesicular storage of catecholamines such as 
DA and NA. Acute MPH treatment did not significantly alter TH density in any of the examined 


































nucleus accumbens (F(1,44) = 6.6, p = 0.001), with the density of TH being significantly 
upregulated in this region (p < 0.05) (Figure 3.3). In the parietal cortex, there was a significant 
‘drug’ x ‘duration’ interaction effect (F(1,44) = 7.2, p = 0.02) and a significant effect of ‘drug’ 
(F(1,44) = 4.5, p = 0.04) and ‘duration’ (F(1,44) = 9.1, p = 0.008) and the post-hoc analysis revealed 
MPH-induced increase of TH levels following chronic treatment (p < 0.01) (Figure 3.3). 
 
Figure 3.3: Effect of (A) acute, and (B) chronic MPH treatment on TH protein density.  
TH density was measured in the nucleus accumbens (NAc), frontal cortex (FC), parietal cortex 
(PCx), striatum (DS), and hippocampus (HIP) of adolescent rats. Values represent percentage ± 
S.E.M (n=6 rats/group but two data points from the left and right sides of each brain region). *p < 
0.05, **p < 0.01 (two-way ANOVA).   
 
Similar to the effect of MPH on TH expression, acute MPH treatment had no significant effect on 
VMAT2 expression in any of the investigated regions (Figure 3.4). The two-way ANOVA 
indicated a significant ‘drug’ x ‘duration’ interaction effect (F(1,44) = 8.7, p = 0.005), and a 
significant effect of both ‘drug’ (F(1,44) = 8.2, p = 0.02) and ‘duration’ (F(1,44) = 8.7, p = 0.005) in 
the parietal cortex. The post-hoc analysis indicated that MPH increased VMAT2 protein 
expression in the parietal cortex following chronic treatment (p < 0.01) (Figure 3.4). In contrast, 
there was only a significant effect of ‘drug’ in the accumbens (F(1,43) = 3.5, p = 0.02) and frontal 



































increased VMAT2 expression in the accumbens (p < 0.05) and frontal cortex (p < 0.05) following 
chronic treatment (Figure 3.4). 
 
Figure 3.4: Effect of (A) acute, and (B) chronic MPH treatment on VMAT2 protein density. 
VMAT2 density was measured in the nucleus accumbens (NAc), frontal cortex (FC), parietal 
cortex (PCx), striatum (DS), and hippocampus (HIP) of adolescent rats. Values represent 
percentage ± S.E.M (n=6 rats/group but two data points from the left and right sides of each brain 
region). *p < 0.05, **p < 0.01 (two-way ANOVA).   
 
3.3.3 MPH and D1 receptor expression  
Consistent with the previous findings obtained in this study (i.e. findings on NET, TH and 
VMAT2 expression), acute 2.0 mg/kg MPH treatment had no significant effect on D1 receptor 
expression. However, there was a significant interaction between ‘drug’ x ‘duration’ (F(1,44) = 6.5, 
p = 0.01) and a significant effect of both ‘drug’ (F(1,44) = 2.9, p = 0.02) and ‘duration’ (F(1,44) = 
4.6, p = 0.04) in the parietal cortex, with MPH increasing D1 receptor expression in this region 
following chronic treatment (p < 0.05) (Figure 3.5). Moreover, there was a significant effect of 
‘drug’ (F(1,44) = 4.9, p = 0.03) in the accumbens, with chronic MPH treatment increasing D1 



































Figure 3.5: Effect of (A) acute and (B) chronic MPH treatment on D1 protein density.  
D1 receptor (D1) density was measured in the nucleus accumbens (NAc), frontal cortex (FC), 
parietal cortex (PCx), striatum (DS), and hippocampus (HIP) of adolescent rats. Values represent 
percentage ± S.E.M (n=6 rats/group but two data points from the left and right sides of each brain 
region). *p < 0.05 (two-way ANOVA).   
 
3.3.4 Effects of MPH on whole tissue levels of DA and its metabolites in the striatum and 
frontal cortex  
3.3.4.1 MPH-induced modulation of DA and its metabolites in the striatum 
Here, the lateralised effect of both acute and chronic MPH administration on DA and its 
metabolite (DOPAC and HVA) levels were investigated and analysed using three- and two-way 
ANOVAs. In the striatum, acute MPH treatment did not significantly alter the whole tissue levels 
of DA in the left and right sides compared to their corresponding controls but DA concentration 
in the MPH-treated rats was significantly higher (F(1,20) = 20.7, p < 0.001) in the left compared to 
the right side (i.e. ‘hemisphere effect’; Figure 3.6). In comparison, DA levels were significantly 
increased by chronic MPH treatment (F(1,20) = 4.85, p = 0.03) in the left striatum compared to 
controls (Figure 3.6). Comparison of the acute and chronic MPH-treated samples revealed a 
significant effect of ‘duration’ (F(1,20) = 11.7, p < 0.001), resulting from the potent drug effect on 
the chronic samples relative to the acute samples. The concentrations of DA, its metabolites and 










































































Figure 3.6: DA concentration in the left (LB) and right (RB) hemispheres of the striatum.  
Box plots showing DA concentration in the striatum (DS) was measured following (A) acute, and 
(B) chronic MPH treatment using HPLC-EC. Each box shows the 25th and 75th percentiles, the 
‘whiskers’ show the 10th and 90th percentile, while the solid line inside the box shows the median. 
###p < 0.001 (significant hemisphere effect i.e. left MPH-treated vs. right MPH-treated group), 
*p < 0.05 (MPH-treated vs. control). 
 
Unlike DA, no significant effects of ‘drug’ and ‘hemisphere’ were observed on DOPAC and 
HVA levels. However, while no significant changes were observed in the acute group, in the 
chronic group DA turnover, i.e. DOPAC/DA ratio was significantly influenced by ‘hemisphere’ 
(F(1,20) = 7.11, p = 0.01), with the ratio being higher in left striatum of the control group than the 
right (p < 0.05). A significant effect of ‘hemisphere’ (F(1,20) = 5.86, p = 0.02) on HVA/DA ratio 
was also recorded following acute treatment with no changes observed after chronic treatment. 
Pairwise comparisons indicate a higher HVA/DA turnover ratio in the right acute MPH-treated 








Table 3.1: DA and its metabolite levels in the striatum following acute and chronic MPH 
treatment 
  Acute  Chronic 
Striatum Brain 
region 
Control MPH  Control MPH  
DA (µg/g) Left 1.22 ± 0.06 1.30 ± 0.05# 1.62 ± 0.06 1.92 ± 0.08* 
 Right 1.08 ± 0.05 0.99 ± 0.03 1.82 ± 0.05 1.85 ± 0.09 
DOPAC (µg/g) Left 0.10 ± 0.01 0.12 ± 0.02 0.13 ± 0.007 0.14 ± 0.01 
 Right 0.11 ± 0.01 0.09 ± 0.01  0.13 ± 0.007 0.13 ± 0.009 
HVA (µg/g) Left 0.045 ± 0.004 0.051 ± 0.006 0.040 ± 0.003 0.037 ± 0.006 
 Right 0.049 ± 0.004 0.052 ± 0.004 0.042 ± 0.003 0.044 ± 0.002 
DOPAC/DA Left 0.0846 ± 0.005 0.09295 ± 0.01 0.0797 ± 0.004# 0.0732 ± 0.002 
 Right 0.0997 ± 0.003 0.0974 ± 0.008 0.0686 ± 0.002 0.0680 ± 0.001 
HVA/DA Left 0.0370 ± 0.003 0.0392 ± 0.005 0.0227 ± 0.001 0.0195 ± 0.003 
 Right 0.0453 ± 0.004 0.0537 ± 0.005# 0.0231 ± 0.001 0.0242 ± 0.001 
Values (mean ± SEM, n=6 rats/group) were determined using HPLC-EC. *p < 0.05 (significant 
effect of ‘drug’ i.e. MPH vs. control), #p < 0.05 (significant ‘hemisphere effect’ i.e. left vs. right 
hemisphere). 
 
3.3.4.2 MPH-induced modulation of DA and its metabolites in the frontal cortex 
In the frontal cortex, there was a significant ‘drug’ x ‘hemisphere’ interaction (F(1,20) = 4.64, p = 
0.04) and significant effects of both ‘drug’ (F(1,20) = 15.5, p < 0.001) and ‘hemisphere’ (F(1,20) = 
17.7 p < 0.001) influencing DA levels following acute MPH treatment. The post-hoc 
comparisons indicated that MPH induced a significant increase of DA levels in both the left (p < 
0.001) and right (p < 0.05) sides following acute MPH administration in comparison to the 
controls (Figure 3.7). After chronic MPH treatment, significant effects of ‘drug’ (F(1,20) = 11.1, p 
= 0.003) and ‘hemisphere’ (F(1,20) = 3.64, p = 0.05) were observed to be influencing DA levels, 
with the levels being significantly increased by MPH in the left side (p < 0.01) but not the right 
side (Figure 3.7). The concentrations of DA, its metabolites and the turnover ratios in the frontal 
















































Figure 3.7: DA concentration in the left (LB) and right (RB) hemispheres of frontal cortex. 
Box plots showing DA concentration in the frontal cortex (FC) was measured following (A) 
acute, and (B) chronic MPH treatment using HPLC-EC. Each box shows the 25th and 75th 
percentiles, the ‘whiskers’ show the 10th and 90th percentile, while the solid line inside the box 
shows the median. #p < 0.05, ###p < 0.001 (significant ‘hemisphere effect’ i.e. left MPH-treated 
vs. right MPH-treated group), *p < 0.05, **p < 0.01, ***p < 0.001 (MPH-treated vs. control). 
 
With regards to DOPAC levels in the frontal cortex, there was a significant effect of ‘drug’ (F(1,20) 
= 15.9, p < 0.001) after acute treatment, with the levels being increased in both the left (p < 0.01) 
and right (p < 0.05) sides of the MPH-treated groups relative to the controls (Table 3.2). In the 
chronic samples, a significant effect of ‘hemisphere’ (F(1,20) = 3.64, p = 0.04) was observed, with 
the levels being higher in the left hemisphere relative to the right (p < 0.05) of the control groups. 
Moreover, a ‘drug’ x ‘duration’ ANOVA analysis showed a significant effect of ‘duration’ (F(1,20) 
= 6.61, p = 0.018) to be influencing cortical DOPAC levels. In addition, a significant ‘drug’ 
(F(1,20) = 22.7, p < 0.001) and ‘hemisphere’ (F(1,20) = 16.09, p < 0.001) effect on cortical HVA 
levels were also observed following acute treatment but not chronic treatment. The post-hoc 
analysis revealed high cortical HVA levels in the left (p < 0.05) and right (p < 0.05) MPH-treated 
groups compared to the controls (Table 3.2). Also, chronic MPH treatment significantly 
decreased (F(1,20) = 5.69, p = 0.027) DA turnover as measured by DOPAC/DA ratio, in the left 
cortical hemisphere (p < 0.05). Similarly, both acute (F(1,20) = 50.5, p < 0.001) and chronic (F(1,20) 
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= 4.84, p = 0.039) MPH treatment significantly decreased HVA/DA ratio in the left side of both 
control and drug-treated groups (p < 0.01) relative to the right side (i.e. ‘hemisphere effect’). 
Table 3.2: DA and its metabolite levels in in the frontal cortex following acute and chronic MPH 
treatment 
   Acute    Chronic 
Frontal cortex Brain 
region 
Control MPH  Control MPH  
DA (µg/g) Left 0.057 ± 0.004 0.098 ± 0.01*** 0.068 ± 0.004 0.105 ± 0.01** 
 Right 0.043 ± 0.001 0.055 ± 0.004* 0.064 ± 0.006 0.079 ± 0.007# 
DOPAC (µg/g) Left 0.004 ± 0.0001 0.010 ± 0.001** 0.0124 ± 0.004# 0.0124 ± 0.008 
 Right 0.004 ± 0.0004 0.006 ± 0.0004* 0.0082 ± 0.0008 0.0084 ± 0.0007 
HVA (µg/g) Left 0.023 ± 0.0002 0.029 ± 0.001* 0.0276 ± 0.001 0.0298 ± 0.001 
 Right 0.029 ± 0.0005 0.036 ± 0.002* 0.0284 ± 0.002 0.0319 ± 0.001 
DOPAC/DA Left 0.076 ± 0.05 0.115 ± 0.02 0.175 ± 0.01 0.124 ± 0.01* 
 Right 0.097 ± 0.01 0.113 ± 0.01 0.142 ± 0.02 0.109 ± 0.01 
HVA/DA Left 0.428 ± 0.03 0.324 ± 0.03 0.328 ± 0.07 0.308 ± 0.05 
 Right 0.666 ± 0.03## 0.674 ± 0.05## 0.472 ± 0.05## 0.425 ± 0.05## 
Values (mean ± SEM, n=6 rats/group) were determined using HPLC-EC. *p < 0.05, **p < 0.01, 
***p < 0.001 (significant effect of ‘drug’ i.e. MPH vs. control); #p < 0.05, ##p < 0.05 (significant 
‘hemisphere effect’ i.e. left vs. right hemisphere). 
 
3.3.5 Effects of MPH on extracellular DA and DOPAC levels in the striatum  
3.3.5.1 Baseline extracellular DA levels 
The baseline levels (i.e. levels before MPH injection) of DA in dialysates collected from the 
striatum did not differ significantly (p = 0.312; Students t-test) between saline (1.79 ± 0.41 
ng/ml) and MPH-treated (1.78 ± 0.76 ng/ml) animals. The basal level of DA in striatal samples 
reported in this study is comparable, albeit slightly higher (1.79 ng/ml in this study vs. 1.09 ng/ml 
in the study by Sharp et al. 1986) to previously reported striatal DA levels in adult rats. This 
difference could be attributed to several factors including the different types of dialysis probes, 
the anaesthesia used, or the age of the rats used (i.e. adolescent rats used in the present study vs. 
the adult rats used by Sharp et al. 1986).  
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3.3.5.2 Drug-induced extracellular DA and DOPAC levels  
Dialysates collected from the 5.0 mg/kg MPH-treated animals (n=6 rats/group) showed increased 
levels of DA, compared to the samples collected from the corresponding saline-treated controls 
(Figure 3.8), with a maximum level post-MPH treatment average of 3.99 ± 1.1 ng/ml at 20 min 
after the injection. The two-way repeated ANOVA revealed significant ‘drug’ x ‘time’ interaction 
(F(8, 80) = 3.108, p = 0.004) and significant effect of ‘drug’  (F(1, 80) = 5.197, p = 0.002) on DA 
levels. The Bonferroni post-hoc test showed this difference to be at time points, 20 min (p < 0.01) 
and 40 min (p < 0.02) after drug injection (Figure 3.8A). In contrast, there was no significant 
effect of MPH treatment on DOPAC levels in striatal dialysates, although there appeared to be a 
trend towards decreased DOPAC levels after drug treatment (Figure 3.8B). 
 
Figure 3.8: (A) DA, and (B) DOPAC concentrations in the striatum.  
DA and DOPAC concentrations were measured following acute 5.0 mg/kg MPH or saline 
treatment. Values represent percentage of baseline values (i.e. time point 0; representing 100%) ± 
S.E.M (n=6 rats/group). *p < 0.05, **p < 0.01 (MPH-treated vs. control). 
 
3.3.5.3 Hemisphere-specific effects of MPH on extracellular DA and DOPAC in the striatum 
The two-way repeated ANOVA of ‘drug’ x ‘time’ revealed a significant effect of ‘drug’ 
treatment at the time point 40 min (F(1, 8) = 6.017, p = 0.039) on striatal DA concentration in the 
left striatum (i.e. MPH increased striatal DA 40 min after injection in the left side; n=3) (see 
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Figure 3.9A). Conversely, there were no significant changes observed in the right striatum 
(Figure 3.9B). Also, there was no significant effect of ‘drug’ treatment on DOPAC levels in both 
the left and right hemispheres.  
 
Figure 3.9: DA levels in the (A) left, and (B) right striatum.  
DA levels were measured following saline or acute MPH treatment. Values represent percentage 
of baseline values (i.e. time point 0; representing 100%) ± SEM (n=3 rats/group). *p < 0.05 
(MPH-treated vs. control); statistical power = 0.943 (G*Power, version 3.1).   
 
3.4 Discussion 
3.4.1 Principal findings and MPH dosing 
The present chapter describes the effects of acute and chronic MPH treatment on the expression 
of protein targets involved in monoamine synthesis and release (i.e. TH and VMAT2), DA and 
NA uptake (i.e. DAT and NET) and the DA D1 receptor. These measurements were done in brain 
regions implicated in the symptoms of ADHD including: the nucleus accumbens, frontal cortex, 
parietal cortex, striatum, and hippocampus. In addition, this chapter examined the acute and 
chronic effect of MPH on whole tissue levels of DA and its metabolites DOPAC and HVA, as 
well as its acute effect on extracellular levels of striatal DA and DOPAC using in vivo 
microdialysis.  
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The study shows that MPH induced upregulations of DAT, NET, TH, VMAT2, and D1 receptor 
in the investigated brain regions in a ‘treatment duration’ dependent manner. Apart from DAT 
which was upregulated in the nucleus accumbens after both acute and chronic treatment, the 
significant protein upregulations were all recorded following chronic treatment but not acute 
treatment. There were also marked regional variations (i.e. brain region-specific effects) 
associated with the enhanced protein expressions recorded in the examined brain regions. 
Significant upregulations of all the examined monoaminergic protein targets were found in the 
nucleus accumbens, while the hippocampus failed to show any significant changes. Data from 
these studies also revealed that acute MPH treatment increased whole tissue levels of DA in the 
frontal cortex, while chronic treatment increased whole tissue levels of DA in both the frontal 
cortex and striatum, with the changes being more prominent in the left sides of these brain 
regions. Further, extracellular DA levels were increased by acute MPH treatment in the striatum, 
with the increase also being more prominent in the left side. This dominating effects of MPH on 
the left sides of these brain regions appear to be consistent with another study on humans 
suggesting that MPH may have more pronounced effects on neurochemicals in the left sides of 
the brain (Ben Amor 2014).  
In these sets of experiments, 2.0 mg/kg and 5.0 mg/kg MPH doses were used. High doses of 
psychostimulants (e.g. 10.0 mg/kg) are reported to impair cognition and induce prominent 
reinforcing and locomotor-activating functions (Arnsten 2009). In contrast, at low and clinically 
relevant doses, these drugs are without the locomotor-activating effects and rather reduce 
movement (hyperactivity) and impulsivity, while improving cognitive functions such as working 
memory and sustained attention (Solanto 1998). MPH doses (i.e. 2.0 mg/kg and 5.0 mg/kg) used 
in the current studies have been previously estimated to yield peak plasma levels (8-40 ng/ml) 
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that are associated with clinical efficacy in humans (Berridge et al. 2006; Kuczenski and Segal 
2002; Swanson and Volkow 2003). While 5.0 mg/kg i.p MPH treatment may seem moderately 
high, in rodents it has been shown to maintain drug levels within the therapeutic range over a 
longer period (> 30 minutes) compared to much lower doses (Kuczenski and Segal 2005). 
Overall, these doses improve sustained attention and working memory in rats (Berridge et al. 
2006; Kuczenski and Segal 2002).  
3.4.2 Effect of MPH on dopamine and noradrenaline transporters 
There appears to be some support for the hypothesis that catecholamine dysregulation in the 
frontostriatal circuit is the main factor underlying ADHD symptoms (Spencer et al. 2005; 
Volkow et al. 1998; Volkow et al. 2009). The catecholamines, DA and NA play central roles in 
executive functioning, reward-seeking behaviour and motor activity. DAT and NET are key 
regulators of DA and NA function respectively, making them critical targets in studies on 
ADHD. Here, the effects of acute and chronic MPH treatment on these transporters have been 
assessed. 
3.4.3 MPH induced DAT overexpression 
DAT remains a major target for stimulant medications and has therefore been the focus of several 
neuroimaging studies in ADHD patients. Despite being the focus of several ADHD studies, 
however, findings on DAT have been inconsistent. While some initial studies observed elevated 
striatal DAT in ADHD patients (Cheon et al. 2003; Dougherty et al. 1999; Spencer et al. 2005), 
other recent studies have reported significant decreases of the transporter in some medication 
naïve patients (Volkow et al. 2009; Volkow et al. 2007b; Volkow et al. 2007a). The DAT 
hypothesis in ADHD stems from the fact that administering DAT blockers such as amphetamine 
(also a DA releasing agent) and MPH ensures an increase in extracellular DA levels in some 
	117	
brain regions (e.g. frontal cortex and striatum), resulting in the enhancement of the brain’s 
executive functions, which is underactive in ADHD patients (Del Campo et al. 2011).  
In this study, we report that while acute MPH treatment showed a trend towards decreased DAT 
levels in the striatum, there was a significant increase of DAT in the nucleus accumbens (Figure 
3.1). Following chronic 2.0 mg/kg MPH treatment, however, DAT density in both the striatum 
and accumbens was significantly elevated (Figure 3.1). These findings emphasise the importance 
of the accumbens and striatum in the mechanism of action of MPH, especially as these regions 
are reported to have abnormal DAT levels in ADHD patients (Spencer et al. 2005). 
Abnormalities in the striatum and accumbens are linked with cognitive/motor dysfunctions and 
altered reward-seeking behaviour in both humans and rodents. Indeed, a previous MRI study 
demonstrated improper striatal activation in ADHD patients (Vaidya et al. 2005).  
The present finding of elevated DAT in the accumbens following MPH treatment is supported by 
a recent clinical study which also observed DAT upregulation in the accumbens following long-
term MPH therapy (Wang et al. 2013). In line with the present findings, clinical studies on other 
psychostimulants such as cocaine (a DAT blocking drug) have also reported upregulated striatal 
DAT expression in chronic users of the drug compared with controls (Little et al. 1999). MPH is 
known to block DAT, which increases the extracellular levels of DA. However, presynaptic DAT 
levels are in turn regulated by extracellular DA levels, with DAT levels decreasing when 
extracellular DA levels are low and increasing when extracellular levels are high (Zahniser and 
Sorkin 2004). In ADHD, it is hypothesised that elevated DAT could be a ‘trait’ or a ‘state’ 
(Spencer et al. 2007). A ‘trait’ could be as result of ‘hypertrophy’ of dopaminergic neurons or 
dendritic trees arising from abnormalities in the DAT gene or inadequate pruning during 
neurodevelopment. A ‘state’, on the other hand, may arise from neuroadaptive processes to 
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compensate for altered DA transmission (Spencer et al. 2007). Based on the present findings and 
emerging findings from literature therefore, it is possible that the increased DAT density 
observed in the accumbens and striatum reflect an adaptational response to prolonged stimulant 
(i.e. chronic MPH) treatment. Thus, it is hypothesised that the upregulated DAT observed in the 
present study could be a response to elevated extracellular DA levels. In support of this 
hypothesis, the present study also shows increased extracellular levels of DA in the striatum 
following acute MPH treatment (Figure 3.8). Additional support for this hypothesis comes from 
previous studies that have shown that both acute and chronic MPH treatment increase 
extracellular DA levels in the striatum and accumbens, as well as in other brain regions such as 
the cortex and midbrain (e.g. VTA and SN) of rats (Calipari et al. 2014; Calipari and Jones 2014; 
Koda et al. 2010; Wagner et al. 2009). This idea of a neuroadaptative increase of DAT is 
consistent with previous studies that have shown that MPH is effective in the short-term but that 
its long-term clinical effectiveness may be limited, as larger doses may be required to ensure 
clinical effectiveness, and the long-term effectiveness waning after years of medication i.e. 
increased DAT levels require higher drug doses to reach functional blockade of DAT (Hazell 
2011; Wang et al. 2013). 
3.4.4 MPH induced NET overexpression 
Beside DAT, MPH has also been shown to block NET. Reports from several studies indicate that 
clinical doses of MPH significantly block NET in the cortex, increasing extracellular levels of 
NA (Berridge et al. 2006; Hannestad et al. 2010). Clinical doses of MPH have also been shown 
to preferentially increase extracellular DA and NA levels in the cortex relative to the subcortical 
areas (Berridge et al. 2006; Kuczenski and Segal 2002). Moderate extracellular levels of NA in 
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the cortex stimulate α2–adrenergic receptors and improves attention, while extracellular DA acts 
on D1 receptors to regulate working memory, attention, and behaviour (Arnsten 2009).  
In the present study, while acute MPH treatment had no significant effects on NET density in the 
investigated brain regions, chronic MPH treatment increased NET density in the accumbens and 
parietal cortex (Figure 3.2). This finding is in line with existing studies highlighting the 
importance of NET and the noradrenergic system in the mechanism of action of MPH. While no 
studies have, to our knowledge, examined the effects of chronic MPH treatment on NET density, 
studies on the transporter following chronic cocaine (which is also a DAT and NET blocker) 
administration have revealed significant upregulations of the transporter in the thalamic area 
(Beveridge et al. 2005; Macey et al. 2003). It is conceivable that similar to DAT, the levels of 
NET could vary as a function of its substrate, NA. Therefore, the increased NET density in the 
parietal cortex and accumbens provides an additional support that repeated MPH treatment 
elevates transporter levels (i.e. DAT and NET), thereby regulating the extracellular levels of 
catecholamines. Indeed, NET blockade by MPH has been shown to increase extracellular NA 
(Berridge et al. 2006; Kuczenski and Segal 2002). Thus, an upregulation of both NET and DAT, 
emphasise the idea that the long-term efficacy of MPH may be limited. However, further clinical 
studies are required to confirm this finding on NET. 
3.4.5 Effect of MPH on tyrosine hydroxylase and the vesicular transporter 
Catecholamines such as DA and NA are synthesised from tyrosine. TH catalyses the rate-limiting 
step in the synthesis of these catecholamines. Specifically, TH catalyses the hydroxylation of L-
tyrosine to dihidroxyphenylalanine (L-DOPA) (Fossbakk et al. 2014). Given that the activity of 
TH is the slowest in the catecholamine synthesis pathway (i.e. rate-limiting), this enzyme is of 
major interest in ADHD research and its treatment. VMAT2 is also an important regulator of 
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intraneuronal catecholamine concentrations, as this protein transports the synthesised DA into 
synaptic vesicles, thereby preventing the cytoplasmic breakdown of DA by monoamine oxidase 
and therefore contributes to the amount of this neurotransmitter that is stored and subsequently 
released via exocytosis.  
3.4.6 MPH induces an overexpression of TH 
When catecholamine levels are low in the catecholaminergic synapse (e.g. during excessive 
uptake via DAT and NET), autoreceptor mediated feedback inhibition of catecholamine synthesis 
is reduced and TH is activated to produce more DOPA, which is then decarboxylated into DA 
and transferred into synaptic vesicles by VMAT2 (Daubner et al. 2011). An influx of Ca2+ into 
the presynaptic terminal results in the emptying of the content of the vesicles into the synaptic 
cleft (Daubner et al. 2011). We initially postulated that if MPH elevates whole tissue and 
extracellular levels of DA, the changes might be explained by alterations in TH expression.  
In the present study, we report that acute MPH treatment does not alter TH levels significantly in 
any of the investigated brain regions. However, chronic MPH treatment significantly elevates TH 
expression in the nucleus accumbens and the parietal cortex (Figure 3.3). This finding is in line 
with a recent study reported increased TH densities in the core and shell of the nucleus 
accumbens following chronic MPH exposure to young rats (Lepelletier et al. 2015). That TH 
levels in the striatum and the other brain regions were not significantly altered is also consistent 
with a previous study that found no changes in either the mRNA or the protein levels of TH in the 
striatum and some other brain regions (e.g. VTA) following chronic MPH treatment in rats 
(Calipari et al. 2014). Given that MPH treatment failed to enhance TH expression in striatum and 
frontal cortex, it is unlikely that the measured increase of whole tissue levels of DA by MPH 
treatment in these brain regions is related to increased TH expression (see Figures 3.6 and 3.7).   
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3.4.7 MPH induced VMAT2 overexpression 
VMAT2 has historically been considered as one of the markers of monoaminergic (including 
dopaminergic and noradrenergic) neuronal integrity. This has particularly been the case in 
disorders that result in the loss dopaminergic neurons such as Parkinson’s disease. In this disorder 
VMAT2 levels are significantly lower compared to healthy volunteers (Pifl et al. 2014). Studies 
on transgenic VMAT2 knockout mice have demonstrated that impulse-dependent DA release is 
significantly lower compared to wild type mice, while VMAT2 over-expressing mice show 
increased intracellular DA concentration and DA release relative to controls (Lohr et al. 2014). 
Furthermore, psychostimulant (e.g. amphetamine) induced increases of extracellular DA is 
significantly dampened in VMAT2 knockout animals relative to controls (Patel et al. 2003). 
Given the MPH-induced increase of TH in the accumbens and parietal cortex following chronic 
MPH treatment, it was hypothesised that such increases in TH may be associated with a 
corresponding increase of VMAT2 in these brain regions.  
In this study, we report that acute MPH treatment does not significantly alter VMAT2 density in 
any of the brain regions investigated. In comparison, chronic MPH treatment (2.0 mg/kg) induced 
a significant increase of VMAT2 in the nucleus accumbens, frontal cortex and parietal cortex 
(Figure 3.4). Thus, these findings point to ‘treatment duration-dependent’ differences in the 
mechanism of action of MPH regarding this transporter. Elevated VMAT2 density in the parietal 
cortex and nucleus accumbens following chronic MPH treatment correspond with our finding of 
increased TH density in these brain regions. Overall, this provides more support for a potential 
enhancement of DA synthesis, requiring increased vesicular storage capacity, which would be 
aided by the enhanced VMAT2 expression. In addition, like TH, no significant changes in 
VMAT2 density was recorded in the striatum, and this appears to be in line with a previous study 
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in SHR rats that also showed that chronic MPH treatment failed to alter striatal VMAT2 protein 
expression (Simchon et al. 2010). However, in contrast to our findings in the striatum following 
acute treatment, a previous study has reported an increase in striatal VMAT2 density following 
acute MPH treatment (Sandoval et al. 2002). The difference in findings could be related to the 
difference in response to MPH treatment by animals of different ages (180-220 g animals were 
used in the present study vs. 280-340 g used in the study by Sandoval et al. 2002), as well as the 
differences in dosing regimen (2.0 mg/kg in this study vs. 1.0 mg/kg in their study). 
In general, two types of presynaptic vesicles have been described: a membrane associated 
fraction and a cytoplasmic fraction (Sandoval et al. 2002). Interestingly, some researchers have 
proposed that MPH treatment redistributes VMAT2 protein from the membrane associated 
vesicle fraction to the cytoplasmic vesicle fraction, leading to an increase in VMAT2 density and 
an increase in vesicular DA content in the cytoplasmic fraction (Fleckenstein et al. 2009). The 
data reported in this study would suggest that any increase in DA (both whole tissue and 
extracellular DA) induced by chronic MPH treatment might be related to the enhanced expression 
of VMAT2, particularly in the cortices and the nucleus accumbens (as TH is also increased in 
these regions). Alternatively, increased VMAT2 density could be due to an increased reuptake of 
DA and NA. In this context, the present study shows that chronic MPH upregulates DAT and 
NET in the nucleus accumbens and parietal cortex respectively, an effect that coincided with the 
increased levels of both VMAT2 and TH. Taken together, an upregulation of these two reuptake 
transporter proteins (i.e. DAT and NET), as well as TH could lead to enhanced cytoplasmic 
catecholamine levels (albeit not measured in the present study for the accumbens and parietal 
cortex), and hence would require enhanced VMAT2 protein expression for transporting the 
neurotransmitters into the vesicles. 
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3.4.8  MPH induced D1 receptor overexpression 
MPH has been shown to improve working memory in both ADHD patients and healthy 
volunteers. As previously mentioned, MPH acts as a DAT and NET blocker, increasing 
extracellular levels of both DA and NA. The increased synaptic levels of these catecholamines 
stimulate postsynaptic receptors. In particular, DA stimulates D1-like and D2-like receptors, 
resulting in behavioural changes such as improved attention and concentration (Arnsten 2009; 
Arnsten 2011).  
In this study, while acute MPH treatment does not significantly alter D1 receptor expression in 
the examined brain regions, chronic MPH treatment significantly elevates the density of this 
receptor in the nucleus accumbens and the parietal cortex (Figure 3.5). This finding may support 
the role of this brain region in attention and memory. Although MPH is thought to have more 
effect on NA than DA in the cortex, it has long been known that DA is essential to the working 
memory functions of the cortex. Recent findings obtained from studies on monkeys indicated that 
MPH improves attention and working memory performance in the cortex by indirectly enhancing 
D1 and α2A receptor actions (Gamo et al. 2010). Other studies on rodents have shown that 
moderately enhanced stimulation of D1 receptors has beneficial outcomes on working memory 
(Arnsten 2009; Arnsten 2011). 
Moderate stimulation of D1 receptor enhances spatial memory by selectively suppressing firing 
to non-preferred inputs i.e. decreases ‘noise’ (Arnsten 2009; Arnsten 2011). Modest stimulation 
of D1 receptor occurs with clinically relevant doses of MPH (as used in the present study), 
however when extremely high doses of MPH (e.g. 10.0 mg/kg dose) or when other D1 receptor 
agonists are administered it suppresses all neuronal firing, impairing working memory (Arnsten 
2009; Arnsten 2011). Given that previous studies have shown increased DA release and increased 
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extracellular DA in the cortex and other brain regions following both acute and chronic MPH 
exposure (Calipari et al. 2014; Calipari and Jones 2014; Koda et al. 2010; Wagner et al. 2009), it 
is hypothesised that the increased extracellular DA in the cortex could activate the upregulated 
cortical D1 receptor (observed in the present study) and its signalling pathway in the cortex and 
possibly improve working memory (Gamo et al. 2010). Activation of the upregulated D1 receptor 
and its signalling pathway in the nucleus accumbens by extracellular DA could, on the other 
hand, have effects on drug-seeking behaviour and drug-induced long-term plasticity (Fricks-
Gleason and Marshall 2011; Gong et al. 1999).  
3.4.9 Lateralised effect of MPH on DA and its metabolites 
Similar to a previous report, analysis of the data on whole tissue levels of striatal DA following 
acute (2.0 mg/kg) MPH treatment revealed no significant effect of MPH (Schaefer et al. 2006). 
However, there was a trend towards an increased whole tissue DA level in the left striatum 
(Figure 3.6). Further evaluation of the effect of acute MPH administration in the striatum 
examined via in vivo microdialysis (single 5.0 mg/kg MPH) revealed significantly elevated 
extracellular DA levels in the striatum, but not its main metabolite DOPAC (Figure 3.8). This 
increase in extracellular DA was more pronounced in the left side of the striatum (albeit a small 
sample size, n=3 rats/hemisphere). Similar enhancements of DA levels following acute MPH 
treatment has consistently been reported in both preclinical and clinical studies (Berridge et al. 
2006; Kuczenski and Segal 2002; Swanson and Volkow 2003). Indeed, a number of studies have 
suggested a role for striatal DA in the stimulant treatment of ADHD (Volkow et al. 2001; Wang 
et al. 2013). Other studies have also observed a significant increase of DA in the 
mesocorticolimbic pathway following acute MPH administration to rats (Kuczenski and Segal 
2002) and adult human volunteers (Volkow et al. 2001). In the present study, acute MPH 
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treatment induced significant increases in extracellular DA levels 20 min and 40 min after drug 
administration (Figure 3.8). This finding is consistent with other studies using similar MPH doses 
that also observed increases in extracellular DA levels at these time points in the striatum, 
accumbens and other regions in the mesocorticolimbic pathway (Kuczenski and Segal 2002; 
Schiffer et al. 2006).  
On the other hand, after chronic MPH treatment, whole tissue levels of DA were significantly 
elevated in the left but not the right striatum (Figure 3.6). This elevated whole tissue levels of 
striatal DA is unlikely to be driven by altered TH, as striatal TH was not increased by chronic 
MPH administration in this region. However, DAT was increased by chronic MPH treatment in 
the striatum suggesting an enhanced reuptake of DA back into DA nerve terminal. The 
DOPAC/DA and HVA/DA ratios are frequently used as indicators of dopaminergic activity 
(Lavielle et al. 1979). In addition to the elevated whole tissue levels of DA in the striatum, there 
was a significant increase in the DOPAC/DA ratio in the left striatum (‘hemisphere effect’) but 
not in the right side (Table 3.1), further suggesting an enhanced dopaminergic activity in the left 
striatal area. The increase of whole tissue DA levels in the striatum of genetically unmodified 
(i.e. normal) animals following chronic MPH treatment in the present study is not consistent with 
findings from a previous study on ‘Naples High excitability rats’ that showed decreased whole 
tissue striatal DA and DOPAC levels following chronic drug treatment (Ruocco et al. 2010). The 
differences in findings could be due to the type of rats used, as the ‘Naples High excitability rats’ 
have been shown to have abnormal mesocortical dopamine function (due to abnormal levels of 
DAT, TH, and D1 receptor) and are not hyperactive or impulsive and are therefore not considered 
to satisfy the criteria for animal models of ADHD (Russell et al. 2005). In addition, although the 
extracellular levels of striatal DA after chronic treatment was not measured in the present study, 
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several studies have previously found increased extracellular DA concentrations in the striatum, 
accumbens, and other brain regions following repeated MPH treatment (Calipari et al. 2014; 
Calipari and Jones 2014; Koda et al. 2010; Wagner et al. 2009). 
A dysfunction of the left striatum is considered to be a core abnormality in ADHD (Vaidya et al. 
2005). In particular, while some studies have shown improper activation of the striatum in 
ADHD patients, other studies have reported that individuals suffering from left striatal lesions 
have deficits in attention and executive function (Vaidya et al. 2005; Benke et al. 2003). 
Therefore, an MPH-induced increase of DA levels in the left striatum may be critical to the 
normalisation of striatal functions. In addition, the non-significant changes to the levels of 
DOPAC and HVA by MPH in the present study is comparable to findings from some previous 
studies (Panos et al. 2014; Nielsen et al. 1983). 
Unlike the changes in the striatum, both acute and chronic MPH treatment increased the whole 
tissue levels of DA and its metabolites (DOPAC and HVA) in the frontal cortex (Table 3.2). 
Further evaluation showed that although the increase in cortical DA occured in both the left and 
right sides, the left cortical DA increase was more pronounced (Figure 3.7). The frontal cortex is 
suggested to play important roles in the processes that have been implicated in ADHD 
(Kuczenski and Segal 2002; Arnsten 2009). For instance, functional imaging studies have found 
an under-activation of several areas of the cortex including the frontal and parietal areas in 
ADHD patients during tasks related to attention and motor activity (Dickstein et al. 2006; Rubia 
et al. 1999; Vance et al. 2007). This under-activation is suggested to be particularly prominent in 
the right cortex (Rubia et al. 1999; Vance et al. 2007). However, in the present study, although 
both acute and chronic MPH treatment increased whole tissue levels of DA in the frontal cortex, 
the increase was much more prominent in the left side. The present finding is consistent with a 
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previous clinical study which has also shown that MPH may have a more pronounced effect on 
neurochemicals in the left frontal cortex and left striatum (Ben Amor 2014). The increase of 
whole tissue levels of DA in the frontal cortex is unlikely to be related to TH density, as both 
acute and chronic MPH treatment did not significantly alter TH levels. Catecholamines 
(including DA and NA) exert pronounced modulatory actions on cortical neuronal activity and 
cortex-dependent behaviour, including attention and working memory (Arnsten 2009). Although 
the extracellular levels of DA in the frontal cortex following acute and chronic MPH treatment 
were not measured in the present study, previous studies have reported increased extracellular 
DA in this region following MPH treatment (Berridge et al. 2006; Kuczenski and Segal 2002). If 
the present finding of elevated whole tissue levels of DA in the frontal cortex correlates with an 
increased extracellular DA (as shown previously by other researchers), it would activate the 
enhanced cortical D1 receptor density and aid in the improvement of working memory and 
sustained attention (Berridge et al. 2006; Kuczenski and Segal 2002). 
3.5 Conclusion 
The current study shows that both acute and chronic MPH treatment increases whole tissue levels 
of DA in the frontal cortex and the striatum, with the effect being more pronounced in the left 
side of both regions. Further evaluation revealed increased extracellular DA in the striatum after 
acute MPH treatment, also more prominent in the left side. These changes in DA levels, 
particularly in the frontal cortex, coincided with increased D1 receptor levels recorded in the 
cortex (both frontal and parietal). Further evaluation of the protein markers showed increased 
expression of TH and VMAT2 in the frontal and parietal cortex, and nucleus accumbens after 
chronic but not acute MPH treatment. Interestingly, chronic MPH treatment increased the density 
of DAT in the nucleus accumbens and striatum and increased NET density in the nucleus 
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accumbens and parietal cortex. Given that DAT and NET increase DA and NA reuptake 
respectively, the increase of these two protein targets by chronic MPH treatment indicates that the 
long-term effects of the drug could be limited, as larger doses may be required to block the 
overexpressed DAT and NET in order to achieve clinical effectiveness. In addition, although 
ADHD is suggested to be a right hemisphere disorder due to studies showing right cortical 
(frontal and parietal) under-activation in patients (Rubia et al. 1999; Vance et al. 2007), the 
present findings indicate that MPH may have more pronounced effect on DA systems in the left 
frontal cortex as opposed to the right side. Further investigations may establish the clinical 




























































Along with the dysfunctional dopaminergic and noradrenergic systems postulated to be 
underlying the pathophysiology of ADHD, there are neurochemical theories suggesting that 
alterations to more global brain biomolecules such as glutamate, glutamine, GABA and creatine 
may also be associated with ADHD (Jin et al. 2001; Moore et al. 2006; Carrey et al. 2007; Perlov 
et al. 2009). However, despite these observed metabolic changes in ADHD patients, the impact 
of MPH treatment on most of these biochemicals in the brain remains to be determined. 
Anatomical theories of ADHD indicate a reduced size of the corpus callosum, which leads to 
insufficient transmission between the two cerebral hemispheres. Some studies also suggest a right 
hemisphere dysfunction amongst ADHD children (Waldie and Hausmann 2010). This hypothesis 
is supported by the fact that the symptoms of ADHD are similar to those observed in patients 
with right parietal lobe lesions (Voeller and Heilman 1988). More recent brain imaging studies 
also link the behavioural symptoms of ADHD to the smaller and less activated anterior regions of 
the right cerebral hemisphere relative to the left hemisphere (Stefanatos and Wasserstein 2001). 
Therefore, in order to identify any potential hemisphere-specific differences involved in the 
mechanism of action of MPH, samples from both the left and right cerebral hemispheres were 
investigated in the present study.  
The symptoms of ADHD are successfully treated with the psychostimulant MPH, which blocks 
the re-uptake of transporter proteins for both dopamine and noradrenaline, thereby increasing the 
transmission of these neurotransmitters in the synaptic cleft (Volkow et al. 1998; Kuczenski and 
Segal 2002). With an increasing rate of ADHD diagnosis worldwide, a sharp rise in the number 
of prescriptions of MPH to young children and adolescents has been recorded (Rabiner 2013), 
despite an incomplete understanding of the drug’s effects on the adolescent brain. Non-stimulant 
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alternative treatments, such as the noradrenaline re-uptake inhibitor atomoxetine, are also often 
prescribed (Warrer et al. 2016), and more recently, administration of the aromatic amino acid, 
tyrosine, a precursor of dopamine and noradrenaline, has also been tested and shown to be 
effective (Hinz et al. 2011). Alternatively, the use of exercise as a non-drug treatment paradigm 
is also recently gaining increasing support, both alone and in combination with MPH (Choi et al. 
2015).  
In humans, metabolomics-type studies employing proton magnetic resonance spectroscopy (1H-
MRS) is increasingly used for the study of psychiatric disorders and their treatments, including 
schizophrenia (Marsman et al. 2014) and bi-polar disorders (Brambilla et al. 2005), together with 
ADHD (Perlov et al. 2007). However, 1H nuclear magnetic resonance (1H-NMR) spectroscopic 
analysis of biofluids and tissues, although related to 1H-MRS, offers higher spectral resolution, in 
addition to more accurate quantification and greater sensitivity, allowing the detection of less 
abundant metabolites, including the neurotransmitter GABA (Du et al. 2015). Indeed, 1H-NMR 
spectroscopy has already been successfully applied to study alterations in human metabolite 
levels in post-mortem tissue and cerebrospinal fluid collected from patients diagnosed with 
various psychiatric and neurological disorders (Prabakaran et al. 2004; Holmes et al. 2006; Lan 
et al. 2008). Notwithstanding, surprisingly few studies have explored drug-inducible metabolic 
changes in human or animal brain tissue using high-resolution 1H-NMR analysis. Drugs already 
investigated using this 1H-NMR-linked metabolomics strategy include lithium ions (Li+), 
antipsychotic drugs and methamphetamine (McLoughlin et al. 2009; Bu et al. 2013). However, to 
the best of our knowledge, this approach has not yet been applied to determine the effects of 
MPH on the brain metabolome.   
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In this study, we have employed, for the first time, a 1H-NMR-based metabolomics approach in 
order to simultaneously explore the effects of MPH on a wide range of brain metabolites in 
adolescent rats. We also sought to determine if MPH influences brain metabolites differently in 
the left and right cerebral hemispheres. The biochemical, therapeutic and physiological 
significance of the research work performed is discussed in detail.     
4.1.1 Aims 
This study was aimed at evaluating the effect of acute MPH treatment on cerebral neurochemistry 
and levels of metabolic markers. The experiment tests the hypothesis that acute MPH treatment 
elevates cerebral metabolites and precursors within the catecholamine synthesis pathway. 
Specifically, the experiment was to assess the effect of the drug on:  
 
§ Large neutral amino acids such as tyrosine and phenylalanine that are involved in 
catecholamine synthesis. 
§ Excitatory and inhibitory amino acid transmitter levels. 
§ Amino acids and biomolecules associated with energy and membrane metabolic 
pathways. 
§ The hypothetical presence of a differential effect on brain metabolites and neurochemicals 
in the left and right cerebral hemispheres. 
4.2 Methods 
4.2.1 Drug treatment and brain dissection 
For a detailed description of the animal housing and MPH treatment procedures see Chapter 2. In 
brief, the animals were assigned to two treatment groups i.e. saline-treated control group and 
drug-treated group. The animals in the saline-treated control group received a single 1.0 ml/kg 
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saline dose, while the animals in the drug-treated group received a single 5.0 mg/kg MPH dose 
intraperitoneally. One hour after the last treatment, the animals were killed via a rapid dislocation 
of the neck and the left and right cerebral hemispheres were dissected out on ice, snap-frozen in 
isopentane on dry ice and stored at -80°C until required for 1H-NMR analysis.  
4.2.2 Preparation of brain extracts and 1H-NMR experiments  
The brain sample preparation and 1H-NMR experiments were performed as described in Chapter 
2, section 2.2.1 and 2.2.3.  
4.2.3 Pre-processing of NMR spectra  
The 1H-NMR spectra acquired were phase and baseline-corrected using ACD/NMR processor 
(academic edition; Ontario, Canada) software prior to the univariate and multivariate data 
analysis. Subsequently, the ‘intelligent-bucketing’ procedure was applied, giving a full dataset of 
71 rows (samples) and 301 columns (variables). The resulting intelligently-selected bucket (ISB) 
integral intensity values were normalised to the TSP signal (s, δ = 0.00 ppm). Spectral regions 
that did not contain any resonances (i.e., noise regions) were edited and removed, so that a final 
dataset of 71 (samples/rows) x 113 (potential predictor ISB variables/columns) was obtained for 
further analysis. The intense δ = 4.65-5.16 ppm residual H2O/HOD signal region was also 
removed from all the 1H-NMR profiles acquired prior to the univariate and multivariate data 
analysis strategies.  
4.2.4 Multivariate and univariate analysis of rat cerebral data 
Multivariate and univariate statistical analyses were performed on the TSP-normalised integral 
values as described in Chapter 2, section 2.2.5. Following the multivariate analysis, the 
performance of the different subsets and combination of discriminatory metabolites selected by 
PLS-DA (as described in section 2.2.5) was further explored using a ROC curve analysis. The 
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ROC curve analysis was conducted using the Biomarker Analysis option available in 
MetaboAnalyst 3.0. The univariate statistical analysis was then carried out in R statistical package 
based on equation 1. 
Yij= µ + Ti + Hj + THij + eij                                                (1) 
In addition, to explore the effect of MPH on the left and right cerebral hemispheres, simultaneous 
multivariate evaluation of the main experimental factors i.e. ‘treatment status’ (i.e. MPH vs. 
control) and ‘brain hemisphere’ (i.e. left vs. right side) was conducted using ANOVA 
simultaneous component analysis (ASCA) via the two-factor independent samples option of 
MetaboAnalyst 3.0 (which is based on equation 1) to detect any significant major metabolic 
patterns arising from each experimental factor, including the multivariate !"#$ interaction 
component of variance. The significance of each of these multivariate variance components was 
determined via associated permutation testing with 2,000 permutations.    
4.2.5 Retrospective multivariate power analysis of the rat cerebral data 
The minimum sample sizes required to achieve multivariate statistical significance between the 
MPH-treated and saline-treated control groups were retrospectively determined by applying the 
‘Power Analysis’ option of MetaboAnalyst 3.0 to a dataset consisting of the 13 key biomarker 
variables discovered via PLS-DA analysis (i.e., GABA, alanine, aspartate, phosphocreatine, 
phosphocholine, hypoxanthine, myo-inositol, glutamate, lysine, taurine, valine, phenylalanine and 
tyrosine; Table 4.1). With an FDR-adjusted p-value of 0.005, predicted multivariate test powers 
of 0.61, 0.86, 0.96, 0.99 and 1.00 were calculated for sample sizes of 3, 6, 10, 16, and 24 per 
group (Figure 4.1), and this clearly confirms that the sample sizes selected for a biomarker 
variable-optimised NMR-linked metabolomics study would indeed be more than sufficient (i.e. 
n=18 rats per group).     
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Figure 4.1: Retrospective multivariate power calculations.  
This was performed for a model incorporating 13 key cerebral biomarker variables for MPH 
treatment status (alanine, aspartate, phosphocreatine, phosphocholine, hypoxanthine, myo-
inositol, GABA, glutamate, lysine, taurine, valine, phenylalanine and tyrosine). 
 
4.2.6 Metabolic pathway analysis of the cerebral dataset  
Analysis of the most relevant cerebral metabolic pathways altered following MPH treatment was 
performed using the MetaboAnalyst 3.0 tool, as described in Chapter 2, section 2.2.7. 
4.3 Results 
4.3.1 1H-NMR profiles of rat brain extracts  
Representative, mean 1H-NMR spectrum acquired on an aqueous cerebral extract from saline-
treated controls and MPH-treated rats spanning spectral regions (a) 0.80-4.50 ppm, and (b) 5.6-
8.9 ppm, are shown in Figure 4.2. These spectra contained a large number of prominent 
resonances assignable to a wide range of low-molecular-mass metabolites, including amino acids 
(e.g., alanine, aspartate, GABA, lysine, tyrosine and phenylalanine), organic acid anions (acetate, 
formate, lactate, etc.), as well as creatine, phosphocreatine, and myo-inositol, together with 
purines and pyrimidines, and their nucleoside adducts (hypoxanthine, inosine, etc.). 
























Figure 4.2: Average 400 MHz 1H-NMR spectra of the cerebral extracts.   
The spectra were obtained from the saline-treated controls (red) and MPH-treated rats (green) (A) 
0.8 to 4.5 ppm, and (B) 5.6-8.9 ppm (resonance intensity amplitude enhanced 20-fold of that of 
(A)] spectral region. Abbreviations: BCAA, branched chain amino acids (valine, isoleucine, 
leucine); GABA, γ-amino butyric acid; NAA, N-acetylaspartate; NAAG, N-
acetylaspartylglutamate; Glu, glutamate; Gln, glutamine; PCr, Phosphocreatine; Chol, choline; 
PChol/PC, phosphocholine; GPChol, glycerol-phosphocholine; Phe, phenylalanine; NAD, 
nicotinamide adenine dinucleotide. 
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4.3.2 Classification of the 1H-NMR profiles according to their treatment status  
Of the 113 ‘intelligently-selected’ buckets variables investigated, 103 variables had higher mean 
values for the MPH-treated group relative to the saline-treated control group, while 10 variables 
had higher mean values for the saline-treated control group relative to the MPH-treated group 
(i.e. MPH treatment resulted in 103 positive and 10 negative fold-changes). Primarily, PLS-DA 
was employed to analyse the 1H-NMR dataset in order to classify the samples according to their 
treatment status. The 3D scores plot for the first three components showed that the MPH-treated 
cerebral regions can be clearly distinguished from the saline-treated controls (Figure 4.3A). 
Indeed, a 10-fold cross-validation procedure was also applied to the PLS-DA analysis in order to 
evaluate the performance of the classification when checked with an independent subset from the 
original dataset. This strategy achieved a maximum accuracy of 0.87 with a total of 5 
components, and a Q2 value of 0.50, which were the maximum values achieved using this 
parameter (Q2 ≥ 0.3 was considered statistically significant) (McLoughlin et al. 2009; Worley 
and Powers 2013). To evaluate the performance of class discrimination, a permutation test was 
conducted with 2,000 permutations, where the ratio of the between-sum-of-squares to the within-
sum-of-squares (B/W-ratio) for the class assignment prediction of each model was computed, and 
this yielded a p-value of 5.0 x 10-4, indicating a strong discrimination between the MPH-treated 
and saline-treated control groups. PCA analysis of the dataset also revealed a variable loadings 
plot of PC1 vs. PC2, the former representing the component most responsible for these 
discrimination observed between the two classifications (see Appendix 1; Figure A1).  
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Figure 4.3: PLS-DA scores plot and ROC analysis curve of the cerebral samples.  
(A) PLS-DA scores plot demonstrating a clear separation between the MPH-treated and control 
groups (the contribution of each PLS-DA component to the total variance is provided in 
brackets), and (B) ROC (receiver operating characteristic) curve for the 13 selected metabolites 
by PLS-DA and their respective AUROC (area under ROC) values for biomarker models with 
increasing numbers of predictor (X) variables. 
 
4.3.3 MPH-induced metabolic alterations in brain samples 
Treatment of experimental animals with MPH was found to significantly alter the metabolic 
profiles of rat cerebrum (Figure 4.3). Indeed, metabolites identified as significantly different in 
the MPH-treated rats when compared to the controls were all elevated in the MPH-treated group. 
The top 22 discriminating metabolites identified by PLS-DA based on their VIP (variable 
importance in projection) scores, together with their p-values obtained from the ANOVA model 
depicted in equation 1, are shown in Table 4.1. This table also lists the assignments for the 
discriminatory ‘intelligently-selected’ buckets, the multiplicity, coupling constants, and fold-
changes. Positive fold-change values indicate an increased level of the specified metabolite in the 





















Table 4.1: Top 22 discriminatory variables for the MPH-treated and control cerebral extracts 
selected by PLS-DA based on their VIP scores.  
Variable 
Ranking 
ISB Assignment Multiplicity 
(j, Hz) 
Raw ANOVA p-values 




1 1.85-1.95 GABA-C3-CH2 q (7.47, 7.48) 4.53 x 10-4 +1.49 
2 2.99-3.03 GABA-C2-CH2 d (2.95) 6.06 x 10-4 +1.45 
3 2.25-2.33 GABA-C4-CH2 t (7.31) 9.25 x 10-4 +1.39 
4 0.91-1.00 Valine-C4-CH3 m (3.85, 4.25) 1.42 x 10-3 +1.51 
5 3.51-3.58 Myo-inositol-C3-CH2 dd (2.96, 2.81) 3.21 x 10-3 +1.29 
6 1.45-1.53 Alanine-C3-CH3 d (7.39) 2.44 x 10-3 +1.43 
7 1.66-1.75 Lysine-C5-CH2 m (1.66, 1.57) 4.07 x 10-3 +1.43 
8 1.00-1.08 Valine-C4’-CH3 d (7.24) 3.57 x 10-3 +1.53 
9 8.21-8.23 Hypoxanthine-C7-CH s 7.64 x 10-6 +1.76 
10 8.17-8.21 Hypoxanthine-C2-CH s 1.16 x 10-5 +1.68 
11 3.58-3.66 Myo-inositol-C4-CH t (3.70) 6.75 x 10-3 +1.26 
12 3.21-3.25 Phosphocholine/Glycerol-
phosphocholine-N(CH3)3 
s 5.22 x 10-3 +1.29 
13 2.73-2.81 Aspartate-C3-CH2a d (4.58) 8.56 x 10-3 +1.31 
14 3.08-3.13 Phenylalanine-β-CH2 dd (4.88, 6.51) 2.96 x 10-3 +1.48 
15 7.40-7.48 Phenylalanine-C2-CH m (7.38, 6.89) 3.51 x 10-4 +1.85 
16 3.39-3.48 Taurine-C1-CH2 t (3.39) 8.86 x 10-3 +1.26 
17 3.25-3.33 Myo-inositol-C5-CH t (6.36) 1.53 x 10-2 +1.23 
18 4.03-4.08 Myo-inositol-C2-CH t (4.06) 7.83 x 10-3 +1.26 
19 2.33-2.39 Glutamate-C4-CH2 m (6.90, 7.14) 4.07 x 10-2 +1.20 
20 7.16-7.23 Tyrosine-C6-CH m (7.87, 6.89) 4.66 x 10-3 +1.41 
21 2.81-2.88 Aspartate-C3-CH2b d (4.44) 6.29 x 10-3 +1.34 
22 3.94-3.96 Phosphocreatine-C2-CH2 s 2.94 x 10-3 +1.44 
 
4.3.4 ROC curve analysis  
ROC (receiver operating characteristic) curve analysis provides a graphical view of the degree to 
which the discriminant metabolites are successfully classified into one of the two groups 
explored, based on their treatment status (i.e. either MPH or control group). Here, a maximum of 
13 discriminant metabolites selected from the top 22 ISB variables listed in Table 4.1 were 
employed for this ROC curve analysis. Selection was based on variable rankings, and therefore in 
cases where two or more resonances arising from the same metabolite were selected as 
discriminatory features, only the highest ranked ISB variable was included in the analysis. The 13 
variables included in the ROC curve analysis were GABA-C3-CH2 (1.85-1.95 ppm), valine-C4-
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CH3 (0.91-1.00 ppm), myo-inositol-C3-CH2 (3.51-3.58 ppm), alanine-C3-CH3 (1.45-1.53 ppm), 
lysine-C5-CH2 (1.66-1.75 ppm), hypoxanthine-C7-CH (8.21-8.23 ppm), 
phosphorocholine/glycero-phosphorocholine-N+(CH3)3 (3.21-3.25 ppm), aspartate-C3-CH2a 
(2.73-2.81 ppm), phenylalanine-β-CH2 (3.08-3.13 ppm), taurine-C1-CH2 (3.39-3.48 ppm), 
glutamate-C4-CH2 (2.33-2.39 ppm), tyrosine-C6-CH (7.16-7.23 ppm), and phosphocreatine 
(3.92-3.96 ppm). The ROC curve in Figure 4.3(B) shows the AUROC range values for the 
metabolites included. Overall, this analysis indicates a good separation between the MPH-treated 
and control groups (mean AUROC value > 0.8), which provides further evidence that the two 
treatment groups differed significantly in terms of their 1H-NMR metabolic profiles. 
4.3.5 Multifactorial multivariate ASCA analysis 
The ‘treatment status’ and ‘between-cerebral hemispheres’ variance components were 
simultaneously explored using an ASCA (ANOVA-spontaneous component analysis) two-factor 
independent sample analysis option. No significant differences were observed for the ‘between-
cerebral hemispheres’ factor after performing this analysis (i.e. p > 0.05). Furthermore, the 
‘treatment status x brain hemisphere’ interaction component of variance was also found not to be 
significant for the first two (major) principal components explored (p > 0.05). However, as 
expected, the ‘treatment status’ factor was indeed significant (p = 0.006).   
4.3.6 Exploration of differences between right and left cerebral hemispheres  
The paired option PLS-DA analysis performed on the dataset using ‘brain hemisphere’ as a 
response variable showed no significant differences between the left and right cerebral 
hemispheres for both the MPH-treated and the control rats. In both cases, the maximum accuracy 
value was 0.54 for a model containing 3 components and the Q2 values obtained were below 0.1. 
Additionally, the p-value obtained from the permutation test (2,000 permutations) was non-
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significant (p = 0.44). The ANOVA analysis performed also did not reveal any significant 
differences the two brain (i.e. cerebral) hemispheres and the ‘brain hemisphere x treatment status’ 
interaction effect was also not significant. Similarly, as noted above, the ASCA strategy 
performed on the complete ISB variable dataset failed to detect any differences between the two 
brain hemispheres and their interaction with the ‘treatment status’ factor.  
4.3.7 Quantitative network metabolic pathway analysis 
Quantitative network pathway analysis (involving pathway enrichment analysis and pathway 
impact from pathway topology) (Xia et al. 2015; Xia et al. 2012) revealed statistically-significant 
MPH-induced modulations to a series of metabolic pathways (Table 4.2). Those with the greatest 
metabolic impact were: tyrosine biosynthesis > alanine, aspartate and glutamate metabolism > 
taurine and hypotaurine metabolism > phenylalanine metabolism > tyrosine metabolism > 
arginine and proline metabolism. Pathway impact indices, together with false discovery rate 
(FDR)-adjusted p-values (computed from a quantitative comparison of the MPH-treated and 
control groups performed on the full dataset), are also listed in Table 4.2.    
Table 4.2. Quantitative network pathway analysis involving pathway enrichment analysis and 
pathway impact from pathway topology 
Metabolic Pathway Total 
Compounds 




Tyrosine biosynthesis 4 2 0.006692 1 
Phenylalanine metabolism 9 2 0.006692 0.41 
Alanine, aspartate and glutamate metabolism 24 4 0.008495 0.57 
Tyrosine metabolism 42 1 0.008821 0.14 
Arginine and proline metabolism 44 4 0.012328 0.11 
Taurine and hypotaurine metabolism 8 1 0.11743 0.43 
NB: Hits – refers to the number of metabolites in the specified pathway that were impacted by 
drug treatment e.g. 2 out of 4 metabolites in the ‘tyrosine biosynthesis’ pathway (i.e. 
phenylalanine and tyrosine) were impacted by MPH treatment in this study. The ‘pathway 
impact’ values give an indication of how crucial changes to the ‘hit’ metabolites are in their 
respective networks/pathways (i.e. scores for each hit). This implies that hit metabolites that have 
key positions/roles and hence have severe impact on a network when altered are assigned higher 




4.4.1 Principal findings  
The psychostimulant drug MPH is increasingly used for the treatment of ADHD symptoms in 
children, despite the availability of only a limited amount of knowledge regarding its effects on 
the developing brain. Here, we provide some novel insights into the biochemical and metabolic 
mechanism of action of MPH on the adolescent brain. For this purpose, a 1H-NMR-linked 
metabolomics approach was employed to analyse the left and right cerebral hemispheres of rats 
that have not been genetically manipulated. Non-genetically modified animals were used in this 
study as no currently existing ADHD animal model adequately reflect the neurobiological basis 
of the disorder (Andersen and Navalta 2011). Moreover, the use of non-modified animals also 
ensured that only drug-specific changes are observed independent of underlying disease state, 
which is something that still remains quite difficult to tease apart in clinical studies (Andersen 
and Navalta 2011). Our data indicate that MPH significantly elevates amino-acid transmitters 
(e.g. GABA, glutamate, and aspartate), large neutral amino-acids (e.g. phenylalanine, tyrosine, 
and valine), energy metabolites (e.g. phosphocreatine), and purine metabolism (e.g. 
hypoxanthine), as well as metabolites associated with membrane dynamics (e.g. phosphocholine, 
myo-inositol, and taurine), among others. 
4.4.2 MPH increases amino-acid neurotransmitter levels 
One major finding in the present study is the increased level of GABA in cerebral extracts of the 
adolescent rats treated with MPH compared to those of the corresponding saline-treated controls 
(Table 4.1). Compared to the high number of clinical and preclinical studies addressing the 
involvement of monoamines (in particular dopamine) in the symptoms and treatment of ADHD, 
previous investigations of the primary brain inhibitory neurotransmitter GABA in ADHD are 
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limited and inconsistent. A previous study using magnetic resonance spectroscopy (MRS) 
reported diminished GABA concentrations in sensorimotor cortex of children diagnosed with 
ADHD (Edden et al. 2012). However, a more recent study which explored different parts of the 
brain (including the sub-cortical regions) demonstrated developmental changes in GABA levels 
in ADHD individuals, with an increase in adults and no changes in children (Bollmann et al. 
2015). The enhancement of GABA levels following MPH treatment observed in this study is 
likely to indicate a general enhancement of inhibitory neurotransmission and supports an earlier 
electrophysiological study which demonstrated that MPH increases GABAergic 
neurotransmission in the sensory thalamic nuclei of rat cerebrum (Goitia et al. 2013). Given that 
MPH’s ability to block monoamine transporters including DAT and NET (a process leading to 
increased extracellular levels of DA and NA) is well established, the link between this effect and 
increased whole tissue levels of GABA remains somewhat unclear. The upregulated GABA 
levels are, however, not unique to MPH, since previous animal studies using high-resolution 1H-
NMR analysis have detected similar effects following both single and repeated injections of the 
anti-manic drugs lithium (Li+) and carbamazepine (McLoughlin et al. 2009; Lan et al. 2008). 
Importantly, the Li+-induced enhancement of GABA levels was replicated in human brain tissues 
(Lan et al. 2008). In contrast, a range of antipsychotic drugs failed to increase rat brain levels of 
GABA, an observation indicating that this effect does not appear to be a general one observed 
with all brain-active amphiphilic drugs (McLoughlin et al. 2009). 
This study also detected enhanced levels of glutamate in brain samples from MPH-treated rats 
when compared to those of the saline-treated control group (Table 4.1). Since it is well known 
that GABA is generated from glutamate in GABAergic neurons via glutamic acid decarboxylase, 
it is possible that elevated glutamate levels may indeed be related to our finding of MPH-induced 
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enhancement of GABA levels. Consistent with this postulate, a corresponding PCA revealed that 
the ISBs containing all 3 of GABA’s 1H-NMR resonances (see Table 4.1) were found to strongly 
and positively load (loading scores 0.89-0.96) on the same principal component as that of the 
glutamate’s C4-CH2 signal (loading score 0.88). In addition, glutamatergic abnormalities have 
also been implicated in the pathophysiology of ADHD (Moore et al. 2006), and anti-ADHD 
drugs such as MPH modulate glutamate neurotransmission in animal models, including glutamate 
receptor function, long-term potentiation and cognition (Chen et al. 2015; Schmitz et al. 2016; 
Rozas et al. 2015; Di Miceli and Gronier 2015). Given that glutamate is stored in both neuronal 
and glial cells, it is unclear if the MPH-induced enhancement of whole tissue levels of glutamate 
in this study is related to an enhanced level of excitatory neuronal transmission.  
Brain levels of aspartate and taurine were also enhanced by MPH in this study. The non-essential 
amino acid aspartate, like glutamate, is stored in both glia cells and neurons. Indeed, some studies 
have suggested vesicular co-storage of glutamate and aspartate (Patneau and Mayer 1990; 
Morland et al. 2013). Based on the fact that aspartate acts as a full agonist on the glutamatergic 
NMDA (N-methyl-D-aspartate) receptors, it has been proposed that aspartate also acts as a co-
transmitter with glutamate in excitatory synapses (Patneau and Mayer 1990; Morland et al. 
2013). Such a role for aspartate has, however, recently been contested (Herring et al. 2015). The 
enhancement of taurine in brain samples of rats treated with MPH could also be of much 
neurochemical importance. Taurine is one of the most abundant amino acids in the brain, and it’s 
involved in a variety of brain functions including cytoprotection and brain development (Ripps 
and Shen 2012). The chemical structure of taurine is similar to GABA, and it acts as an agonist 
on GABAB (Kontro and Oja 1990), as well as on the glycine site of the NMDA receptors (Chan 
et al. 2014). MPH is known to enhance monoamine function, and this effect is implicated in the 
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drug’s promotion of long-term potentiation at excitatory synapses (Jenson et al. 2015). In this 
regard, it is interesting to note that previous studies have found that taurine affects dopamine 
release, and together with D1 receptor activation, it promotes long-term potentiation, an NMDA 
receptor-dependent mechanism (Salimäki et al. 2003; Suárez et al. 2014). Hence, it is possible 
that the MPH-induced upregulation of brain tissue levels of both taurine and aspartate observed 
here is involved in MPH-induced long-term potentiation (Jenson et al. 2015). 
4.4.3 MPH increases brain levels of large neutral amino acids 
The present study also demonstrated significant MPH-induced upregulations of some large 
neutral amino acids (LNAA), including the aromatic amino acids (AAAs) tyrosine and 
phenylalanine, in addition to the branched-chain amino acid (BCAA) valine. However, these 
LNAAs are all polar compounds and cannot pass across the blood-brain barrier (BBB) freely. In 
order to enter the brain from blood plasma, they alternatively utilise an active transport system, 
the large neutral amino acid transporter LAT-1 (Fernström 2013). Different types of LNAAs 
compete with each other for transport from the plasma to the brain via the LAT-1 system, and it 
cannot be excluded that MPH may indeed modify the physiological balance of LNAAs in the 
plasma, a process that may favour the entry of some of these LNAAs into the brain over others 
(Fernström and Fernström 2007). In this study, adolescent rats were treated with a moderate dose 
of MPH (5.0 mg/kg, i.p.), which gives rise to pronounced behavioural activation including 
increased locomotion, sniffing and rearing. It may therefore be speculated that such an MPH-
induced increase in motor activity enhances the plasma to brain transport of selected LNAAs, 
including tyrosine and its precursor phenylalanine. In support of this, rats exposed to treadmill 
running show increased brain levels of tyrosine (Acworth et al. 1986). Similar to our findings on 
MPH in this study, another psychostimulant, d-amphetamine, which is also used in the treatment 
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of ADHD, has been shown to increase rat brain levels of LNAAs, including tyrosine (Fernando 
and Curzon 1978). A possible contributing factor for a psychostimulant-induced upregulation of 
brain levels of LNAAs may also include their known body temperature rising action (as 
increasing body temperature increases metabolism), observed in both animals and humans 
(Fernando and Curzon 1978; Hetzler et al. 2014). 
Dysfunctional neurotransmission of the DA and NA systems are implicated in the symptoms of 
ADHD, and these catecholamines play important roles in the control of motor activity and 
executive brain function (Del Campo et al. 2011). Further, both animal and clinical studies 
clearly demonstrate that MPH blocks the presynaptic DAT and NET, and thereby increase 
extracellular levels of these catecholamines (Berridge et al. 2006; Kuczenski and Segal 2002; 
Volkow et al. 1998). Here, we have demonstrated that MPH significantly increased levels of the 
AAA tyrosine and its precursor phenylalanine in the brain of MPH-treated adolescent rats over 
those of the corresponding saline-treated rats (Table 4.1). Tyrosine functions as a precursor for 
both DA and NA in the brain. Unlike almost all other neurotransmitter biosynthetic pathways, the 
rates of synthesis of DA and NA are sensitive to local substrate concentrations, particularly in the 
ranges normally found in vivo. Consequently, ex vivo factors such as diet and exercise that 
enhance the brain pool of tyrosine also increase the rate of conversion to DA and NA in their 
respective nerve terminals, ultimately elevating their synaptic concentrations (Fernström and 
Fernström 2007). In contrast, when tyrosine transport into the brain is suppressed by the 
administration of a tyrosine/phenylalanine-free LNAA mixture, the physiological- and 
amphetamine-evoked release of DA in animal models is impaired (Le Masurier et al. 2013; 
McTavish et al. 2001). Similarly, in humans dietary tyrosine/phenylalanine depletion attenuates 
reward-related behaviour, which is driven by DA (Bjork et al. 2014).  
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The MPH induced increase of brain tyrosine levels may indeed be relevant to recent 
neuropsychological studies reporting that tyrosine-free amino acid mixtures disrupt performance 
in a range of behavioural and cognitive tasks that are dependent on DA and NA (Coull et al. 
2012). Also of interest to this study is a recent clinical finding which demonstrates that 
administration of a tyrosine-rich amino acid mixture effectively reduces ADHD symptoms in 
some children (Hinz et al. 2011). Therefore, it is possible that MPH alleviates ADHD symptoms 
in two ways: (1) via blockage of DAT and NET, and (2) by enhancing the brain pool of tyrosine 
and phenylalanine as demonstrated here. 
In addition, brain levels of the non-essential amino acid alanine were significantly higher in brain 
samples from MPH-treated rats when compared to those of the corresponding controls. Alanine is 
involved in glucose generation, and can be manufactured in the body from the BCAA valine, 
which as noted above was also upregulated by MPH in this investigation. Although the brain is 
normally not associated with glycogenesis some previous data suggest that this might indeed be 
the case; however, it might be at a much less efficiency in the brain than that occuring hepatically 
(Bhattacharya and Datta 1993). Moreover, brain levels of the essential amino acid lysine were 
also found to be significantly elevated in MPH-treated rats. Although the direct functional impact 
of this effect is not yet clear, lysine has been reported to block serotonin receptors, and a reduced 
lysine intake is associated with anxiety, a symptom occasionally coinciding with ADHD (Smriga 
et al. 2002; Mulraney et al. 2016). 
4.4.4 MPH alters energy metabolism 
Previous studies have suggested that MPH alters brain energy metabolism. Specifically, it has 
been shown to alter cerebral glucose utilisation (Porrino and Lucignani 1987), and serves to 
increase uptake of this molecule in the brain of young and adult rats (Réus et al. 2015). In the 
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present study, we detected a significant MPH-induced upregulation of phosphocreatine levels in 
the cerebrum (Table 4.1). Indeed, it is possible that this finding is related to an earlier study 
showing that MPH (2.0-10.0 mg/kg) increases creatine kinase activity in several regions of rat 
cerebrum, including the prefrontal cortex, hippocampus and striatum, all of which are implicated 
in the mechanisms of action of MPH (Scaini et al. 2008). Creatine kinase catalyses the transfer of 
a phosphoryl group from adenosine triphosphate (ATP) to creatine, producing phosphocreatine 
and adenosine diphosphate, and our results indicate an imbalance in this transfer, with brain 
phosphocreatine levels being upregulated in the MPH-treated group when compared to that of the 
corresponding saline-treated control group. This reaction is, of course, reversible, and hence 
creatine kinase may play an important role in the rapid regeneration of ATP in high energy-
consuming tissues such as the cerebrum. Furthermore, MPH is known to elevate neuronal 
activity, as evident from its ability to increase the transcription of several activity-dependent 
genes, together with their corresponding proteins (Yano and Steiner 2007; Banerjee et al. 2009; 
Gronier et al. 2010), and it is likely that this effect is dependent on a local elevated level of ATP 
metabolism. Although it is not possible to establish the precise mechanism behind the MPH-
induced elevation of phosphocreatine levels in this study, it is likely that this effect is related to 
the known blockade of DAT by MPH, which increases synaptic DA levels and hence DA 
receptor stimulation. In support of this, antipsychotic drugs known to block DA receptors reduce 
creatine kinase activity and creatine levels in the brains of rats and humans respectively (Assis et 
al. 2007; Sarramea Crespo et al. 2008).  
In addition to the creatine/phosphocreatine cycle, purine metabolism is also closely linked to 
ATP production and utilisation. Here, we found that the purine derivative hypoxanthine was 
significantly enhanced in the cerebrum of the MPH-treated rats compared to the controls (Table 
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4.1). This could give rise to increased levels of the final metabolite of purine catabolism, urate. 
Indeed, like MPH, d-amphetamine, which also increases synaptic levels of DA, and is also used 
in the treatment of ADHD, has been shown to increase brain levels of this metabolic product 
(Miele et al. 2000).  
4.4.5 MPH and metabolites affecting cell membranes  
Brain levels of myo-inositol were also significantly increased following MPH administration 
(Table 4.1). Myo-inositol is abundant in both neurons and glial cells, and it is known to be a 
marker of membrane turnover as well as glial integrity (Brand et al. 1993). In contrast to the 
present findings, other psychoactive drugs, including antipsychotic drugs, Li+ and valproate have 
been found to reduce brain levels of myo-inositol in both animal and human studies (McLoughlin 
et al. 2009; Lan et al. 2008). 
Phosphocholine is a known precursor to various membrane phospholipids in both glial cells and 
neurons (Paoletti et al. 2011). Significantly increased concentrations of this metabolite were also 
observed in the MPH-treated brain samples, and this may indicate that altered lipid turnover may 
be involved in the mechanism of action of the drug. Taken together, the enhancement of 
phosphocholine and myo-inositol by MPH could indicate that the drug acutely alters the 
dynamics of brain cell membranes. 
4.4.6 Comparison of the left and right cerebral hemispheres 
Some studies have previously suggested that ADHD may be a right hemisphere dysfunction 
(Waldie and Hausmann 2010). Consequently, here we also sought to establish if MPH influences 
brain metabolites differentially in the right and left cerebral hemispheres. However, both the 
univariate and paired multivariate analysis approaches employed for this purpose failed to detect 
any significant metabolic differences between these two cerebral hemispheric groups. 
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4.5 Conclusions 
This study was aimed at detecting MPH-induced alterations of multiple cerebral metabolites in 
order to improve our understanding of the mechanisms of action of this drug in the adolescent 
brain. Our results indicate that acute MPH treatment significantly increased several rat cerebral 
metabolites, including amino acid neurotransmitters such as GABA and glutamate, and also 
upregulated LNAAs such as tyrosine and its precursor phenylalanine. The present study also 
indicated that a single administration of MPH alters membrane and energy metabolism in brain 
cells. The acute effects of MPH observed in the present study could be related to the mechanism 
of action of the drug in the adolescent brain, and in the reduction of ADHD symptoms. It will be 
important for future studies to investigate the effect of MPH in distinct brain regions that are 
implicated in the symptoms of ADHD, as well as the persistence of its observed effects following 
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MPH reduces the primary ADHD symptoms in approximately 70% of patients (Wilens 2008; 
Zhang et al. 2016). MPH is suggested to exert its therapeutic effects via a blockade of the DAT 
and the NET, culminating in an increase of synaptic monoaminergic signalling (Berridge et al. 
2006; Kuczenski and Segal 2002; Volkow et al. 1998). In recent times, there appears to be an 
increased diagnosis of ADHD, as a consequence there is an increased usage of MPH (Dietz et al. 
2013; Gahr et al. 2014; Klein-Schwartz 2003). While MPH is an effective therapeutic drug, its 
long term effects on brain neurochemicals and metabolites remains unclear.  
Several genetic and functional genomic studies have been conducted to determine the aetiology 
of ADHD and the mechanism of action of anti-ADHD medications, including MPH on the 
central DA system. However, to our knowledge there are no studies exploring the MPH-induced 
effects following acute and chronic administration on metabolic changes in the plasma and brain 
regions implicated in the pathophysiology of ADHD such as the frontal cortex, striatum, and 
hippocampus. Water-soluble metabolites play crucial roles in metabolic pathways and provide 
crucial information regarding the biological activities of a particular tissue or fluid. The relative 
concentration of metabolites in the brain gives useful insights into the functional and structural 
integrity of astrocytes and neurons (McLoughlin et al. 2009). Studying metabolite alterations in 
brain tissue and biological fluids following MPH treatment could, therefore, provide important 
information related to the mechanism of action and long-term effects of the drug.  
Interestingly, previous studies employing proton magnetic resonance spectroscopy (1H-MRS) to 
examine ADHD patients have identified some prominent changes in various brain metabolites, 
particularly in the frontal cortex, basal ganglia and cerebellum. For instance, glutamate and 
glutamine ratio has been shown to be reduced in the frontal cortex of medication naïve ADHD 
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patients (Perlov et al. 2007) but increased in the cerebellum (Perlov et al. 2010). In addition, 
other studies have shown altered levels of GABA (Bollmann et al. 2015), choline (Colla et al. 
2008), N-acetylaspartate (NAA), and myo-inositol (Courvoisie et al. 2004) in the frontal cortex, 
striatum and/or hippocampus of some ADHD patients. Given that glutamate and GABA are 
excitatory and inhibitory neurotransmitters respectively, perturbations in these amino acids 
suggest a disturbance in the balance between excitatory/inhibitory neurotransmission in ADHD 
(Bollmann et al. 2015; Perlov et al. 2007). In terms of stimulant actions, 1H-MRS has been used 
in some ADHD patients to identify a few metabolites altered by MPH including NAA, glutamate 
and myo-inositol (Carrey et al. 2003; Soliva et al. 2010). However, due to limited sensitivity, the 
1H-MRS is currently unable to detect drug-induced changes in other metabolites with lower-
relative abundance, and it also remains difficult to distinctly distinguish the effect caused by drug 
treatment alone, given that some changes could occur as part of the normal course of a disease. 
Thus, 1H-NMR spectroscopy was employed to detect the changes caused by MPH treatment in 
normal (genetically-unmodified) rats in this study.  
1H-NMR spectroscopy-based metabolomics could be used to detect a wide array of metabolites in 
biological samples. 1H-NMR may be used to evaluate changes in a large variety of biofluids and 
tissues. Compared to 1H-MRS, the 1H-NMR technique has a far greater sensitivity and gives a 
better spectral resolution. The 1H-NMR technique has been used extensively in studies on several 
brain disorders including schizophrenia, bipolar disorder, and autism, as well as stimulant and 
psychotropic drugs (McLoughlin et al. 2009; Lan et al. 2008; Tsang et al. 2006).  
In this study, we used high-resolution 1H-NMR spectroscopy to explore and compare the acute 
and chronic effect of MPH on plasma and brain metabolites. For this purpose we selected, based 
on their involvements in ADHD symptoms, the following brain regions: frontal cortex, striatum, 
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and hippocampus. Most of the identified alterations were related to neurotransmission, energy 
metabolism, and membrane dynamics. The observed treatment duration- and brain region-
specific neurochemical alterations induced by MPH are discussed. 
5.1.1 Aims  
This study was aimed at comparing the effect of acute and chronic MPH treatment on water-
soluble metabolites in the plasma and brain regions implicated in the symptoms of ADHD. The 
objectives of this chapter were:  
§ To evaluate the effects of MPH on brain regions associated with ADHD symptoms such 
as striatum, frontal cortex and hippocampus. 
§ To assess the effects of MPH on water-soluble metabolites in the plasma. 
§ To compare the acute and chronic effects of MPH on the developing brain. 
 
5.2 Methods 
5.2.1 Drug Treatment and sample collection 
For a detailed description of the animal housing and MPH treatment procedures see Chapter 2, 
section 2.1. In brief, the animals were assigned to two treatment groups i.e. acute treatment group 
(saline-treated controls and drug-treated) and chronic treatment group (saline-treated controls and 
drug-treated). The animals (180-220 g; post-natal day 40) in the acute treatment group received 
either a single saline injection (1.0 ml/kg) or a single MPH dose (2.0 mg/kg; n=12 rats/group) 
intraperitoneally. The animals in the chronic treatment group, on the other hand, received either 
saline or MPH (2.0 mg/kg) twice-daily for 15 days, with the last injection being on postnatal day 
40. One hour after the last injection, the rats were sacrificed by a rapid dislocation of the neck. 
The brain was removed and trunk blood was collected from each animal. Brain regions 
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corresponding to the frontal cortex, striatum, and hippocampus were dissected according to the 
Paxinos and Watson rat brain atlas (see Chapter 2, section 2.13). The dissected tissues were snap-
frozen, and then stored at -80°C until 1H-NMR analysis. 
5.2.2 Plasma and brain extract preparation and 1H-NMR experiments  
The plasma and brain sample preparation, as well as the 1H-NMR experiments were performed as 
described in Chapter 2, sections 2.2.1, 2.2.2 and 2.2.3.  
5.2.3 Pre-processing of NMR spectra  
Using ACD/NMR processor (academic edition; Ontario, Canada), the acquired 1H-NMR spectra 
were phase and baseline-corrected prior to multivariate and univariate data analysis. The 1H-
NMR spectra of the brain samples were referenced to the TSP resonance at δ = 0.00 ppm, while 
the plasma spectra were referenced to the methyl doublet of lactate (1.26-1.33 ppm). The 1H-
NMR spectra were then automatically reduced into consecutive integrated spectral regions 
referred to as the ‘intelligent-bucketing’ procedure. This procedure yielded a full dataset of 24 
rows (samples) and 315 columns (variables) for the frontal cortex of the chronic treatment group. 
On the other hand, there was a full dataset of 24 rows (samples) and 292 columns (variables) for 
the plasma samples of the chronic treatment group. To eliminate spectral variations due to 
differences in the quality of water suppression in each individual spectrum, the region containing 
residual H2O/HOD signal (δ = 4.50-5.00 ppm) in both the brain and plasma spectra was not 
included in the analysis. In addition, spectral regions that did not contain any resonant signals 
(i.e. noise regions) were also removed from further analysis.  
5.2.4 Multivariate and univariate analysis of the plasma and brain extracts 
Multivariate and univariate statistical analyses were performed on the TSP-normalised integral 
values as described in Chapter 2, section 2.2.5. PCA was initially used to visualise the datasets. 
	156	
OPLS-DA classification (which introduces an orthogonal signal correction filter to the PLS-DA 
classification method) was also performed along with a 10-fold cross-validation. In addition, a 
permutation test was also conducted with 2,000 permutations, to ascertain the performance of 
class discrimination. For the OPLS-DA analysis, while any Q2 value > 0 has predictive relevance, 
to ensure comparability and reliability of models across the different brain regions a Q2 ≥ 0.3 was 
used as a cut off for all models as previously described (McLoughlin et al. 2009; Worley and 
Powers 2013). Where models showing a clear difference between the control and drug-treated 
rats could be constructed and cross-validated (i.e. Q2 ≥ 0.3), the discriminating metabolites were 
identified using the VIP (variable importance in projection) scores. 
In addition, the metabolite changes were further confirmed by comparing the mean resonance 
intensities for the MPH-treated samples and the controls using an ANOVA model (univariate 
analysis) from the R statistical package. This univariate analysis enabled the verification of the 
metabolite changes detected from the multivariate analysis, and as well enabled the determination 
of the level of metabolite changes associated with MPH treatment. The ANOVA p-values, fold 
changes, and multiplicities of the discriminant metabolites for all the plasma and brain samples 
analysed were presented in Tables 5.2 and 5.3. Bonferroni correction [where p = (0.05/total 
number of buckets for each sample)] was further applied on those samples that were statistically 
significant following the univariate analysis but not significant after the multivariate analysis, in 
order to guard against type I error (false positives).  
5.2.5 Metabolic pathway analysis of the brain and plasma datasets 
Detailed analysis of the most relevant metabolic pathways altered following MPH treatment was 
performed using the MetaboAnalyst 3.0 tool, as described in Chapter 2, section 2.2.7. 
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5.3 Results 
5.3.1 Spectral profiles and statistical analyses of extracts from the rat brain 
5.3.1.1 Multivariate and univariate analysis of 1H-NMR datasets from brain tissue extracts 
The 1H-NMR datasets were visualised with an S-plot, which demonstrated significant MPH-
induced upregulations of some prominent metabolites in the frontal cortex following chronic 2.0 
mg/kg MPH treatment compared to controls (Figure 5.1). The plot indicates MPH-induced 
changes of resonant signals belonging to some notable metabolite categories such as energy and 
membrane-related metabolites (e.g. lactate, creatine, phosphocholine, taurine etc.), and amino 
acids (e.g. lysine, aspartate, GABA, glutamate, alanine, tyrosine etc.). 
              
Figure 5.1: S-plot showing the most important discriminant variables in the frontal cortex 
following chronic 2.0 mg/kg MPH treatment. 
Most of the important cortical variables were increased (above 0.0), although there were also a 
few decreased variables (below 0.0). 
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To test the statistical significance of the MPH-induced changes in the 1H-NMR datasets, PCA 
was used for an initial visualisation of the datasets and for identifying potential outliers. The PCA 
analysis showed a clear separation between the chronic 2.0 mg/kg MPH-treated dataset compared 
with the corresponding controls in the frontal cortex (Figure 5.2) but not for any of the other 
investigated brain regions after either acute or chronic treatment. OPLS-DA was then used to 
analyse the 1H-NMR datasets in order classify the samples based on their treatment status. The 
OPLS-DA scores plot provided added support for a clear distinction between the chronic MPH-
treated and the saline-treated controls in the frontal cortex (Figure 5.2B), but not for the treatment 
groups in the other examined brain regions when compared with their corresponding controls.  
To ensure reliability of models across the different brain regions examined, a Q2 value ≥ 0.3 was 
used as a cut off for all models as previously described (McLoughlin et al. 2009; Worley and 
Powers 2013). Here, while the OPLS-DA Q2 = 0.30 (statistically significant) was obtained in the 
frontal cortex following chronic treatment, the Q2 < 0.1 (non-significant) was obtained for the 
other examined brain regions following acute and chronic treatment. There was also a 
corresponding p < 0.05 arising from the permutation test (2,000 permutations) for the 
chronically-treated frontal cortex samples, emphasising a clear separation between the MPH-
treated and the control cortical groups. 
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Figure 5.2: PCA and OPLS-DA scores plots of the chronically-treated frontal cortex samples.  
(A) PCA scores plot demonstrating a clear separation between the chronic 2.0 mg/kg MPH-
treated and saline-treated control groups in the frontal cortex, and (B) OPLS-DA scores plot 
showing 95% confidence ellipses that further supports the clear distinction between the chronic 
MPH-treated and saline-treated control groups in the frontal cortex (R2X = 0.58, Q2 = 0.30, 
permutation p-value < 0.05). 
 
In addition to the multivariate analysis, further univariate analysis of the 1H-NMR datasets were 
performed using the ANOVA model previously described (see Chapter 2, section 2.2.5). This 
analysis revealed statistically significant changes to a number of variables in most of the 
examined brain regions following either acute or chronic MPH treatment. To guard against false 
positives in the datasets that did not show statistical significance following multivariate analysis, 
a correction factor was introduced (Bonferroni correction), where the α-values were adjusted 
based on the total number of variables (i.e. p = (0.05/total number of bucketed variables for each 
brain region)) (see Chapter 2, section 2.2.5). The significantly altered variables in the individual 
brain regions are presented below.  
 
5.3.1.2 Metabolite changes in the frontal cortex following MPH treatment 
Acute and chronic MPH treatment increased a number of metabolites in the frontal cortex. 













0.30, permutation p-value < 0.05; OPLS-DA analysis) compared with the acute treatment group. 
Figure 5.3 gives the most important metabolite changes in the frontal cortex following acute and 
chronic treatment. Following acute treatment, four variables were increased (obtained following 
the ANOVA analysis), with these four variables being assigned to two metabolites (i.e. valine 
and lysine) (Figure 5.3A). In contrast, chronic treatment increased the levels of twenty variables, 
which included amino acid transmitters and LNAAs, as well as energy and membrane-related 
metabolites (see Figure 5.3B). 
 
Figure 5.3: Boxplots showing the most important metabolite changes in the frontal cortex. 
(A) Metabolite changes observed from the ANOVA analysis following acute MPH treatment, (B) 
Top 20 variables altered following chronic MPH treatment based on both the OPLS-DA and 
ANOVA analysis. *p < 0.05; **p < 0.01; ***p < 0.001. Abbreviations: NAAG, N-
acetylaspartylglutamate; PChol, phosphocholine. 
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5.3.1.3 Quantitative metabolic pathways altered in the frontal cortex  
Further, quantitative network pathway analysis was conducted (Xia et al. 2015; Xia et al. 2012). 
This analysis revealed statistically significant MPH-induced alterations to a number of metabolic 
pathways in the frontal cortex following chronic MPH treatment (Table 5.1). 
 
Table 5.1: Quantitative network pathway analysis for the chronic frontal cortical samples.  
This involves pathway enrichment analysis and pathway impact from pathway topology 
Metabolic Pathway Total 
Compounds 




Alanine, aspartate and glutamate metabolism 24 5 0.00021 0.457 
Arginine and proline metabolism 44 4 0.00212 0.024 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 
4 1 0.00487 0.500 
Taurine and hypotaurine metabolism 8 1 0.00624 0.428 
Valine, leucine and isoleucine biosynthesis 11 1 0.00697 0.333 
 
5.3.1.4 Metabolite changes in the hippocampus following MPH treatment 
Similar to the changes in the frontal cortex, 2.0 mg/kg MPH treatment increased a number of 
metabolites in the hippocampus following both acute and chronic MPH treatment, although it 
was acute treatment that had more prominent effect compared to the chronic treatment group 
(Table 5.2). The ANOVA p-values, fold changes, and multiplicities of the most important 









Table 5.2: Important metabolites altered in the hippocampus following acute and chronic MPH 













  Acute      
1 0.91-0.97 Valine-C4-CH3a m (3.84) 1.4 x 10-5 +1.21b 
2 1.03-1.09 Valine-C4-CH3b d (7.84) 9.9 x 10-8 +1.39b 
3 1.46-1.51 Alanine-C3-CH3 d (7.24) 1.3 x 10-3 +1.33 
4 1.67-1.73 Lysine-C5-CH2a d (7.54) 2.3 x 10-5 +1.91b 
5 1.73-1.78 Lysine-C5-CH2b d (7.85) 6.6 x 10-6 +1.79b 
6 1.88-1.90 GABA-C3-CH2 t (7.39) 1.1 x 10-2 +1.59 
7 1.90-1.96 Acetate-C2-CH3 s 4.6 x 10-2 +1.54 
8 2.18-2.22 Glutamate-C3-CH2 m (4.88) 3.2 x 10-2 +1.16 
9 2.26-2.31 GABA-C4-CH2 t (7.24) 1.3 x 10-2 +1.38 
10 3.19-3.21 Choline-N(CH3)3 s 4.5 x 10-2 +1.19 
11 3.42-3.48 Taurine-C1-CH2 t (6.65) 3.4 x 10-2 +1.33 
12 3.91-3.96 Creatine-C2-CH2 s 2.3 x 10-2 +1.68 
13 4.03-4.08 Myo-inositol-C2-CH t (2.96) 3.4 x 10-2 +1.55 
14 4.11-4.15 Lactate-C2-CH d (6.95) 7.8 x 10-3 +1.16 
15 4.15-4.21 Phosphocholine-C1-CH2 m (2.22) 1.6 x 10-2 +1.22 
16 6.88-6.91 Tyrosine-C3-CH d (8.58) 1.6 x 10-2 +1.74 
17 7.20-7.24 Tyrosine-C6-CH d (8.72) 3.9 x 10-3 +1.31 
18 7.30-7.35 Phenylalanine-C2-CH m (6.36) 2.9 x 10-3 +1.23 
19 8.21-8.26 NAD-N5-CH s 4.5 x 10-3 +1.17 
20 8.44-8.47 Nicotinamide-C5-CH s 5.2 x 10-3 +1.20 
Chronic      
1 0.91-0.96 Valine-C4-CH3a m (3.84) 2.2 x 10-2 +1.05 
2 1.01-1.07 Valine-C4-CH3b d (7.84) 2.3 x 10-3 +1.10 
3 1.45-1.51 Alanine-C3-CH3 d (7.24) 3.1 x 10-2 +1.08 
4 6.87-6.93 Tyrosine-C5-CH m (2.37) 3.2 x 10-2 +1.24 
 5 7.28-7.33 Phenylalanine-C2-CHa d (6.95) 7.2 x 10-5   +1.15b 
(b) Significant even after Bonferroni correction 
 
 
5.3.1.5 Metabolite changes in the striatum following MPH treatment 
Unlike the changes in the frontal cortex and hippocampus, MPH decreased several metabolites 
following acute MPH treatment (p < 0.05 for all metabolites based on the ANOVA model) but 
chronic MPH treatment normalised metabolite levels in this region (with no statistically 
significant changes observed following chronic MPH treatment; p > 0.05) relative to the saline-
treated controls (Table 5.3).  
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Table 5.3: Important metabolites altered in the striatum following acute and chronic MPH 














Acute      
1 0.91-0.97 Valine-C4-CH3a m (3.84) 7.9 x 10-3 -1.08 
2 1.03-1.09 Valine-C4-CH3b d (7.84) 8.2 x 10-3 -1.17 
3 1.67-1.73 Lysine-C5-CH2a d (7.54) 4.0 x 10-5 -1.23b 
4 1.73-1.78 Lysine-C5-CH2b d (7.85) 1.9 x 10-4 -1.25b 
5 2.00-2.04 N-acetyl-aspartate-C2-CH3 s 3.9 x 10-2 -1.84 
6 2.43-2.45 Glutamine-C4-CH2a d (2.37) 2.9 x 10-2 -1.35 
7 2.45-2.51 Glutamine-C4-CH2b m (3.84) 5.1 x 10-2 -1.10 
8 2.98-3.03 GABA-C2-CH2 d (7.69) 4.9 x 10-2 -1.26 
9 3.30-3.33 Myo-inositol-C5-CH t (6.21) 3.7 x 10-2 -1.44 
10 3.50-3.53 Myo-inositol-C3-CH2 dd (2.96) 3.6 x 10-2 -1.29 
11 3.87-3.91 Glycerol-phosphocholine-
C3-CH3 
d (3.10) 1.0 x 10-2 -1.45 
12 4.15-4.21 Phosphocholine-C1-CH2 m (4.88) 1.2 x 10-2 -1.24 
13 4.36-4.42 N-acetyl-aspartate-C2-CH m (3.99) 1.7 x 10-2 -1.78 
14 6.09-6.13 NAD-N1’-CH d (5.62) 1.1 x 10-2     -1.59 
15 8.33-8.39 NAD-A1’-CH s 2.3 x 10-2 -1.56 
    Chronic     
1 2.00-2.04 N-acetyl-aspartate-C2-CH3 s 8.6 x 10-1 -1.04# 
2 2.45-2.51 Glutamine-C4-CH2 m (3.84) 8.2 x 10-1 +1.04# 
3 3.50-3.53 Myo-inositol-C3-CH2 dd (2.96) 4.6 x 10-1 -1.07# 
4 3.87-3.91 Glycerol-phosphocholine-
C3-CH3 
d (3.10) 3.6 x 10-1 -1.13# 
 5  6.09-6.13 NAD-N1’-CH d (5.62)  4.9 x 10-1   +1.07# 
(b) Significant even after Bonferroni correction; # Statistically insignificant. Abbreviation: NAD, 
Nicotinamide adenine dinucleotide. 
 
5.3.2 Spectral profiles and statistical analyses of plasma samples  
5.3.2.1 1H-NMR profile of rat plasma 
The average spectra obtained from the plasma of the control (dark red) and MPH-treated (green) 
rats is shown in Figure 5.4, spanning the (A) 0.66-4.60 ppm and (B) 5.0-8.56 ppm spectral 
regions. This plasma spectrum contained several prominent resonant signals including branched 
chain amino acids (BCAAs), low-density lipoproteins, lipids, glucose, and glutamate, among 




Figure 5.4: Average 1H-NMR spectra from the control and MPH-treated rats.  
The spectra display the average of (A) 0.66-4.60 ppm (the expanded BCAA region has been 
shown in the insert), and (B) 5.0-8.56 ppm spectral regions. Abbreviations: VLDL/LDL, low-
density lipoprotein; BCAA, branched chain amino acids; 3HB, 3-hydroxybutyrate; NAG, N-










































































5.3.2.2 Multivariate and univariate analysis of the plasma data 
Similar to the brain dataset, the integral data from plasma spectra were analysed using both 
multivariate and univariate statistical parameters. The PCA and OPLS-DA scores plots showed a 
clear separation between the drug-treated and saline-treated controls following chronic MPH 
treatment (Figure 5.5) but not acute treatment (i.e. treatment duration-dependent effect). The 
OPLS-DA analysis yielded a Q2 = 0.46 (statistically significant) and a permutation p < 0.0005 
(2,000 permutations) for the chronic MPH-treated plasma samples, emphasising a clear 
separation between the chronic MPH-treated plasma samples and the controls. However, a Q2 < 
0.1 (i.e. statistically non-significant effect) was obtained for the acute MPH-treated plasma 
samples.  
      
Figure 5.5: PCA and OPLS-DA scores plot of the chronically-treated plasma samples.  
(A) PCA scores plot demonstrating a clear separation between the chronic 2.0 mg/kg MPH-
treated plasma samples and the corresponding saline-treated controls, and (B) OPLS-DA scores 
plot showing 95% confidence ellipses that further supports the clear distinction between the 
chronic MPH-treated plasma samples and the corresponding saline-treated controls (R2X = 0.62, 
Q2 = 0.46, permutation p-value < 0.0005). 
 
Further, ANOVA was performed (using the R statistical package) to confirm the identities of the 













analysis showed that indeed none of the metabolites were significantly altered in the plasma 
samples following acute treatment (p > 0.05 for all metabolites) but there were significant 
alterations to several metabolites following chronic treatment as shown in Figure 5.6. In the 
chronic treatment group, the increased metabolites included α- and β-glucose, glutamate, and 
phosphocholine whereas the decreased metabolites included lactate, acetate, threonine, tyrosine, 
phenylalanine, formate, and 3-methylhistidine (Figure 5.6). 
 
Figure 5.6: S-plot and boxplots displaying the important variables altered in the rat plasma 
samples following chronic MPH treatment.  
The S-plot shows the most important variables that were either increased (upper portion of the 
plot) or decreased (lower portion of the plot) in rat plasma following chronic 2.0 mg/kg MPH 
treatment. The discriminating variables in the S-plot are displayed in boxplots along with their 
significance level from the ANOVA model. *p < 0.05; **p < 0.01; ***p < 0.001. 
 
5.3.2.3 Metabolite set enrichment and metabolic pathway analysis of plasma samples 
The quantitative network pathway analysis of the chronically-treated plasma samples revealed 
statistically significant MPH-induced alterations to a series of metabolic pathways, including 
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phenylalanine, tyrosine and tryptophan biosynthesis, as well as phenylalanine and tyrosine 
metabolism, among others (Table 5.4).  
Table 5.4: Quantitative network pathway analysis for the chronic plasma samples.  
This involves pathway enrichment analysis and pathway impact from pathway topology 
Metabolic Pathway Total  
Compounds 




Phenylalanine, tyrosine and tryptophan 
biosynthesis 
4 2 0.000221 1 
Phenylalanine metabolism 9 2 0.000434 0.407 
Starch and sucrose metabolism 23 1 0.010 0.038 
Galactose metabolism 26 1 0.010 0.036 
Glycerophospholipid metabolism 30 1 0.010 0.044 
Tyrosine metabolism 42 1 0.010 0.140 
 
5.4 Discussion 
5.4.1 Principal findings 
Here, spectral profiles from rat plasma and three brain regions implicated in the symptoms of 
ADHD have been examined with regards to metabolic changes induced by MPH, which is the 
commonest drug prescribed for the treatment of ADHD. The data showed that MPH has both 
region- and treatment-duration specific effects on plasma and brain metabolites. The drug-related 
metabolic changes observed following both acute and chronic MPH treatment are likely to 
provide novel insights into the mechanism of action of the drug.  
Specifically, this study revealed that chronic MPH treatment but not acute treatment influenced 
the metabolic pattern in the plasma samples of the MPH-treated rats when compared to the 
corresponding control samples (Figure 5.6). In addition, metabolites including those related to 
amino acid transmission (glutamate, glutamine and GABA), LNAAs (tyrosine, phenylalanine and 
valine), energy metabolism (lactate, acetate and creatine), and membrane activity (NAA, myo-
inositol and taurine) were mostly increased in the frontal cortex and hippocampus following both 
acute and chronic MPH treatment (Figure 5.3 and Table 5.2). In contrast, while no significant 
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changes were observed in the striatum following chronic treatment, acute MPH treatment 
decreased some metabolites including the amino-acid neurotransmitters (e.g. GABA and 
glutamine), energy and membrane-related metabolites (e.g. phosphocholine, glycerol-
phosphocholine, NAA, myo-inositol and NAD), as well as valine and lysine (Table 5.3).  
5.4.2 Metabolic alterations in rat plasma 
Chronic but not acute MPH treatment was effective at altering several metabolites in the plasma, 
with 10 different metabolites (glutamate, lactate, acetate, glucose, phenylalanine, tyrosine, 
phosphocholine, threonine, formate, and 3-methylhistidine) being significantly altered (Figure 
5.6). Three of these metabolites were significantly increased, including the amino acid 
neurotransmitter glutamate, the membrane metabolite phosphocholine and the energy metabolite 
glucose (α and β anomers). Given that earlier studies have indicated that MPH enhances 
excitatory neurotransmission and brain energy metabolites (Berridge et al. 2006; Réus et al. 
2015), the present data suggest that MPH may not only enhance brain levels of these metabolites 
but that it also elevates these metabolites in the circulatory system. On the other hand, the levels 
of seven other metabolites were significantly decreased. The decreased metabolites were LNAAs 
(including phenylalanine and tyrosine) and metabolites related to energy metabolism (including 
lactate, acetate, formate, 3-methylhistidine and threonine). Threonine can be converted to 
pyruvate which can also be converted to lactate or formate in some reversible reactions (Buis and 
Broderick 2005; Leibig et al. 2011). The decrease of threonine would imply that chronic MPH 
treatment may increase the conversion of threonine to lactate and formate in the plasma. The 
lactate and/or formate formed in the plasma may, however, be carried across the BBB into some 
brain areas, since a transport system for carrying monocarboxylates across the BBB has been 
described for which lactate has a high permeability for within young/adolescent animals (Cremer 
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et al. 1976; Deelchand et al. 2009; Waniewski and Martin 1998). Similarly, acetate is also carried 
across the BBB by this monocarboxylate transport system (Cremer et al. 1976; Deelchand et al. 
2009; Waniewski and Martin 1998).  
In the present study, plasma levels of amino acid precursors of catecholamine synthesis, 
including tyrosine and phenylalanine were also decreased by chronic MPH treatment. Similar to 
the monocarboxylate system, a transport system (L-amino acid transporter-1; LAT-1) for 
carrying the polar LNAA compounds across the BBB has also been characterised (Fernström 
2013). Therefore, the mechanism of action of MPH could involve an alteration of the balance of 
plasma LNAAs, favouring the uptake and transport of tyrosine and phenylalanine into the brain 
where they could be utilised in the synthesis of DA and NA, two catecholamine neurotransmitters 
implicated in ADHD and the therapeutic action of MPH (Berridge et al. 2006; Kuczenski and 
Segal 2002; Del Campo et al. 2011). To determine if indeed brain levels of LNAAs and energy 
metabolites are enhanced following acute and chronic MPH administration, we examined the 
metabolic patterns in three brain regions (frontal cortex, striatum, and hippocampus), which are 
all associated with ADHD and the mechanism of action of MPH.  
5.4.3 Metabolic alterations in the frontal cortex 
Both acute and chronic MPH treatment significantly increased water-soluble metabolites in the 
frontal cortex of adolescent rats (Figure 5.3). Acute MPH treatment increased only two 
metabolites significantly in the frontal cortex (i.e. valine and lysine) based on the ANOVA 
model. These two metabolites were also increased following chronic MPH treatment, along with 
13 other metabolites (Figure 5.3). These 13 increased metabolites include LNAAs (tyrosine and 
valine), energy metabolites (lactate and creatine), and amino acid-related neurotransmitters 
(glutamate, glutamine, GABA, NAAG and aspartate), as well as membrane-related metabolites 
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(NAA, phosphocholine, taurine, and myo-inositol). Following chronic MPH administration, the 
LNAA tyrosine and the energy-related metabolite lactate were significantly increased in the 
frontal cortex. Given that both of these metabolites were decreased in the corresponding plasma 
samples it is possible that MPH elevates the levels of these metabolites in the frontal cortex, by 
enhancing their transport from the plasma into the brain (see Figure 5.6). Enhanced levels of 
tyrosine in the frontal cortex would potentially enhance the synthesis and storage of DA and NA 
in this brain region and indeed in Chapter 3, this thesis showed that chronic MPH treatment 
enhances whole tissue levels of DA in the frontal cortex (Figure 3.7). In this context, tyrosine-
rich amino acid mixtures have been shown to reduce ADHD symptoms in young patients, an 
effect which could also be attributed to enhanced synthesis and storage of catecholamines such as 
DA (Hinz et al. 2011).  
Excitatory amino acid transmitters and related metabolites including: glutamate/glutamine, 
NAAG and aspartate, as well as the main inhibitory amino acid transmitter (GABA) were also 
found to be increased in this brain region following chronic but not acute MPH treatment. Thus, 
it is possible that MPH act by ensuring a balance between excitation and inhibition, as abnormal 
alterations of these glutamatergic and GABAergic metabolites in the frontal cortex have indeed 
been shown to be involved in the symptoms of ADHD (Bollmann et al. 2015; Perlov et al. 2007). 
Further, the glutamate/GABA-glutamine cycle is a metabolite shuttle that determines the release 
of the neurotransmitters, glutamate and GABA from neurons and their subsequent uptake by 
astrocytes (i.e. star-shaped glial cells). Astrocytes, in turn, release glutamine that is taken up by 
neurons for the generation of neurotransmitters (Bak et al. 2006; Rowley et al. 2012). This cycle 
between neurons and astrocytes is crucial to the normal functioning of the brain and it is 
indicative of glutamatergic and GABAergic activity (Bak et al. 2006; Rowley et al. 2012). 
	171	
Increases in glutamate/glutamine levels in the frontal cortex of chronically MPH-treated rats in 
this study may therefore suggest an enhanced but still balanced excitatory/inhibitory 
transmission. Moreover, the MPH-induced enhancements of metabolite indicators of membrane 
activity (such as NAA, phosphocholine, taurine and myo-inositol) are suggestive of changes in 
the functional integrity of mitochondria and neuronal energy utilisation (as indicated by the 
enhanced NAA), membrane integrity (as indicated by the enhanced phosphocholine), and a 
general protection against glutamate, NAAG, and aspartate mediated excitotoxicity (as indicated 
by the enhanced taurine and myo-inositol).  
5.4.4 Metabolic alterations in the hippocampus  
Similar to the frontal cortex, both acute and chronic MPH treatment significantly elevated 
metabolites in the hippocampus based on the ANOVA model (Table 5.2). However, in contrast to 
the findings in the frontal cortex, acute treatment showed more pronounced effect on metabolite 
levels compared to chronic MPH treatment. The increased variables in this brain region following 
acute MPH treatment included 16 different metabolites i.e. LNAAs (phenylalanine, tyrosine, 
valine), amino acid neurotransmitters (GABA, glutamate), brain energy-related metabolites 
(lactate, acetate, creatine, nicotinamide adenine dinucleotide (NAD), nicotinamide), and 
membrane metabolites (taurine, choline, phosphocholine, myo-inositol), together with alanine and 
lysine. Conversely, chronic MPH treatment elevated the levels of only four metabolites compared 
to the saline-treated controls. These metabolites were the LNAAs (phenylalanine, tyrosine, and 
valine), as well as alanine (Table 5.2). Thus, in the hippocampus, phenylalanine, tyrosine, valine 
and alanine are altered by MPH irrespective of treatment-duration (i.e. altered after both acute or 
chronic treatment). Taken together, the increase of the LNAAs tyrosine and phenylalanine, as 
well as the energy metabolites lactate and acetate in the hippocampus (and also the frontal cortex) 
following MPH treatment further indicates that the drug likely acts by increasing the brain pool 
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of these metabolites, perhaps by increasing their transport across the blood-brain barrier into 
these two brain regions (i.e. hippocampus and frontal cortex). The hippocampus is a key region 
involved in cognition and memory, thus MPH-induced increases of these metabolites (e.g. 
tyrosine and phenylalanine) in this brain region could contribute to the therapeutic action of 
MPH. Like lactate, acetate is also carried across the blood-brain barrier by the monocarboxylate 
transport system and this occur at a greater level in young/adolescent animals compared to adults 
and also serves as an important alternative energy source (Cremer et al. 1976; Deelchand et al. 
2009; Waniewski and Martin 1998). The MPH-induced increase of brain energy-related 
metabolites such as creatine, NAD, and nicotinamide in the hippocampus is noteworthy. The 
increase of creatine, a major brain energy source is compatible with previous studies 
demonstrating that MPH increases creatine kinase activity in the hippocampus, as well as in the 
frontal cortex of rats (Scaini et al. 2008). Similar to the changes in frontal cortex, hippocampal 
glutamate and GABA were both significantly increased by acute MPH treatment, supporting the 
idea that MPH may indeed enhance the glutamatergic/GABAergic pathway in these brain regions 
while also ensuring a balance between excitatory and inhibitory transmission. Moreover, MPH 
induced an increase of the membrane metabolites (taurine, choline, phosphocholine, myo-
inositol) that are required for maintaining membrane integrity. For example, taurine is thought to 
be released in response to toxic concentrations of excitatory transmitters (e.g. glutamate) in 
hippocampal slices of mice, therefore enhanced levels of taurine by MPH might serve as a 
general protective mechanism for cell membranes against potential MPH-induced excitotoxicity 
(Saransaari and Oja 2000). 
5.4.5 Metabolic alterations in the striatum 
In the striatum, acute MPH treatment but not chronic treatment resulted in significant alterations 
of metabolites (Table 5.3). Unlike the frontal cortex and hippocampus where increases in 
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metabolites were recorded, acute MPH treatment resulted in significant reductions of metabolites 
in the striatum. In total, 9 metabolites were decreased in the striatum including metabolites 
related to neurotransmission (i.e. GABA and glutamine) and energy/membrane integrity (i.e. 
phosphocholine, glycerol-phosphocholine, NAA, myo-inositol and NAD). The other decreased 
metabolites were lysine and the BCAA valine (Table 5.3). The mechanism underlying the MPH-
induced decreases of metabolites in the striatum remains to be established, but this finding could 
be specific to the striatum (i.e. region-specific effect). Interestingly, abnormally high 
glutamate/glutamine levels have been recorded in the striatum of some young medication naïve 
ADHD patients (Carrey et al. 2007), and a previous 1H-MRS (magnetic resonance spectroscopy) 
study on young ADHD patients treated with MPH reported decreased striatal levels of 
glutamate/glutamine/GABA compared to the levels before treatment was initiated (Carrey et al. 
2003), thus these previous clinical studies are consistent with the present findings in the 
adolescent rat striatum. While both glutamate and DA are implicated in the mechanism of action 
of MPH, this study shows that the drug acutely changes the striatal levels of these two 
neurotransmitters in opposite directions. In accordance with our findings some previous studies 
have shown that such opposite drug induced actions on glutamate and DA is not unique to MPH. 
For example, Caravaggio et al. (2016) concluded that an increase in striatal DA often do not 
correlate with an increase in striatal glutamate and that a corresponding increase (or decrease) of 
both neurotransmitters may occur in a treatment-duration dependent manner. Indeed, Holmer et 
al. (2005) used MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to deplete striatal DA (DA 
denervation) and observed increased striatal extracellular glutamate two-hours (four 20 mg/kg 
MPTP doses in this time frame) after treatment (acute effect). However, seven days of MPTP (30 
mg/kg) treatment decreased striatal extracellular glutamate (chronic effect), with the decrease of 
glutamate reversed upon L-DOPA injection (Holmer et al. 2005). Kalivas and Duffy (1997) 
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further showed that the changes in striatal extracellular glutamate may be D2/3 receptor 
mediated. While extracellular glutamate was not measured in the present study, the increased 
extracellular DA induced by acute 5.0 mg/kg MPH treatment (Figure 3.8) could result in 
decreased striatal glutamate/glutamine levels, and may partly support the decreased glutamine 
levels observed in this study after acute treatment (Table 5.3). In addition, the MPH-induced 
decrease of striatal GABA levels in this study could be related to the density of glutamate 
decarboxylase (GAD; responsible for catalysing the decarboxylation of glutamate to GABA). As 
previously indicated in rodents, MPH treatment elevates the mRNA of glutamate decarboxylase 
isoenzymes (GAD65 and GAD67) in the frontal cortex, but the drug significantly dampens the 
transcription of GAD65 in the striatum (Freese et al. 2012).  
In addition, previous rodent studies have shown that brain NAA, myo-inositol and glycerol-
phosphocholine levels are related to mitochondrial function and energy metabolism. Indeed, it 
has been demonstrated that NAA synthesis is reduced when ATP production is decreased (Bates 
et al. 1996; Clark 1998). It is possible that the MPH induced reduction of striatal NAA levels in 
the present study is related to the decreased NAD levels also detected here. NAD is a coenzyme 
that exist either in the oxidised (NAD+) or reduced (NADH) forms. In the mitochondria, NAD 
(reduced form) is converted to ATP (in the presence of oxygen), which is required to fuel and 
maintain neuronal function. Thus, NAD loss inhibits cellular respiration, resulting in a decline of 
mitochondrial ATP production (Kristian et al. 2011). Overall, our data suggest that the decreased 
amino acid neurotransmitters and energy/membrane metabolites in the striatum following acute 
MPH administration (although normalised following chronic treatment), may be related to altered 
glutamate decarboxylase density and a possible altered mitochondrial function.  
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5.4.6 Implications of the duration- and region-specific action of MPH  
The observed MPH-induced elevation of metabolite levels in the frontal cortex and hippocampus 
following both acute and chronic treatment is consistent with our previous findings in the 
cerebrum following acute 5.0 mg/kg MPH treatment (see Chapter 4). Given that some of the 
metabolites (such as glutamate and glutamine) identified to be elevated by MPH in the frontal 
cortex and hippocampus in this study have been previously shown to be decreased in these brain 
regions in ADHD patients (Perlov et al. 2007), the effect of MPH on metabolites in these brain 
regions and in the plasma may be involved in the therapeutic action of this anti-ADHD 
medication. Moreover, given that the drug decreased the plasma levels of LNAAs (including 
tyrosine and phenylalanine) and energy metabolites (including lactate and acetate) and the 
concurrent increase of these metabolites in the frontal cortex and hippocampus, it appears that the 
drug alters the balance of plasma levels of these metabolites possibly by favouring their uptake 
and transport across the blood-brain barrier into the brain (particularly into the frontal cortex and 
hippocampus) via the LAT-1 and the monocarboxylate transport systems (see Figure 5.7), 
respectively (Cremer et al. 1976; Deelchand et al. 2009; Waniewski and Martin 1998; Fernström 
2013). In the brain, tyrosine and phenylalanine serve as precursors of catecholamine (i.e.  DA and 
NA) synthesis. In addition, these monoamine systems (i.e. DA and NA) are often reported to be 
dysfunctional or underactive in ADHD, therefore the MPH-induced increase of their precursors 
(i.e. tyrosine and phenylalanine) may be important in addressing monoaminergic deficits 
associated with ADHD. Indeed, it is reported that tyrosine-rich amino acid mixtures can be 
effective in reducing the symptoms of ADHD in some children (Hinz et al. 2011). Primarily, 
MPH is thought to exert its therapeutic effect via a blockade of the DA and NA transporters (see 
Figure 5.7). Following transporter blockade, the clinically relevant MPH dose administered in 
this study is reported to increase the extracellular levels of both DA and NA in some brain 
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regions including the frontal cortex and hippocampus, hence improving cognition and working 
memory (Volkow et al. 2001; Berridge et al. 2006; Kuczenski and Segal 2002; Spencer et al. 
2012). Given that elevated levels of tyrosine in the brain could result in an enhancement of DA 
and NA synthesis (Hinz et al. 2011), it is possible that the increased levels of tyrosine and its 
precursor phenylalanine may be an additional mechanism by which MPH elevates DA and NA 
levels in these brain regions. Therefore, based on the present findings, as well as the previous 
findings in the cerebrum, we hypothesise that at least in the frontal cortex and hippocampus, 
MPH may reduce the symptoms of ADHD by: (1) the classical pathway involving DAT and NET 
blockade, and (2) driving the plasma to brain pool of tyrosine and phenylalanine, as shown in the 
present study (see Figure 5.7).   
 
Figure 5.7: MPH-induced transport of some metabolites across the blood-brain barrier. 
The blood-brain barrier is a semi-permeable membrane barrier formed by brain endothelial cells 
which are connected by tight junctions, which separates the circulating blood from extracellular 
fluid. Metabolites such as tyrosine, phenylalanine, lactate, and acetate, etc., are unable to cross 
this barrier freely, and therefore rely on transporters such as LAT-1 (L-type amino acid 
transporter) and MCTs (monocarboxylate transporters) for transport from the plasma into the 
brain. The present study indicates that MPH may induce an increased transport of these 
metabolites (i.e. tyrosine, phenylalanine, lactate, and acetate) from the plasma into the brain. 
Once in the nerve terminals, tyrosine is utilised in the synthesis of dopamine, which subsequently 
binds to its receptors (e.g. D1 receptor) and trigger a signal cascade. 
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Consistent with our findings in the cerebrum (see Chapter 4), GABA, glutamate, and/or 
glutamine were also increased in the frontal cortex and hippocampus following either acute or 
chronic MPH treatment. Glutamatergic transmission that regulates cortical and hippocampal 
activity is vital to cognitive function such as working memory (Goldman-Rakic 1995). The 
enhancement of GABA/glutamate levels following MPH treatment is likely to indicate a general 
enhancement of inhibitory and excitatory neurotransmission, and is supported by earlier 
electrophysiological studies which demonstrated that MPH increases GABAergic and 
glutamatergic neurotransmission in the cortex and hippocampus (Goldman-Rakic 1995). 
Interestingly, however, GABA and glutamine as well as membrane metabolites (including NAA, 
myo-inositol and phosphocholine) were significantly decreased in the striatum after acute MPH 
treatment with no major striatal changes observed after chronic drug treatment. The 
glutamate/GABA-glutamine cycle is an important shuttle between neurons and astrocytes and it 
is crucial to the normal functioning of the brain, while also providing an indicator of 
glutamatergic and GABAergic activity (Bak et al. 2006; Rowley et al. 2012). The MPH-induced 
decrease of striatal GABA levels in the present study could be related to the density and activity 
of enzymes involved in this pathway, such as those involved in the conversion of glutamate to 
GABA (e.g. glutamate decarboxylase). In support of this, the density of the GAD 65 glutamate 
decarboxylase enzyme is reported to be significantly dampened in the striatum following MPH 
treatment (Freese et al. 2012). Similarly, in support of the present findings, a previous study on 
young ADHD patients receiving MPH treatment reported decreased levels of 
glutamate/glutamine/GABA in the striatum (Carrey et al. 2003). 
Moreover, NAA, myo-inositol and phosphocholine are known to play diverse roles in myelin 
synthesis, neuron-glial signalling, osmoregulation and glutamate/NAAG turnover (Baslow 2003; 
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Moffett et al. 2007). NAA synthesis is closely associated with the functional integrity of 
mitochondria and neuronal energy utilisation, hence NAA is widely accepted as an indicator of 
neuronal mitochondrial function and neuronal density (Moffett et al. 2007). Indeed, NAA is 
thought to increase during neurogenesis, and may decrease due to diverse neural pathologies 
(Maltezos et al. 2014; Yao et al. 1999). Thus, the increase of NAA in the frontal cortex following 
MPH therapy could be related to an enhanced energy utilisation in this region, while the 
reductions of NAA as well as myo-inositol and phosphocholine in the striatum observed 
following acute but not chronic MPH administration in the present study could be related to 
possible aberrations in mitochondrial function. Similar to our findings, a previous clinical study 
on young ADHD patients also reported a significantly decreased striatal NAA levels following 
MPH treatment (Ben Amor 2014). 
5.5 Conclusion 
In summary, this study shows that acute and chronic MPH treatment alter adolescent rat plasma 
and brain metabolic profiles. These changes were both treatment duration-dependent and region-
specific. Acute MPH significantly decreased striatal amino-acid transmitters, as well as 
membrane and energy-related metabolite levels, but these effects were not detected after chronic 
treatment. In contrast, both acute and chronic MPH treatment elevates amino-acid transmitters, 
LNAAs, energy, and membrane metabolite levels in the frontal cortex and hippocampus. In 
addition, the present study also suggest that MPH may increase catecholamine synthesis and 
lactate/acetate levels in the frontal cortex and hippocampus. It was hypothesised that these 
increases occur via MPH-induced enhancement of tyrosine/phenylalanine and lactate/acetate 




































Current etiological theories of ADHD focus on morphological and functional abnormalities in the 
fronto-striatal networks (Semrud-Clikeman et al. 2000; Castellanos et al. 1996; Ashtari et al. 
2005). However, recent reports indicate that ADHD could also be associated with dysfunctions in 
neuronal structures beside the fronto-striatal circuitry, including the substantia nigra, thalamus, 
and cerebellum (Valera et al. 2007). In particular, the cerebellum appears to be emerging as one 
of the important brain structures altered in ADHD, as well as some neuropsychiatric disorders 
(Ivanov et al. 2014). The motor functions of the cerebellum including coordinated voluntary 
movements have been well established (Fine et al. 2002). However, recent findings from 
neuroanatomical and neuroimaging studies have provided evidence for the involvement of 
cerebellum in non-motor functions including a variety of linguistic, affective and cognitive 
processes (De Smet et al. 2013). Indeed, the cerebellum is now thought to play crucial roles in 
cognitive processes such as learning, visuo-spatial processing, emotion, attention shifting, and 
working memory (Golla et al. 2005; Ivry et al. 2002; Schmahmann and Sherman 1998; Steinlin 
2008; Stoodley et al. 2012). 
The involvement of the cerebellum in cognitive processes suggests that it could potentially have a 
role in the cognitive and attentional deficits underlying ADHD. Indeed, research shows that the 
cortex and the basal ganglia (including the striatum and the nucleus accumbens), which are often 
reported to be dysfunctional in ADHD, are interconnected with the cerebellum, with outputs of 
the cerebellum targeting non-motor areas in the posterior parietal and prefrontal cortex as well as 
the cortical motor areas (Strick et al. 2009). The strong connection with the cortex and other 
cerebral areas, places the cerebellum in a position to influence neural networks in these 
structures. In addition, neuroimaging studies have provided evidence of consistent cerebellar 
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morphological abnormalities in ADHD patients (Berquin et al. 1998). With regards to this, some 
structural imaging studies have reported decreased cerebellar volume and abnormal 
developmental changes of the cerebellum of ADHD patients (Castellanos et al. 1996; Castellanos 
et al. 2001; Berquin et al. 1998). More specifically, some studies have indicated that the 
decreased cerebellar volume may be localised to the left anterior and the right posterior cerebellar 
hemispheres (Ivanov et al. 2014). The involvement of the right posterior cerebellar hemisphere in 
ADHD fits well with studies suggesting a greater involvement of the right hemisphere in ADHD, 
particularly the right cortex (Voeller and Heilman 1988; Castellanos et al. 1996; Semrud-
Clikeman et al. 2000). The dysfunctional right hemisphere hypothesis in ADHD appears to be 
supported mostly by functional brain imaging studies, which have linked the 
cognitive/behavioural abnormalities in ADHD with significant under-activation of the right 
cortex and right caudate (Vance et al. 2007; Rubia et al. 1999).  
The cerebellum may represent a possible target for anti-ADHD drugs, since deficits in cerebellar 
grey matter and vermis size associated with ADHD patients have been reported to be normalised 
following both chronic psychostimulant drug treatment, as well as after cognitive behavioural 
training programs (Bledsoe et al. 2009; Hoekzema et al. 2011). Stimulants, such as MPH are 
often prescribed for individuals with ADHD. The rationale for MPH prescription is based on the 
assumption that the central catecholamine systems are dysfunctional in ADHD and also based on 
the known enhancing effect of these drugs on the fronto-striatal dopaminergic and noradrenergic 
systems (Dougherty et al. 1999; Del Campo et al. 2011). In rodent studies, MPH use has been 
linked with changes in the density of DAT (Roessner et al. 2010) and DA receptors, as well as 
the densities of proteins involved in monoamine synthesis and vesicular packaging such as 
tyrosine hydroxylase (TH) (Panos et al. 2014) and vesicular monoamine transporter (VMAT2) 
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(Simchon et al. 2010) in the fronto-striatal circuit, but it is unclear whether these proteins are 
affected by MPH in the cerebellum.  
Interestingly, previous studies using the 1H-MRS technique, a non-invasive technique that 
permits the quantification of metabolites in ADHD patients in vivo, have shown that some 
neurochemicals including glutamate, glutamine, and creatine exist in abnormally high 
concentrations in the cerebellum of individuals with ADHD compared to normal controls (Perlov 
et al. 2010). In addition, a previous clinical study has demonstrated that psychostimulant intake 
by ADHD patients decrease myo-inositol and NAA levels (Soliva et al. 2010). However, in 
comparison with the 1H-NMR technique, the 1H-MRS technique is less sensitive and detects 
fewer brain metabolites (Du et al. 2015). Consequently, several studies have utilised 1H-NMR 
spectroscopy in analysing biofluids and tissue samples from both patients and animal models of 
various brain disorders (Lan et al. 2008; Holmes et al. 2001). However, to our knowledge, the 
effects of MPH on a broad range of neurochemicals and brain metabolites, as well as 
monoaminergic protein markers in the cerebellum of rats using 1H-NMR and Western blotting 
respectively have not yet been investigated.  
In the present study, we explored the acute and chronic effects of MPH on adolescent rat 
cerebellar metabolic profiles via 1H-NMR spectroscopy. Further, we investigated the effects of 
the drug on monoaminergic protein markers implicated in the pathophysiology of ADHD and in 
the mechanism of action of MPH using Western blotting. We hypothesised that acute and chronic 




This study was aimed at examining the role of the cerebellum in the mechanism of action of 
MPH. These experiments were set up to test the hypothesis that MPH alters biomolecules and the 
expression of monoaminergic protein targets in the cerebellum. The experiments specifically 
examined the following: 
§ The dose-dependent effects of acute MPH treatment on the cerebellar metabolic pathways 
using 1H-NMR spectroscopy. 
§ Treatment duration-dependent effects of the drug on biomolecules in the cerebellum using 
1H-NMR spectroscopy. 
§ The acute and chronic effects of MPH treatment on the protein expression of 
monoaminergic targets in the cerebellum via Western blotting. 
§ The effects of MPH treatment on whole tissue levels of DA and its metabolites in the left 
and right cerebellar hemispheres using HPLC-EC. 
§ The differences in the effect of MPH in the left and right cerebellum. 
 
6.2 Methods 
6.2.1 Drug Treatment and sample collection 
Chapter 2, section 2.1 contains a detailed description of the animal housing and MPH treatment 
procedures. Here, the following animal treatment groups were investigated via: 
(a) 1H-NMR analysis: (i) Acute high dose (5.0 mg/kg MPH dose or 1.0 ml/kg saline), n=36 rats 
(18 MPH-treated and 18 saline-treated controls; cerebellar samples were collected from the left 
and right sides), (ii) Acute low dose (2.0 mg/kg MPH dose or 1.0 ml/kg saline), n=24 rats (12 
MPH-treated and 12 saline-treated controls), (iii) Chronic (2.0 mg/kg MPH or 1.0 ml/kg saline, 
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twice daily for 15 days), n=24 rats (12 MPH-treated and 12 saline-treated controls). The animals 
were sacrificed 1 h after the last injection. 
(b) Western blot analysis: (i) Acute (2.0 mg/kg MPH dose or 1.0 ml/kg saline), n=12 rats (6 
MPH-treated and 6 saline-treated controls), (iii) Chronic (2.0 mg/kg MPH dose or 1.0 ml/kg 
saline, twice daily for 15 days), n=12 rats (6 MPH-treated and 6 saline-treated controls; samples 
were collected from the left and right cerebellum). The animals were sacrificed 24 h after the last 
injection.  
(c) HPLC-EC analysis: (i) Acute (2.0 mg/kg MPH dose or 1.0 ml/kg saline), n=12 rats (6 MPH-
treated and 6 saline-treated controls), (iii) Chronic (2.0 mg/kg MPH dose or 1.0 ml/kg saline, 
twice daily for 15 days), n=12 rats (6 MPH-treated and 6 saline-treated controls). The animals 
were sacrificed 1 h after the last injection.  
Animals receiving chronic injections were 20-25 days old (75-90 g) on the first day of treatment 
and the last injections were given when the animals were 35-40 days old (180-220 g). Following 
the last injections, the animals were killed by rapid dislocation of the neck and the cerebellum 
removed and hemi-sected along the midline i.e. through the vermis (for the rats in the Western 
blot, HPLC-EC, and the acute high dose NMR groups only). The excised cerebellar samples were 
quickly snap-frozen in isopentane, and then stored at -80°C until analysis.  
6.2.2 1H-NMR Spectroscopic experiments 
6.2.2.1 Brain extract preparation and 1H-NMR experiments  
The brain sample preparation and the 1H-NMR experiments were performed as described in 
Chapter 2, sections 2.2.1 and 2.2.3.  
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6.2.2.2 Pre-processing of NMR spectra  
Before multivariate and univariate data analysis, the ACD/NMR processor (academic edition; 
Ontario, Canada) software was used to correct the 1H-NMR spectra manually for phase and 
baseline. The 1H-NMR spectra of the tissue samples were referenced to the TSP resonance at δ = 
0.00 ppm. The ‘intelligent bucketing’ procedure was then employed to divide the spectra into 
integral segments. This yielded a full dataset of 71 rows (samples) and 313 columns (variables) 
for the acute high dose treatment group and then 24 rows (samples) and 311 columns for the 
chronic low dose treatment group. The resulting integral intensity values were normalised to the 
TSP signal (s, δ = 0.00 ppm). Subsequently, the spectral regions that did not contain any 
resonances (i.e. noise regions) and the intense δ = 4.65-5.16 ppm residual H2O/HOD signal 
region were removed from all the 1H-NMR datasets. This resulted in a final dataset of 71 
(samples/rows) and 119 (variables/columns) for the acute high dose treatment group and then 24 
(samples/rows) and 131 (variables/columns) for the chronic treatment group. The integral data 
was then analysed using multivariate and univariate data analysis strategies.  
6.2.3 Multivariate and univariate statistical analysis of the cerebellar datasets 
Multivariate and univariate statistical analysis were performed on the TSP-normalised integral 
values as described in Chapter 2, section 2.2.5. The multivariate analysis performed using 
MetaboAnalyst 3.0 tested the performance of the different subsets of the datasets and revealed the 
discriminatory metabolites selected by OPLS-DA. PCA, OPLS-DA and S-plots were generated 
for the datasets. In addition, univariate analysis was also performed using an ANOVA model 
(conducted with the corresponding function in R 3.1.2 statistical software), where 2 factors and 3 
primary sources of variation were incorporated: (1) 'treatment status’ (Control vs. MPH-treated 
rats, Ti); (2) ‘brain hemisphere’ (right vs. left, Hj) and the (3) ‘treatment status’ x ‘brain 
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hemisphere’ (THij) interaction effect. This ANOVA model is represented by equation 1 (Chapter 
2, section 2.2.5). In order to ensure a strong performance for multiple comparisons, the FDR 
(False Discovery Rate) and Bonferroni correction criteria were employed to adjust the 
significance (p-value) of each of the components contributing to the observed variations.  
Yij= µ + Ti + Hj + THij + eij                                                (1) 
To determine any significant metabolic patterns arising from each of the experimental factors, 
including the multivariate !"#$ interaction component of variance, simultaneous multivariate 
analysis of the main variables (i.e. ‘brain hemisphere’ and ‘MPH treatment’) was conducted 
using ASCA (ANOVA simultaneous component analysis), via the two-factor independent 
samples option available in MetaboAnalyst 3.0 (which is based on equation 1). Permutation test 
with 2,000 permutations was used determine the significance of each of the multivariate variance 
components. 
6.2.4 Metabolic pathway analysis of the cerebellar datasets 
Detailed analysis of the most relevant cerebral metabolic pathways and networks altered 
following MPH treatment was performed using the MetaboAnalyst 3.0 tool, as described in 
Chapter 2, section 2.2.7. 
6.2.5 Immunoblotting  
The frozen tissues were thawed, homogenised in RIPA lysis buffer, run on SDS-PAGE and 
electroblotted as previously described in Chapter 2, section 2.5. The blots were probed with 
primary antibodies, including anti-DA D1 receptor (1:1000, Millipore, UK), anti-
SLC18A2/VMAT2 (1:1000, OriGene, USA), anti-TH (1:1000, Abcam, UK), and anti-β-actin 
(1:2000, Santa Cruz, USA). The secondary antibodies used were horseradish peroxidase (HRP) 
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conjugated (1:2000, Santa Cruz, USA). The blots were developed with enhanced 
chemiluminescent HRP substrate (Amersham Biosciences, UK) and images visualised with an 
MCIDTM
 
core digital imaging system (MCID, UK). Signal intensity was quantified using 
MCIDTM
 
image analysis software (version 7.0). Bands corresponding to VMAT2, TH, and D1 
receptor were normalised to β-actin, and all data were expressed as a percentage of the saline-
treated controls. The data was analysed with GraphPad Prism (version 5.0, Graph Pad software 
Inc., La Jolla, CA). Statistical analyses were performed using two-way ANOVA with the factors 
‘drug’ (MPH, saline), ‘duration’ (acute, chronic) and interactions between ‘drug’ x ‘duration’ 
along with Bonferroni post-hoc test. Differences were considered significant if p < 0.05. Data are 
presented as mean ± S.E.M.  
6.2.6 Analysis of whole tissue levels of dopamine using HPLC-EC  
The effects of both acute and chronic MPH treatment on the whole tissue levels of DA and its 
metabolites were examined using HPLC-EC. Following the intraperitoneal injections of MPH or 
saline, the left and right cerebellar hemispheres were quickly dissected out and homogenised in 
0.2 M perchloric acid (the amount was based on the tissue weights) until all solid tissue was no 
longer visible in the solution (approximately 30 s), as previously described in Chapter 2, section 
2.4. The whole tissue levels of DA were calculated for each sample (with a correction for the 
tissue weight). The data from this study was presented as µg/g for each treatment group. The data 
was analysed using GraphPad Prism (version 5.0, GraphPad Software Inc., La Jolla, CA). Two-
way ANOVA with the factors, ‘drug’ (MPH, saline), and ‘hemisphere’ (left, right), as well as 
interactions between ‘drug’ x ‘hemisphere’ were carried out on DA concentrations.  
	188	
6.3 Results 
6.3.1 Multivariate analysis of cerebellar 1H-NMR spectroscopic data  
The 1H-NMR datasets were initially visualised with PCA, which revealed a clear separation 
between the acute 5.0 mg/kg MPH-treated (high dose) dataset compared with the controls (Figure 
6.1) but not for the acute 2.0 mg/kg (low dose) or the chronic (twice daily 2.0 mg/kg for 15 days) 
MPH-treated datasets. Subsequently, OPLS-DA was used to analyse the 1H-NMR datasets in 
order classify the samples based on their treatment status. The OPLS-DA scores plot provided 
additional support for a clear distinction between the 5.0 mg/kg MPH-treated (high dose) and the 
saline-treated controls (Figure 6.1B), but not for the acute low dose and the chronic groups when 
compared with their corresponding controls. To ensure reliability of models across the different 
treatment regimes, a Q2 value ≥ 0.3 was used as a cut off for all models as previously described 
(McLoughlin et al. 2009; Worley and Powers 2013). The acute high dose yielded R2X = 0.6, Q2 
= 0.46, and a permutation p-value < 0.0005 (indicating statistical significance following 
multivariate analysis on this dataset; where R2X denotes the fraction of the dataset explained by 
the model; Q2 denotes the predictive ability of the model). For the acute 2.0 mg/kg and chronic 
2.0 mg/kg MPH-treated groups, Q2 < 0.1 were obtained for both (i.e. non-significant following 
multivariate analysis). However, these datasets were further analysed using the ANOVA model 
depicted in equation 1 and the results provided in Table 6.2.  
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Figure 6.1: PCA and OPLS-DA scores plots of the acute 5.0 mg/kg dose cerebellar samples.  
(A) PCA scores plot demonstrating a clear separation between the acute high dose (5.0 mg/kg) 
MPH-treated and saline-treated control groups, and (B) OPLS-DA scores plot showing 95% 
confidence ellipses that further supporting the clear distinction between the acute high dose 
MPH-treated and saline-treated control groups (R2X = 0.6, Q2 = 0.46, permutation p-value < 
0.0005).  
 
6.3.2 MPH-induced metabolic alterations in cerebellar samples 
Treatment of experimental subjects with MPH resulted in significant metabolic changes in the 
cerebellum (Table 6.2). The action of MPH was highly dependent on both ‘dose’ and ‘treatment 
duration’, with some of the altered metabolites being decreased and others being increased by 
acute MPH treatment (i.e. for both low and high doses but more pronounced after high dose). In 
contrast, most of the metabolites were significantly increased by chronic MPH treatment in 
comparison with the controls (Table 6.1). The assignments of the most important discriminant 
metabolites identified from the VIP scores of the OPLS-DA analysis and their p-values based on 
the ANOVA model depicted in equation 1, have been presented in Figure 6.2 (for the acute high 
dose only) and Table 6.1 (for the acute low 2.0 mg/kg dose and chronic 2.0 mg/kg MPH-treated 
samples). Table 6.1 also lists the multiplicity, coupling constants, and fold-changes of the 
identified discriminant metabolites. Negative fold change values (as shown in Table 6.1) indicate 







































MPH-induced decrease of the specified metabolites relative to the controls. Bonferroni correction 
[p = (0.05/total number of buckets for each sample)] was further applied on those samples that 
were statistically significant following the univariate analysis but not significant after the 
multivariate analysis (i.e. the acute low dose and chronically treated samples) (see Chapter 2, 
section 2.2.5). All the variables presented in Table 6.1 are statistically significant, but those that 
were significant following Bonferroni correction are marked using (b). 
 
Figure 6.2: S-plot and boxplots revealing the most important discriminant cerebellar 
metabolites following the acute high MPH dose. 
The S-plot shows some increased metabolites (upper portion of the plot) in the cerebellum 
following acute 5.0 mg/kg MPH treatment (high dose) and some decreased metabolites (lower 
portion of the plot). The most important discriminating variables in the S-plot are displayed in 
boxplots together with their significance level from an ANOVA model which included cerebellar 







Table 6.1: Variables significantly discriminating the MPH-treated samples from their 














Acute treatment, low dose (2.0 mg/kg) 
1 0.91-0.97 Valine-C4-CH3a m (3.84) 3.05 x 10-3 -1.10 
2 1.00-1.06 Valine-C4-CH3b m (3.84) 2.03 x 10-3 -1.11 
3 1.45-1.51 Alanine-C3-CH3 d (7.24) 1.09 x 10-4 -1.10b 
4 1.66-1.78 Lysine-C5-CH2 d (7.69) 4.25 x 10-5 -1.14b 
5 2.00-2.04 N-acetyl-aspartate-C3-CH2 s 4.18 x 10-2 -1.34 
6 2.28-2.33 GABA-C4-CH2 t (7.24) 3.55 x 10-2 +1.10 
7 2.43-2.49 Glutamine-C4-CH2 m (4.14, 2.66) 3.69 x 10-2 -1.11 
8 3.01-3.03 GABA-C2-CH2 d (7.69) 3.56 x 10-2 +1.17 
9 4.37-4.40 N-acetyl-aspartate-C2-CHa m (3.99) 8.33 x 10-3 -1.37 
10 4.40-4.42 N-acetyl-aspartate-C2-CHb m (5.32) 2.30 x 10-2 -1.31 
Chronic treatment (2.0 mg/kg) 
1 1.29-1.35 Lactate-C3-CH3 d (6.95)   3.99 x 10-2 +1.11 
2 2.09-2.12 Glutamine-C3-CH2 m (7.54, 2.51) 3.66 x 10-4 +1.14b 
3 2.33-2.39 Glutamate-C4-CH2 m (7.39)   9.87 x 10-3 +1.10 
4 3.56-3.58 Glycine-C2-CH2 s 2.22 x 10-4 +1.24b 
5 3.94-3.97 Phosphocreatine-C2-(CH2) s 4.34 x 10-2 +1.12 
6 3.24-3.30 Taurine-C2-CH2 t (5.91) 2.41 x 10-2 +1.08 
7 6.88-6.93 Tyrosine-C5-CH m (2.37) 2.74 x 10-3 +1.10 
8 7.17-7.23 Tyrosine-C6-CH m (2.22) 4.47 x 10-2 +1.07 
9 7.37-7.40 Phenylalanine-C2-CHb d (6.95) 2.08 x 10-2 +1.07 
 (-), Decreased metabolites in the MPH-treated group relative to the controls; (+), Increased 
metabolites in the MPH-treated group relative to the controls; (b), Statistically significant even 
after Bonferroni correction. 
 
6.3.3 Exploration of differences between the left and right cerebellar hemispheres via 
multivariable ASCA analysis 
To simultaneously explore the ‘treatment status’ and ‘between-cerebellar hemispheres’ variance 
components for the acute high 5.0 mg/kg dose treatment group only, the ASCA two-factor 
independent sample analysis option in MetaboAnalyst 3.0 was used. After performing this 
analysis, no significant differences (i.e. p > 0.05) were recorded for the ‘between-cerebellar 
hemispheres’ factor or the ‘treatment status’ x ‘brain hemisphere’ interaction effect for the first 
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two major principal components explored. However, the ‘treatment status’ factor was indeed 
significant (p < 0.05).  
6.3.4 Quantitative network metabolic pathway analysis 
The quantitative network pathway analysis (with an integrated enrichment analysis and pathway 
impact from topology analysis), revealed statistically significant MPH-induced changes to a 
number of metabolic pathways. The modulated pathways in the acute high dose (5.0 mg/kg) 
MPH treatment group are listed in Table 6.2. In addition, in order to explore connections between 
the discriminant metabolites selected by OPLS-DA and those proteins that might be involved in 
the metabolic changes attributable to MPH treatment, we used Ingenuity Pathway Analysis 
(IPA). Figure 6.3 shows those connections existing between the important metabolites obtained 
from the OPLS-DA analysis and the proteins with which they interact, which are mostly 
glutamatergic and GABAergic receptors. The acute low dose and the chronic groups were left out 
of this analysis as these datasets did not achieve statistical significance from the multivariate 
analysis (i.e. the OPLS-DA analysis showed no significant difference for both datasets). 
Table 6.2: Quantitative network pathway analysis including pathway impact and pathway 
enrichment analysis from pathway topology of the acute high dose MPH-treated samples 
Metabolic Pathway Total  
Compounds 




Alanine, aspartate and glutamate 
metabolism 
24 2 0.000532 0.15 
Glycine, serine and threonine metabolism 32 2 0.000585 0.24 
Taurine and hypotaurine metabolism 8 1 0.000585 0.43 
Nicotinate and nicotinamide metabolism 13 1 0.000765 0.24 
Starch and sucrose metabolism 23 1 0.00885 0.19 
Inositol phosphate metabolism 26 1 0.00938 0.14 





Figure 6.3: Proteomic signalling pathways interconnected with the metabolites altered by 
acute MPH treatment.  
The metabolites that were either increased (green) or decreased (red) following acute 5.0 mg/kg 
MPH treatment interact with several genes and proteins including: GABA receptors such as 
SLC6A11 (encodes GAT3); Lactate dehydrogenase (Ldh); and purinergic receptors (e.g. P2RX2) 
for ATP; and Glutamate receptors such as SLC1A6 (encodes EAAT4), GRIN3B (encodes NMDA 
receptor), and Grik (glutamate receptor, ionotropic, kainate 4), as well as calcium channels and 
NMDA receptors that allow the flow of Ca2+ in response to glutamate binding.  
 
6.3.5 MPH-induced modifications of vesicular monoamine transporter density 
VMAT2, also known as solute carrier family 18 member 2 (SLC18A2), is a membrane protein 
that transports neurotransmitters including DA and NA that are implicated in both the 
pathophysiology and treatment of ADHD (Patel et al. 2003). The present study shows that MPH 
(2.0 mg/kg) alters VMAT2 protein expression in a ‘treatment duration’ dependent manner. The 
two-way ANOVA of ‘drug’ x ‘duration’ indicated a significant interaction effect between ‘drug’ 
and ‘duration’ (F(1,44) = 13.9, p < 0.0001) and a significant effect of both ‘drug’ (F(1,44) = 8.9, p = 
0.019), and ‘duration’ (F(1,44) = 10.1, p = 0.005). The post-hoc analysis revealed that acute 2.0 
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mg/kg MPH treatment significantly down-regulated (p < 0.05) VMAT2 density, while chronic 
treatment significantly upregulated (p < 0.05) the protein in comparison with the corresponding 
controls (Figure 6.4). There was, however, no significant effect of MPH on TH and D1 receptor 
densities in the cerebellum (Figure 6.4).  
 
Figure 6.4: Effect of MPH on monoaminergic markers in the cerebellum.  
(A) Acute, and (B) Chronic MPH treatment on VMAT2, D1 receptor, and TH protein densities in 
the cerebellum of adolescent rats. Values represent percentage ± SEM (n=6 rats/group but twelve 
data points (two from either hemisphere of each animal). *p < 0.05 (MPH-treated vs. control).  
 
6.3.6 MPH-induced modifications in cerebellar dopamine and its metabolite content 
Although DA and its metabolite levels in the cerebellum were very low (lower than the levels in 
the striatum), they were still detectable (Table 6.3) and somewhat comparable to the levels in the 
frontal cortex (see Table 6.3; compare with Chapter 3, Table 3.2). Analysis of the whole tissue 
levels of DA revealed a trend towards decreased DA levels in the acute MPH treated samples 
compared to the controls, but these did not reach statistical significance (p > 0.05). There was 
also no significant effect of ‘hemisphere’. Similarly, chronic MPH treatment did not cause 
statistically significant changes to the levels of DA in the cerebellum and there was also no 












































































Figure 6.5: MPH-induced whole tissue levels of DA in the cerebellum.  
DA levels in the left (LB) and right (RB) cerebellar hemispheres following (A) acute, and (B) 
chronic 2.0 mg/kg MPH treatment. Values (mean ± SEM, n=6 rats/group) were determined using 
HPLC coupled with electrochemical detection. 
 
 
With regards to DOPAC, no significant ‘drug’ or ‘hemisphere’ effect was observed after acute 
treatment (Table 6.3). However, after chronic treatment, there was a significant effect of ‘drug’ 
(F(1,20) = 20.4, p < 0.001) but not ‘hemisphere’, with the pairwise comparisons indicating higher 
DOPAC levels in both the left and right MPH-treated groups compared to the controls (p < 0.05) 
(Table 6.3). On the other hand, no significant changes were observed on HVA levels after both 
acute and chronic treatment. DA turnover as measured by DOPAC/DA ratio was not significantly 
affected by either ‘drug’ or ‘hemisphere’ in the acute samples. However, after chronic treatment, 
there was a significant effect of both ‘drug’ (F(1,20) = 20.6, p < 0.001) and ‘hemisphere’ (F(1,20) = 
10.3, p = 0.004), with higher DOPAC/DA turnover ratio recorded in both the left (p < 0.01) and 
right (p < 0.05) MPH-treated group compared to the controls. No statistically significant effects 





Table 6.3: DA and its metabolite levels in the cerebellum following acute and chronic MPH 
treatment 
  Acute  Chronic  
Cerebellum Brain 
region 
Control MPH  Control MPH 
DA (µg/g) Left 0.050 ± 0.002 0.053 ± 0.001 0.0411± 0.0001 0.0414 ± 0.0002 
 Right 0.042 ± 0.002 0.048 ± 0.002 0.0415± 0.0001 0.0413 ± 0.0002 
DOPAC (µg/g) Left 0.0029 ± 0.0002 0.0032 ± 0.0001 0.005 ± 0.0005 0.007 ± 0.0003* 
 Right 0.0028 ± 0.0001 0.0030 ± 0.0001 0.004 ± 0.0001 0.006 ± 0.0004* 
HVA (µg/g) Left 0.0026 ± 0.0001 0.0027 ± 0.0001 0.0029 ± 0.0004 0.0027 ± 0.0005 
 Right 0.0027 ± 0.0001 0.0027 ± 0.0001 0.0033 ± 0.0002 0.0033 ± 0.0003 
DOPAC/DA Left 0.058 ± 0.004 0.059 ± 0.002 0.133 ± 0.01# 0.180 ± 0.08** 
 Right 0.069 ± 0.002 0.064 ± 0.005 0.102 ± 0.04 0.147 ± 0.01* 
HVA/DA Left 0.052 ± 0.002 0.051 ± 0.001 0.069 ± 0.01 0.066 ± 0.01 
 Right 0.064 ± 0.004 0.056 ± 0.003 0.079 ± 0.005 0.081 ± 0.008 
Values (mean ± SEM, n=6 rats/group) were determined using HPLC-EC. *p < 0.05, **p < 0.01 
(significant effect of ‘drug’ i.e. MPH vs. control); #p < 0.05 (significant ‘hemisphere effect’ i.e. 
left vs. right hemisphere). 
 
6.4 Discussion 
6.4.1 Principal findings 
Cerebellar abnormalities in ADHD patients are frequently detected in magnetic resonance 
imaging (MRI) studies. In particular, such imaging studies have observed decreased cerebellar 
volumes in ADHD patients relative to non-ADHD controls (Castellanos et al. 1996; Berquin et 
al. 1998). However, to our knowledge, this is the first 1H-NMR spectroscopic study along with 
Western blotting and HPLC-EC that examines MPH action on adolescent rat cerebellar tissue 
levels of metabolites and proteins associated with DA and NA function, as well as whole tissue 
levels of DA and its main metabolites. The data obtained in this study shows ‘dose’ and 
‘treatment duration’ dependent differences in the action of MPH. Here, while acute MPH 5.0 
mg/kg treatment decreased metabolites such as NAA, glutamate, glutamine and NAD, it 
increased metabolites such as GABA, glycine, aspartate, acetate and hypoxanthine. Similarly, but 
to a much lesser extent, acute 2.0 mg/kg also increased GABA but decreased membrane-related 
	197	
metabolites (e.g. NAA) in addition to other metabolites such as glutamine, valine, lysine and 
alanine. On the other hand, chronic 2.0 mg/kg MPH treatment elevated most metabolites 
including amino acid transmitters (e.g. glutamate, glutamine and glycine), membrane and energy-
related metabolites (e.g. lactate, creatine and taurine), as well as LNAAs (e.g. tyrosine and 
phenylalanine). 
In addition, while acute MPH treatment decreased cerebellar VMAT2 protein density, chronic 
MPH treatment significantly elevated the expression of VMAT2. However, there were no 
significant MPH-induced changes in the levels of TH and D1 receptor expression in the 
cerebellum. Also, although both acute and chronic MPH treatment failed to significantly alter DA 
levels in the cerebellum, chronic but not acute MPH treatment increased DOPAC and the 
DOPAC/DA ratio in both the left and right cerebellar hemispheres, suggesting increased 
cerebellar DA turnover following chronic treatment. 
6.4.2  MPH effects on cerebellar dopamine, large neutral amino acids and monoaminergic 
markers  
The present study revealed significant MPH-induced modulations to a number of LNAAs. Here, 
the branched chain amino acid (BCAA) valine was decreased after acute administration of the 2.0 
mg/kg MPH dose (but not the 5.0 mg/kg dose). In contrast, the aromatic amino acids (AAAs) 
tyrosine and phenylalanine were increased after chronic MPH treatment (Table 6.1). Given that 
LNAAs are polar compounds and are unable to cross the blood-brain barrier freely, the large 
neutral amino acid transporter (LAT-1), an active transport system is required for their transport 
into the brain (Fernström 2013). LNAAs compete for LAT-1 uptake and subsequent transport 
into the brain; it is therefore possible that MPH modifies the physiological balance of LNAAs in 
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the plasma (as discussed in Chapter 5), resulting in the increased entry of some LNAAs into the 
brain over others.  
Initially, the cerebellum was not thought to be an area of DA-containing axons, as early 
investigations found no projections from DA-containing cell groups to the cerebellum (Lindvall 
and Björklund 1974). However, using more advanced techniques, later studies in rodents revealed 
a projection from the VTA to the cerebellum (Ikai et al. 1992). In addition, results from more 
recent studies indicate moderate levels of DA and NA in the cerebellum, as well as high densities 
of TH immunoreactive axons in both rodents and primates (Glaser et al. 2006; Melchitzky and 
Lewis 2000). In this context therefore, the present study measured tissue levels of DA in the 
cerebellum of MPH-treated and saline-treated rats. Interestingly, the present study has 
demonstrated significantly increased cerebellar levels of the aromatic amino acid (AAA) tyrosine 
and its precursor phenylalanine following chronic MPH treatment compared to the corresponding 
saline-treated control rats (see Table 6.1). These AAAs are involved in the biosynthesis of the 
catecholamines, DA and NA, which play crucial roles in executive brain functions and motor 
activity. Given these increased cerebellar AAAs, and the MPH-induced increases of tyrosine and 
phenylalanine in the cerebral regions such as frontal cortex and hippocampus as described in 
Chapters 4 and 5, it is possible that MPH alleviates ADHD symptoms not only by DAT and NET 
blockade but also by elevating the brain pool of precursors to DA and NA synthesis (i.e. tyrosine 
and phenylalanine). The increased AAAs (i.e. tyrosine and phenylalanine) following chronic 2.0 
mg/kg MPH treatment corresponded with an increased DOPAC and dopamine turnover ratio (i.e. 
DOPAC/dopamine ratio) (Table 6.3) and increased cerebellar VMAT2 density (Figure 6.4), 
while acute treatment decreased VMAT2 density. However, these MPH-induced alterations to 
AAAs and VMAT2 density did not result in significant changes of cerebellar DA after either 
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acute or chronic MPH treatment. This would suggest that, in the cerebellum, over-expression of 
these AAAs and VMAT2 (induced by chronic 2.0 mg/kg MPH treatment in this thesis) does not 
lead to increased DA expression, which contrasts our findings in the cerebral areas showing that 
an increase of these AAAs increase DA levels (see Chapters 3, 4 and 5), as well as a previous 
report that found increased VMAT2 to be associated with increased DA in mice striatum (Lohr et 
al. 2014). It is possible that in the cerebellum, whole tissue DA represents a substrate for NA 
synthesis, rather than acting as a neurotransmitter itself. Indeed, a previous study provided some 
evidence that in the cerebellum, DA may predominantly serve as a substrate for NA synthesis 
(Glaser et al. 2006). Also in support of the present findings, reports from clinical studies indicate 
that acute MPH treatment does not significantly alter extracellular DA in the cerebellum (Volkow 
et al. 2001). 
Further, cerebellar levels of the essential amino acid lysine, the non-essential amino acid alanine, 
and the BCAA valine, were decreased after acute 2.0 mg/kg MPH treatment but not after 5.0 
mg/kg high dose or chronic 2.0 mg/kg MPH treatment. Alanine is involved in glucose production 
and could be made from the BCAA valine, both of which are decreased following acute 2.0 
mg/kg MPH treatment. Moreover, as mentioned above, the cerebellar levels of lysine was also 
reduced after acute treatment. While lysine’s role in the brain remains to be clarified, some 
studies have suggested that decreased or deficient lysine increases serotonin release (but not DA 
release) in some brain regions (e.g. amygdala), which results in an enhancement of the levels of 
anxiety (Smriga et al. 2002), a condition which is often comorbid with ADHD and occasionally 
reported as a side effect of MPH (Mulraney et al. 2016). 
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6.4.3 MPH modulates metabolites in the glutamatergic and GABAergic systems 
A major finding of the present study is the acute MPH-induced (2.0 and 5.0 mg/kg) decrease of 
cerebellar levels of amino acid neurotransmitters involved in the excitatory glutamatergic system 
(e.g. glutamate and glutamine), and the contrasting elevation of the same metabolites following 
chronic treatment (2.0 mg/kg, twice daily for 15 days). On the other hand, the inhibitory 
neurotransmitter metabolite, GABA, was generally increased following acute treatment, with the 
higher dose of MPH (5.0 mg/kg) showing the most pronounced effect. Glycine, which is also an 
inhibitory metabolite was significantly enhanced by the higher (5.0 mg/kg) MPH dose but 
remained unaltered by the lower dose (2.0 mg/kg), but chronic 2.0 mg/kg administration 
significantly up-regulated glycine. The excitatory AAA aspartate, in contrast to glutamate was 
increased by acute 5.0 mg/kg MPH, while the lower (2.0 mg/kg) dose failed to alter its levels 
(Figure 6.2 and Table 6.1).  
When glutamine is taken into the cerebellar cells, a mitochondrial associated enzyme (i.e. 
glutaminase 1) converts it to glutamate (Holten and Gundersen 2008; Marie and Shinjo 2011). 
Glutamate is also converted to α-ketoglutarate, which enters the tricarboxylic acid cycle in the 
mitochondria. However, glutamate can also be converted to aspartate that contributes to nucleic 
acid and serine synthesis. In addition, the inhibitory transmitter GABA is known to be generated 
from glutamate via glutamate decarboxylase in GABAergic neurons (Holten and Gundersen 
2008; Marie and Shinjo 2011). Glutamine, glutamate, and GABA have all been implicated in the 
pathophysiology of ADHD (Moore et al. 2006; Perlov et al. 2010; Perlov et al. 2007; Bollmann 
et al. 2015). In particular, cerebellar glutamine and glutamate are reported to be abnormally high 
in ADHD patients compared to matched controls (Perlov et al. 2010).  
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With glutamate and glutamine expressed in both neurons and glial cells, it is uncertain whether 
the dampened total cerebellar glutamate and glutamine induced by acute 2.0 mg/kg and 5.0 
mg/kg MPH treatment is related to altered neuronal excitatory transmission. However, consistent 
with our findings, previous 1H-MRS studies in young ADHD patients also reported decreased 
cerebellar glutamate and glutamine levels following acute stimulant medication (Ben Amor 2014; 
Soliva et al. 2010). The findings reported in this study would suggest that acute 2.0 mg/kg and 
5.0 mg/kg MPH treatment may enhance the conversion of glutamine to glutamate, and the 
subsequent conversion of glutamate to aspartate and GABA in the cerebellum, resulting in 
decreased levels of glutamine and glutamate but increased levels of aspartate and GABA. Indeed, 
while a previous study has confirmed the existence of GABA and glutamate decarboxylase in the 
cerebellum (Crook et al. 2006), another study has reported that psychostimulant (e.g. cocaine) 
administration increases the protein levels of the glutamate decarboxylase enzyme relative to 
controls (Goitia et al. 2013), which could potentially increase the conversion of glutamate to 
GABA and aspartate. Overall, it is possible that the acute MPH-induced decrease of glutamine 
and glutamate observed in the present study may normalise the levels of these metabolites in the 
cerebellum of those suffering from ADHD, as a previous study found abnormally high levels of 
these metabolites in the cerebellum of ADHD patients (Perlov et al. 2010).  
This dampened cerebellar excitatory amino acid transmitter levels following acute 2.0 mg/kg and 
5.0 mg/kg, however, contrasts our previous findings in the cerebral areas, where these MPH 
doses elevated the excitatory amino acid transmitter glutamate and its precursor glutamine (see 
Chapters 4 and 5). However, similar contrasting findings in the cerebral areas and the cerebellum 
have previously been found following MPH treatment in both humans and rodents, with the 
phenomenon suggested to be mediated by differences between receptor densities (e.g. dopamine 
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D2 and D4 receptors) in these two brain areas (Volkow et al. 1997; Michaelides et al. 2010). 
Also supporting the contrasting findings in the cerebellum and some parts of the cerebrum, some 
clinical studies on medication naïve ADHD patients found increased excitatory transmitter 
(glutamate and glutamine) levels in the cerebellum (Perlov et al. 2010), but decreased excitatory 
transmitter (glutamate and glutamine) levels in the frontal cortex relative to their corresponding 
control groups (Perlov et al. 2007). Moreover, previous studies have suggested co-localisation of 
GABA and glycine in the cerebellum of rats (Crook et al. 2006; Ottersen et al. 1987). Evidence 
shows that in the cerebellum of rats, glycine is used as a fast inhibitory neurotransmitter and that 
it is released together with GABA (Dumoulin et al. 2001; Dugué et al. 2005). Glycine in the 
cerebellum is suggested to play important roles in motor control (Avila et al. 2013; Rees et al. 
2003). Thus, an increase of these inhibitory amino acid transmitters (i.e. glycine and GABA) and 
the decrease of the excitatory transmitter glutamate could have implications on cerebellum-
mediated motor activity and may correspond with the effect of MPH in minimising hyperactivity.  
6.4.4 MPH regulates cerebellar energy metabolism 
Alterations in energy metabolism has been described as a key abnormality in ADHD (Todd and 
Botteron 2001). In this study, acetate was significantly increased in the cerebellum following 
acute 5.0 mg/kg MPH treatment compared to controls (Figure 6.2). In addition, lactate and 
phosphocreatine were also increased following chronic 2.0 mg/kg treatment (Table 6.1). Lactate 
has emerged as a key player in brain energetics. Converging evidence from in vitro and in vivo 
experiments indicate that lactate, a non-glucose fuel, is an efficient energy substrate used 
preferentially by neurons in maintaining synaptic transmission, especially during periods of 
intense activity (Larrabee 1995; Smith et al. 2003). Lactate is produced locally by astrocytes 
within the brain in an activity-dependent glutamate-mediated manner (Pellerin and Magistretti 
1997). Glycolysis is stimulated within astrocytes by the excitatory neurotransmitter glutamate, 
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generating and releasing lactate, which is then used by neurons as an anaerobic energy substrate 
enabling neurons to endure activation (Smith et al. 2003). Given that cerebellar glutamate was 
found in the present study to be increased by chronic MPH administration, it is possible that the 
increased lactate levels may be related to increased glutamate-mediated stimulation of glycolysis 
in cerebellar neuronal and astrocytic cells. In support of this, it has been shown in in vitro 
experiments that increased glutamate usage enhances lactate release via the glycolytic pathway 
(Pellerin and Magistretti 1994). Like lactate, acetate serves as an important alternative energy 
source (Cremer et al. 1976; Deelchand et al. 2009; Waniewski and Martin 1998). Therefore, an 
increase of these metabolites (i.e. acetate and lactate) in the cerebellum may be important for 
cerebellar neurons in maintaining synaptic transmission during periods of intense activity 
(Larrabee 1995; Smith et al. 2003).  
The creatine/phosphocreatine cycle is also linked with brain energy homeostasis, adenosine 
triphosphate (ATP) production, and functions as an alternative energy source (Rae et al. 2003). 
Similar to lactate, we found that the levels of phosphocreatine were increased following chronic 
2.0 mg/kg treatment (Table 6.1). This finding could be related to an earlier study that found no 
significantly altered cerebellar creatine kinase activity after acute (2.0 and 10.0 mg/kg) MPH 
treatment but significantly elevated cerebellar creatine kinase activity following chronic (10.0 
mg/kg) MPH treatment in both young and adult rats (Scaini et al. 2008). In addition to the 
creatine/phosphocreatine cycle, purine metabolism is also closely linked to ATP production and 
utilisation. Here, the purine derivative hypoxanthine was increased following acute 5.0 mg/kg 
MPH treatment relative to the controls (Figure 6.2). Increased hypoxanthine could lead to an 
increased level of the final metabolic product of purine catabolism, uric acid. In support of this, 
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d-amphetamine, which also increases synaptic levels of DA (similar to MPH), and is also used in 
the treatment of ADHD, has been shown to increase brain levels of uric acid (Miele et al. 2000).  
 
NAD is another metabolite that plays a crucial role in brain energy metabolism. NAD is a 
coenzyme that exist either in the oxidised (NAD+) or reduced (NADH) form. NAD is essential 
for several mitochondrial enzymatic reactions and cellular bioenergetic metabolism (Kristian et 
al. 2011). In the mitochondria, NAD (reduced form) is converted to ATP (in the presence of 
oxygen), which is required to fuel and maintain neuronal function. Thus, NAD loss inhibits 
cellular respiration, resulting in a decline of mitochondrial ATP production and potentially cell 
death (Kristian et al. 2011). NAD loss has been associated with an inability to focus (inattention), 
chronic fatigue, anxiety, and substance abuse (Castro-Marrero et al. 2015; Ieraci and Herrera 
2006). Indeed, some recent reports suggest that extracellular NAD may be a candidate 
neurotransmitter, given its neuronal effects (Durnin et al. 2012). In the present study, NAD levels 
were significantly dampened following acute 5.0 mg/kg (high dose) MPH treatment. Previous 
studies have indicated that decreased or extremely low levels of NAD predispose both rats and 
humans to addiction, and that NAD and its precursor, nicotinamide administration protects 
against ethanol-related addiction and neuronal loss (Ieraci and Herrera 2006; Sauve 2008). This 
decrease of NAD following the high MPH dose, in the present study, could therefore potentially 
contribute to the addictive tendencies that may be associated with MPH (Wang et al. 2013; Zhu 
et al. 2011). However, considering that this effect was not seen following either acute or chronic 
2.0 mg/kg treatment, it is possible that NAD loss may contribute to the addictive tendencies 
associated with the intake of high (e.g. ≥ 5.0 mg/kg) MPH doses (Morton and Stockton 2000). 
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6.4.5  MPH and the metabolism of membrane components 
Impairments in membrane components such as NAA, and taurine are often reported in several 
psychiatric and behavioural conditions such as schizophrenia and ADHD, respectively (Maltezos 
et al. 2014; Paslakis et al. 2014). In the present study, we observed that NAA, an acetylated 
derivative of aspartate, was decreased following a single injection of both low (2.0 mg/kg) and 
high (5.0 mg/kg) doses of MPH but unaltered following chronic MPH treatment (Figure 6.2 and 
Table 6.1). Evidence suggests that NAA is involved in the regulation of neuron-glia signalling, 
myelin synthesis, and osmoregulation, as well as the turnover of glutamate and NAAG (Baslow 
2003; Moffett et al. 2007). NAA is synthesised mostly in the mitochondria from aspartate and 
acetyl-CoA and transported into the neuronal cytoplasm and then eventually transferred to 
oligodendrocytes for degradation into acetate and aspartate (Baslow 2010). Interestingly, in the 
present study, the decreased NAA levels following acute MPH treatment coincided with 
increased levels of both acetate and aspartate (Figure 6.2 and Table 6.1). Possibly suggesting an 
increased degradation of NAA into these two metabolites (i.e. acetate and aspartate) in the 
cerebellum following acute MPH treatment. In support of the finding on NAA, other studies on 
young ADHD patients have also reported that acute MPH treatment decrease NAA levels in the 
cerebellum (Soliva et al. 2010) and striatum (Ben Amor 2014) relative to controls. In addition to 
the increased breakdown of NAA into acetate and aspartate, the MPH-induced decrease of NAA 
levels could also be related to impaired energy production, as some studies on rats have shown 
that NAA levels reduce when energy production (i.e. ATP levels) decreases (Bates et al. 1996; 
Clark 1998). Indeed, in the present study, acute 5.0 mg/kg MPH decreased NAD, which is crucial 
for the generation of ATP (as discussed above).   
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Taurine was moderately enhanced following chronic treatment with MPH, this metabolite has a 
neuromodulatory function as well as a range of important functions in neural tissues including 
osmoregulation, antioxidation, and neuroprotection (Saransaari and Oja 2000). The release of 
taurine is evoked in potentially cell damaging conditions such as hypoxia, ischemia, 
hypoglycemia, free radicals and oxidative stress in cerebellar granule neurons (Saransaari and 
Oja 2000). Excitotoxic concentrations of glutamate are also reported to potentiate taurine release 
in mice brain slices (Saransaari and Oja 2000). Therefore, the increased levels of taurine 
observed following chronic 2.0 mg/kg MPH treatment could be linked to the enhanced excitatory 
transmission (i.e. the increased glutamate level) observed after chronic MPH treatment. This 
increased taurine levels could constitute an important protective mechanism preventing 
(glutamatergic) excitation from reaching neurotoxic levels. Taken together, alterations of NAA 
and taurine by MPH suggest that the drug alters neuronal mitochondrial/membrane dynamics in 
the cerebellum. 
6.4.6  Comparison of the left and right cerebellar hemispheres 
Previous studies have linked ADHD with significantly less activation in the right hemisphere of 
several brain regions in both young and adult patients during attention and memory related tasks 
(Vance et al. 2007; Rubia et al. 1999). To determine if there was a differential action of MPH on 
the cerebellar hemispheres, we explored the action of the drug in the left and right cerebellar 
extracts following both acute and chronic MPH treatment. Here, neither the 1H-NMR 
spectroscopic data or the HPLC-EC data on DA and DOPAC levels revealed any significant 
differences regarding the action of MPH on the range of metabolites and neurochemicals 
measured in the left versus the right side of the cerebellum. 
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6.5  Conclusion 
To understand the mechanism of action of MPH, we examined cerebellar neurochemistry and 
protein marker expression for the monoaminergic system following acute and chronic MPH 
treatment. Overall, there was a dose- and treatment duration-dependent effect of the drug on 
cerebellar metabolites. In this regard, acute MPH treatment decreased glutamatergic transmission 
(i.e. glutamate and glutamine), as well as membrane and energy-related metabolites (e.g. NAA, 
NAD) but increased GABA, glycine, aspartate, acetate and hypoxanthine levels. However, these 
effects of acute MPH treatment were mostly more pronounced after the high 5.0 mg/kg dose as 
compared to the low 2.0 mg/kg dose. On the other hand, chronic 2.0 mg/kg MPH dose increased 
several metabolites including the AAAs (e.g. tyrosine and phenylalanine), glutamatergic 
transmitters, energy-related metabolites (e.g. glutamate and glutamine), as well as membrane and 
energy-related metabolites. In addition, acute MPH treatment significantly decreased VMAT2 
levels in the cerebellum, while chronic treatment significantly upregulated the expression of the 
vesicular transporter. These findings indicate that both drug-dosage and treatment-duration are 

































7 Effect of methylphenidate on neuroplasticity mediating proteins and their 


























MPH is often prescribed to alleviate the cognitive deficits, impulsivity and hyperactivity 
symptoms associated with ADHD (Biederman and Faraone 2005). However, the last two decades 
has witnessed a surge in the prescription of the drug for children and adolescents with the 
condition, although the long-term effect of the drug still remains largely unknown. Consequently, 
there are growing concerns over potential long-term adverse effects of the drug, as well as its 
abuse liability (Swanson and Volkow 2003; Teter et al. 2006). Reports indicate that repeated 
exposure to psychostimulants such as MPH causes complex structural, molecular, and plastic 
modifications in the brain’s reward circuitry (Berman et al. 2008; Haydon et al. 2009). It is well 
established that morphological changes of dendrites, particularly at the level of the dendritic 
spines lead to synaptogenesis (Kang et al. 2016). Dendritic spines are small protrusions from a 
neuron’s dendrite and they are at the receiving end of an incoming presynaptic nerve terminal 
seeking to form a synapse with a postsynaptic target. Dendritic spines are crucial for synaptic 
strength and help to transmit signals to the cell body of the post synaptic neurons (Kasai et al. 
2003). Interestingly, a recent study has shown that chronic exposure to MPH and cocaine alter 
dendritic spine density (Kim et al. 2009). Structural and functional changes in spines and 
synapses are known to be important processes mediating memory and learning, as well as drug-
related behaviour (Soria Fregozo and Pérez Vega 2012; Kang et al. 2016). Although MPH has 
been shown to cause morphological changes of dendritic spines, the MPH-induced alterations in 
genes and proteins involved in plasticity-related pathways have not yet been fully determined. 
Alterations of dendritic spine density are often related to the expression patterns of actin-
associated genes (Sarowar and Grabrucker 2016). Thus, actin filaments form dendritic spines at 
the leading edge of cells from their precursors (i.e. filopodia) and the spines cover the surface of 
	210	
several dendrites (see Figure 7.1), serving as the major contact sites for excitatory synapses in the 
cortex, striatum, hippocampus, cerebellum and other brain regions (Soria Fregozo and Pérez 
Vega 2012). Recent studies have increased our understanding of the proteins controlling the 
formation of dendritic spines, which includes the filament nucleating Arp2/3 complex and its Rho 
family of GTPase regulators, Cdc42 and Rac, which promote the formation of filopodia (Soria 
Fregozo and Pérez Vega 2012). Cdc42 and Rac regulate the formation of dendritic spine head by 
activating the Arp2/3 complex and by inhibiting acting depolymerisation. In addition, Cdc42 
serves as one of the main signalling channels that promote branching of dendritic spine heads, 
while the activation of Arp2/3 polymerises actin and causes an extension of spine heads (Kang et 
al. 2016). 
A major actin regulator that has attracted a lot of attention recently is the insulin receptor tyrosine 
kinase substrate protein 53 (IRSp53), which is also known as brain specific angiogenesis 
inhibitor 1 associated protein 2 (BAIAP2) (Yeh et al. 1996). IRSp53 is a multi-domain adaptor 
protein that regulates membrane and actin dynamics at actin-rich subcellular structures (see 
Figure 7.1), such as filopodia and lamellipodia (i.e. broad sheet-like projections containing a 
network of short branched filaments) (Govind et al. 2001; Krugmann et al. 2001; Yamagishi et 
al. 2004). This hypothesis is supported by findings demonstrating that IRSp53 localises to the 
tips of both filopodia and lamellipodia (Nakagawa et al. 2003). Although the functions of IRSp53 
were initially mainly studied in non-neural cells, recent evidence supports neuronal functions, 
particularly in the regulation of actin dynamics at excitatory synapses and dendritic spines. 
Presently, IRSp53/BAIAP2 has been implicated in several brain disorders including ADHD (Liu 
et al. 2013; Ribasés et al. 2009), autism spectrum disorders (Levy et al. 2011; Toma et al. 2011), 
and schizophrenia (Purcell et al. 2014; Fromer et al. 2014). Importantly, studies on the 
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behavioural phenotypes of mice lacking IRSp53 suggest that such mice exhibit social and 
cognitive deficits, as well as hyperactivity, which are among the core symptoms of ADHD (Kim 
et al. 2009; Sawallisch et al. 2009; Chung et al. 2015). Thus, these behavioural phenotypes 
support the usage of IRSp53 knockout mouse models for ADHD and related disorders. 
  
Figure 7.1: Structure and role of IRSp53 in the development of dendritic spines. 
(A) Dendritic spines are small protrusions from a neuron’s dendrite. (B) Spine formation is mediated 
by several genes and proteins including IRSp53, Cdc42, and Arp2/3 complex. (C) Binding of 
activated Cdc42 to the CRIB-PR domain opens up the IRSp53 protein, allowing the SH3 domain to 
bind downstream effectors, including N-WASP and WAVE2. Abbreviations: NMDAR, NMDA 
receptor; AMPAR, AMPA receptor; mGluR, metabotropic glutamate receptor; EphB, Ephrin B 
receptor; Eps8, epidermal growth factor receptor; IMD, IRSp53-MIM homology domain; CRIB-PR, 
Cdc42/Rac interactive binding-proline rich domain; SH3, Src homology 3 domain; WW, WW 
domain; and PDZ-B, PSD-95/Dlg/ZO-1 domain-binding motif (Adapted from Kang et al. 2016). 
 
The IRSp53 protein has multiple domains for protein-protein interactions, including the CRIB-













































also called the I-BAR), SH3 (Src homology 3) domain, and the WW domain, as well as the C-
terminal PDZ-B (PSD-95/Dlg/ZO-1 domain-binding) motif (see Figure 7.1). Binding of activated 
Cdc42 to the CRIB-PR domain allows IRSp53 to promote filopodia formation, suggesting that 
IRSp53 is key for the Cdc42-mediated filopodia and dendritic spine formation (Govind et al. 
2001; Krugmann et al. 2001; Yamagishi et al. 2004).  
 
The Arc (activity-regulated cytoskeleton-associated) gene is also important for dendritic spine 
formation, synaptic plasticity, and cognition, as well as being induced following stress 
(Tzingounis and Nicoll 2006; Banerjee et al. 2009). More specifically, the expression of the Arc 
gene and its corresponding protein is induced when synapses are undergoing modification during 
learning (Steward et al. 2015). Our lab recently reported in an in situ hybridisation study that 
acute administration of both MPH and amphetamine significantly decrease Arc mRNA in the 
hippocampus and parietal cortex of young but not adult rats, suggesting that the immature brain 
respond to MPH differently compared to the adult brain (Banerjee et al. 2009). 
 
In the present study, the effect of both acute and chronic MPH exposure to adolescent rats were 
investigated on the expression of actin dynamics- and plasticity-associated genes and proteins 
such as IRSp53, Cdc42, Arp2, and Arc. The study provides insights into the plastic changes that 
might occur in the adolescent brain following early exposure to the anti-ADHD drug, MPH. 
7.1.1 Aims 
This study was aimed at exploring the effect of MPH on neuroplasticity-related proteins and their 
corresponding genes some of which have been suggested to be involved in the pathophysiology 
of ADHD. The experiments tested the hypothesis that MPH treatment influences neuroplasticity-
related proteins and that the MPH induced effect varies dependent on length or duration of 
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treatment. To support the protein findings after chronic MPH administration, expression of the 
corresponding genes were also measured, this only in selected brain regions previously connected 
with the symptoms of ADHD and its treatment such as: nucleus accumbens, frontal cortex, dorsal 
striatum and cerebellum. Specifically, the study evaluated the following: 
§ The region-specific and treatment duration-dependent effects of MPH treatment on the 
expression of actin-binding and cytoskeletal-associated proteins using Western blotting. 
§ The treatment and region-specific effects of MPH treatment on the expression of actin-
binding and cytoskeletal-associated genes (i.e. mRNA) such as Arc, IRSp53, Cdc42, and 
Arp2 using polymerase chain reaction. 
 
7.2 Methods 
7.2.1 Drug Treatment 
For a detailed description of the MPH treatment procedures see Chapter 2, section 2.1. However, 
in brief, the animals involved in this study were assigned to two treatment groups i.e. acute and 
chronic groups. The animals in the acute group either received a single 1.0 ml/kg, i.p saline dose 
(control group; n=6) or 2.0 mg/kg, i.p MPH dose (drug-treated groups; n=6). On the other hand, 
the animals in the chronic group either received a twice-daily (9 am and 5 pm) 1.0 ml/kg saline 
dose or 2.0 mg/kg MPH dose for 15 days (n=6 rats/group). The last injection in both treatment 
groups was administered on postnatal day 40 and the brain regions removed 24 h after this last 
injection. 
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7.2.2 Measurements of acute and chronic MPH induced expression of proteins mediating 
synaptic plasticity  
The Western blot technique was employed to examine the acute and chronic effects of MPH 
treatment on IRSp53/58 (1:2000; OriGene), Cdc42 (1:1000; Santa Cruz Biotechnology), Arp2 
(1:1000; Santa Cruz Biotechnology), and Arc (1:1000; Santa Cruz Biotechnology), protein 
expression in the frontal cortex, parietal cortex, striatum, nucleus accumbens, hippocampus and 
cerebellum (as previously described in Chapter 2, section 2.5). The proteins were normalised to 
β-actin (1:2000; Santa Cruz Biotechnology). There were six animals assigned to each treatment 
group. The animals were sacrificed 24 h after the last drug treatment (post natal day 40) and the 
brains removed and snap-frozen in isopentane on dry ice and then stored at -80°C until analysis 
(as previously described in Chapter 2, section 2.1).  
7.2.3 Measurements of the mRNA of genes mediating synaptic plasticity following chronic 
MPH administration  
After chronic MPH treatment, the real-time quantitative PCR (RT-qPCR) technique was used to 
quantify the changes in mRNA levels of IRSp53/58 (BAIAP2), Cdc42, Arp2, and Arc genes (see 
Table 2.2). The primers for these genes were selected, designed and verified as previously 
described (Chapter 2, section 2.6). The animals were sacrificed 24 h after the last drug treatment 
and the brains removed and snap-frozen in isopentane on dry ice and then stored at -80°C until 
analysis (as previously described in Chapter 2, section 2.1.3). The RNA extraction procedure, the 
reverse transcription of RNA to complementary DNA (cDNA), and the RT-qPCR processes have 
been described in Chapter 2, section 2.6.  
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7.3 Results 
7.3.1 Effect of MPH on the expression of Arc and its corresponding gene 
Prolonged MPH exposure has been shown to induce neuroadaptive changes in the brain of young 
and adolescent rats (Kim et al. 2009; Allen et al. 2010). The majority of these previous studies 
are, however, performed following acute rather than repeated administrations of MPH. Hence the 
effects of both acute and chronic MPH exposure on the expression of the Arc protein (a 
dendritically located protein strongly associated with neuronal plasticity) were investigated in the 
present study. Using the Western blot technique, the Arc protein was reliably measured in the 
nucleus accumbens, frontal cortex, parietal cortex, hippocampus, dorsal striatum, and the 
cerebellum. The Arc protein showed clear evidence of ‘drug’ (MPH vs. saline) and ‘duration’ 
(acute vs. chronic) dependent differences in response to MPH treatment. In general, chronic MPH 
treatment elicited more pronounced effects (significant changes detected in 4/6 brain region) on 
the Arc protein compared to acute treatment (significant change in only 1/6 brain regions; see 
Figure 7.2). A similar trend was also clear for the other neuroplasticity-associated proteins 
measured in this study (Figures 7.4, 7.6 and 7.8). Overall, apart from the cerebellum that 
responded differently compared to the other regions in the cerebrum, Arc was generally 
upregulated following chronic treatment while acute treatment failed to have an effect. In 
contrast, in the cerebellum acute treatment upregulated Arc and down-regulated the protein after 
chronic treatment (Figure 7.2). The two-way ANOVA revealed a significant ‘drug’ x ‘duration’ 
interaction effect (F(1,20) = 16.4, p < 0.001) in the parietal cortex, as well as significant effects of 
‘drug’ (F(1,20) = 5.09, p = 0.036) and ‘duration’ (F(1,20) = 18.1, p < 0.001). The post-hoc analysis 
indicated increased cortical Arc protein density in the chronic MPH-treated samples compared to 
the controls (p < 0.01) (Figure 7.2). In the striatum and hippocampus, there were significant 
effect of ‘drug’ (F(1,20) = 4.324, p = 0.044 and F(1,20) = 4.697, p = 0.045 respectively). The post-
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hoc analysis showed increased striatal and hippocampal Arc protein expression in the chronic 
MPH-treated samples compared to the controls. Moreover, in the cerebellum, there was a 
significant ‘drug’ x ‘duration’ interaction effect (F(1,20) = 10.9, p = 0.0033) and a significant effect 
of ‘drug’ (F(1,20) = 6.9, p = 0.034) and ‘duration’ (F(1,20) = 12.9, p = 0.0021). The pairwise analysis 
showed increased Arc expression in the cerebellum after acute treatment (p < 0.05) but decreased 
expression after chronic MPH treatment (p < 0.05) compared to controls (Figure 7.2). 
 
Figure 7.2: Effect of MPH on Arc protein density.  
This was measured following (A) Acute, and (B) Chronic 2.0 mg/kg MPH administration. Bars 
represent percentage ± SEM (n=6 rats/group). *p < 0.05, **p < 0.01, indicates significant 
difference as compared to matched saline-treated control groups. Abbreviations: NAc, nucleus 
accumbens; FC, frontal cortex; PCx, parietal cortex; DS, dorsal striatum; HIP, hippocampus; Cer, 
cerebellum. 
 
The Arc mRNA was measured following chronic MPH administration in the nucleus accumbens, 
frontal cortex, striatum and cerebellum. Here, similar to the Arc protein, chronic 2.0 mg/kg MPH 
treatment induced a significant up-regulation of Arc mRNA in the striatum (t10 = 2.14, p = 0.039; 
Student’s t-test) but not in any of the other examined brain regions including those that 

































































Figure 7.3: Effect of MPH on Arc mRNA density.  
This was measured following chronic MPH administration. Bars represent mean values ± SEM 
(n=6 rats/group), data was normalised to both β-actin and GAPDH reference genes. *p < 0.05 
indicates significant difference as compared to matched saline-treated control groups (Students t-
test). Abbreviation: NAc, nucleus accumbens; FC, frontal cortex; DS, striatum; Cer, cerebellum. 
 
7.3.2 Effect of MPH on IRSP53/58 protein and mRNA density   
IRSp53/58 (also known BAIAP2) has been implicated in ADHD (Liu et al. 2013; Ribasés et al. 
2009), and it induces extensive actin-containing filopodia and dendritic spine formation, as well 
as neuronal proliferation (Soria Fregozo and Pérez Vega 2012). Here, the effect of MPH 
treatment on the expression of IRSp53/58 protein (acute and chronic), as well as the mRNA 
levels (chronic only) for its corresponding gene was examined. Similar to the trend found 
regarding the Arc protein, MPH had more pronounced effect on the IRSp53/58 following chronic 
treatment (Figure 7.4). In this regard, while no significant changes were observed following acute 
MPH treatment, the two-way ANOVA showed that, in the striatum, there was a significant ‘drug’ 
x ‘duration’ interaction effect (F(1,20) = 6.36, p = 0.021), as well as a significant effect of both 
‘drug’ (F(1,20) = 10.6, p = 0.0045) and ‘duration’ (F(1,20) = 12.3, p = 0.0029). Further, the 
Bonferroni post-hoc analysis showed increased protein expression in the striatal samples of the 
MPH-treated rats compared to the corresponding controls (p < 0.05) (Figure 7.4). In contrast, in 
the parietal cortex and cerebellum, chronic MPH induced significant reductions of the IRSp53/58 
protein. In the parietal cortex, there was a significant ‘drug’ x ‘duration’ interaction effect (F(1,20) 
= 6.02, p = 0.024) and a significant effect of ‘drug’ (F(1,20) = 7.02, p = 0.012) ‘duration’ (F(1,20) = 
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6.02, p = 0.024). The post-hoc analysis showed significantly decreased IRSp53/58 protein in the 
samples from chronic MPH-treated rats compared to the controls (p < 0.01). In comparison, in 
the cerebellum, there was only a significant effect of ‘drug’ (F(1,20) = 5.32, p = 0.035), with the 
levels being decreased in the chronic MPH-treated sample compared to the controls (Figure 7.4). 
 
Figure 7.4: Effect of MPH on IRSp53/58 protein density.  
This was measured following (A) Acute, and (B) Chronic 2.0 mg/kg MPH administration. Bars 
represent percentage ± SEM (n=6 rats/group). *p < 0.05, **p < 0.01 indicates significant 
difference as compared to matched saline-treated control groups. Abbreviations: NAc, nucleus 
accumbens; FC, frontal cortex; PCx, parietal cortex; DS, dorsal striatum; HIP, hippocampus; Cer, 
cerebellum. 
 
The MPH induced up-regulation of IRSp53/58 protein following chronic treatment coincided 
with increased striatal mRNA levels of the corresponding gene (treatment: t10 = 2.6, p = 0.026) 
(Figure 7.5). The measured reduction of the IRSp53/58 protein in the cerebellum was, however, 































































Figure 7.5: Effect of MPH on IRSp53/58 mRNA density.  
This was measured following chronic MPH administration. Bars represent mean values ± SEM 
(n=6 rats/group), data was normalised to both β-actin and GAPDH reference genes. *p < 0.05 
indicates significant difference as compared to matched saline-treated control groups (Students t-
test). Abbreviation: NAc, nucleus accumbens; FC, frontal cortex; DS, striatum; Cer, cerebellum. 
 
7.3.3 Effect of MPH on Cdc42 protein and mRNA density  
The induction of cell protrusions by IRSp53/58 is known to be Cdc42 (and Arp2) dependent 
(Kang et al. 2016). Here, the effects of MPH on Cdc42 protein (acute and chronic) and mRNA 
levels (chronic only) were examined. In comparison to the Arc and IRSp53/58 proteins, MPH 
had a less pronounced effect on the Cdc42 protein (Figure 7.6). In the acute group, MPH did not 
significantly alter the Cdc42 protein expression in any of the brain regions investigated. 
However, the two-way ANOVA showed a significant effect of ‘drug’ in the nucleus accumbens 
(F(1,20) = 6.82, p = 0.018) but not ‘duration’. Specifically, the post-hoc analysis indicated that 
Cdc42 was significantly elevated in the accumbens of chronic MPH-treated rats compared to the 
controls (p < 0.05). 
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Figure 7.6: Effect of MPH on Cdc42 protein density.  
This was measured following (A) Acute, and (B) Chronic 2.0 mg/kg MPH administration. Bars 
represent percentage ± SEM (n=6 rats/group). *P < 0.05 indicates significant difference as 
compared to matched saline-treated control groups. Abbreviations: NAc, nucleus accumbens; FC, 
frontal cortex; PCx, parietal cortex; DS, dorsal striatum; HIP, hippocampus; Cer, cerebellum.  
 
The expression of Cdc42 mRNA levels was also measured in brain samples from chronically 
treated rats and their controls. The results indicated that chronic MPH treatment does not 
significantly alter mRNA levels for Cdc42 in any of the brain regions investigated. There was, 
however, a trend towards an increased Cdc42 expression (p < 0.1) in both the nucleus accumbens 
and the frontal cortex, while a decrease of the mRNA was observed in the cerebellum (p < 































































Figure 7.7: Effect of MPH on Cdc42 mRNA expression.  
This was measured following chronic MPH administration. Bars represent mean values ± SEM 
(n=6 rats/group), data was normalised to both β-actin and GAPDH reference genes. 
Abbreviation: NAc, nucleus accumbens; FC, frontal cortex; DS, striatum; Cer, cerebellum. 
 
As previously mentioned, the induction of cell protrusions by IRSp53/58 is mediated by both 
Cdc42 and Arp2 (Kang et al. 2016). Thus, the effect of MPH treatment on Arp2 protein 
expression (acute and chronic) and its corresponding mRNA levels (chronic only) was also 
examined. The effect of both acute and chronic MPH treatment on Arp2 protein levels is 
illustrated in Figure 7.8. The two-way ANOVA showed a significant effect of ‘drug’ (F(1,20) = 
4.77, p = 0.043) on Arp2 protein expression in the hippocampus, with the post-hoc analysis 
indicating an increased expression in the acute MPH-treated samples compared to the controls (p 
< 0.05). Similar to the Cdc42 protein, a significant increase of the Arp2 protein was detected in 
the nucleus accumbens of the chronic MPH-treated samples compared to the controls (p < 0.05). 




Figure 7.8: Effect of MPH on Arp2 protein density.  
This was measured following (A) Acute, and (B) Chronic 2.0 mg/kg MPH administration. Bars 
represent percentage ± SEM (n=6 rats/group). *p < 0.05 indicates significant difference as 
compared to matched saline-treated control groups. Abbreviations: NAc, nucleus accumbens; FC, 
frontal cortex; PCx, parietal cortex; DS, dorsal striatum; HIP, hippocampus; Cer, cerebellum.                              
 
The analysis of Arp2 mRNA following chronic MPH treatment demonstrated that the enhanced 
Arp2 protein levels coincided with increased gene expression in the nucleus accumbens (t10 = 2.3, 
p = 0.047). Similar to the Arp2 protein data, chronic MPH treatment failed to alter mRNA levels 
for Arp2 in the other brain regions measured (Figure 7.9).  






















Figure 7.9: Effect of MPH on Arp2 mRNA expression.  
This was measured following chronic MPH administration. Bars represent mean values ± SEM 
(n=6 rats/group), data was normalised to both β-actin and GAPDH reference genes. *p < 0.05 
indicates significant difference as compared to matched saline-treated control groups (Students t-











































7.4.1 Principal findings 
Prolonged exposure of the maturing brain to psychostimulants such as methylphenidate and 
amphetamine is known to induce the expression of immediate early genes (IEGs) including Arc 
that are known to be implicated in neuroplastic changes such as dendritic elongation and altered 
spine density in the immature and adult brain (Kim et al. 2009; Allen et al. 2010; Chase et al. 
2007; Banerjee et al. 2009). However, to the best of our knowledge, this is the first study that 
examines MPH-induced changes of the Arc protein and its mRNA simultaneously with proteins 
and their corresponding genes that are implicated in the insulin receptor (IRSp53/58) signalling 
pathway. Importantly, the IRSp53/58 protein is a mediator in the formation of both filopodia and 
dendritic spines (Kang et al. 2016).  
Here, we report that chronic exposure of adolescent rats to MPH results in significant up-
regulation of the Arc mRNA and protein in several areas of the brain some of which are 
implicated in the symptoms of ADHD (e.g. nucleus accumbens and striatum). The density of Arc 
mRNA did not fully reflect the Arc protein changes indicating that the levels of protein and gene 
expression, most likely due to different turnover rates, do not always correspond (Vogel and 
Marcotte 2012; Greenbaum et al. 2003). The cerebellum is an area of the brain that has been 
recently shown to have a proven role in a number of neuropsychiatric and behavioural disorders 
including ADHD (Ivanov et al. 2014). Interestingly, in the present study, this part of the brain 
reacted to MPH in a very different way in comparison to most parts of the cerebrum. For 
instance, in the cerebellum, MPH increased Arc expression acutely but chronic treatment 
decreased the expression of this protein. This suggests that the cerebellum, although altered 
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differently compared to the regions of the cerebrum, is prone to MPH-induced neuroplastic 
changes in the adolescent (or maturing) brain.    
Similar to the Arc expression, chronic but not acute MPH administration to adolescent rats 
altered IRSp53/58 protein expression in several brain regions. Notably, chronic MPH increased 
IRSp53/58 expression in the striatum, a change that coincided with enhanced mRNA density for 
this protein. In contrast, chronic MPH administration reduced IRSp53/58 protein expression in 
the parietal cortex and the cerebellum, in the latter region this effect was not reflected in the 
corresponding gene, as the IRSp53/58 gene remained unaltered in the cerebellum following 
chronic treatment. In addition, we report that chronic but not acute MPH treatment significantly 
increased Cdc42 and Arp2 protein expression in the nucleus accumbens, for both Arp2 and 
Cdc42, this effect coincided with elevated levels of the corresponding mRNA for Arp2 but not 
Cdc42 (see Figures 7.6-7.9).  
7.4.2 Effect of MPH on the expression of Arc  
In the present study, we report that chronic MPH treatment increased Arc mRNA in the striatum 
and Arc protein in the nucleus accumbens, parietal cortex, and hippocampus of adolescent rats. 
Interestingly, while acute MPH increased the expression of cerebellar Arc protein, chronic MPH 
decreased this protein in the cerebellum. While the mechanism underlying the contrasting 
findings in the cerebellum remains to be elucidated, MPH-induced enhancement of Arc mRNA 
and protein expression in brain regions such as striatum, cortex (parietal), hippocampus and 
cerebellum is consistent with some previous reports. For instance, a previous study reported up-
regulation of striatal and cortical Arc mRNA and protein expression in juvenile rats following 
both systemic and oral MPH administration (Chase et al. 2007). Similarly, a previous study from 
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our laboratory also reported that acute MPH and amphetamine both increased Arc mRNA in the 
striatum of juvenile and adult rats (Banerjee et al. 2009).  
It is possible that the MPH-induced changes in the mRNA and protein expression of Arc are 
related to the levels of glutamate and lactate (see Chapters 4 and 5). In support of this hypothesis, 
glutamate stimulates Arc mRNA expression via NMDA receptor mediated Ca2+ influx (Bramham 
et al. 2010). Indeed, this thesis demonstrates that MPH (acute and/or chronic) increases glutamate 
and its precursor (i.e. glutamine) levels in the hippocampus, striatum, and frontal cortex and 
cerebellum (see Chapters 4, 5 and 6). Interestingly, lactate has also been shown to increase the 
expression of the Arc gene by acting as a positive modulator of the already activated (by 
glutamate or glycine) NMDA receptor (Yang et al. 2014). Like glutamate, lactate was also 
increased by MPH (albeit more pronounced after the chronic treatment) in this thesis in the 
hippocampus, striatum, frontal cortex and cerebellum (see Chapters 4, 5, and 6). Therefore, by 
increasing glutamate/glutamine or lactate levels in these brain regions, MPH might indirectly 
modulate the expression of Arc.  
Arc gene expression is also well known to be triggered by D1 receptor-induced increase in cAMP 
levels, and we have shown in this thesis that D1 receptor is enhanced in brain regions such as the 
nucleus accumbens and parietal cortex (i.e. two regions that also have increased Arc expression) 
following chronic MPH treatment (see Chapter 3). Arc is believed to regulate dendritic spines 
through actin remodelling, thus mice lacking the Arc gene have decreased dendritic spine density 
(Peebles et al. 2010). The Arc mRNA, which is induced by an influx of Ca2+ through NMDA 
receptors and voltage-gated Ca2+ channels, is trafficked to dendrites and then synthesised at the 
synaptic sites (Korb and Finkbeiner 2011). In hippocampal neurons, Arc over-expression 
enhances spine density in vitro and a disruption of Arc formation decreases spine density in vivo 
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(Peebles et al. 2010). The Arc protein is also known to increase the proportion of the so-called 
“learning spines” (thin spines) that are more plastic, while it decreases the proportion of the more 
stable stubby spines (Peebles et al. 2010). Therefore, the increased Arc protein expression 
following the chronic MPH treatment, particularly in the hippocampus may be essential for 
learning. There are further indications that the Arc protein is essential for modifying cellular 
responses to activity and therefore crucial for forming new memories and forgetting old ones 
(Peebles et al. 2010). It is also possible that Arc plays important roles in multiple forms of 
synaptic plasticity, including psychostimulant (MPH and amphetamine)-induced behavioural 
sensitisation and neurobehavioural adaptations (Koob and Volkow 2010; Chase et al. 2007; Korb 
and Finkbeiner 2011; Moro et al. 2007; Bramham et al. 2010). 
7.4.3 Effect of MPH on the expression of IRSp53, Cdc42, and Arp2 
IRSp53/58 is a core component of excitatory (e.g. glutamatergic) synapses (Abbott et al. 1999) 
and it interacts with the membrane bound Cdc42 via the CRIB-PR domain (see Figure 7.1). This 
allows the SH3 domain of IRSp53/58 to bind its effectors, which mostly converge onto the 
Arp2/3 complex (Kang et al. 2016). The Arp2/3 complex has important cellular functions 
including initiating the polymerisation of new actin filaments in both presynaptic terminals and 
postsynaptic spines where they interact with synaptic vesicular movements and the dynamics of 
dendritic spines respectively (Kim and Lisman 1999).    
In this study, we report that while acute MPH treatment had no significant effect on IRSp53/58 
protein, chronic treatment increased both the mRNA and protein expression in the dorsal striatum 
but decreased the protein in the parietal cortex and cerebellum (Figures 7.4 and 7.5). Reports 
indicate that increasing IRSp53/58 expression in most neuronal cell types induces extensive 
actin-containing cell protrusions, increased filopodia formation, and dendritic branching and 
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spine density in a Cdc42 dependent manner as outlined in Figure 7.1 (Krugmann et al. 2001; 
Choi et al. 2005). Indeed, Cdc42-IRSp53/58 interaction is known to be crucial for filopodia (a 
precursor of dendritic spines in neurons) formation and extension (Babitt et al. 2005; Oh et al. 
2013). In this study, we found that chronic MPH treatment significantly increased Cdc42 protein 
expression in the nucleus accumbens (Figure 7.6). When Cdc42 is expressed in higher 
concentrations, it promotes F-actin polymerisation, a process that is essential for a microspike 
(i.e. filopodia) to become long enough to develop into a mature spine (Soria Fregozo and Pérez 
Vega 2012). Therefore, the observed increase of IRSp53/58 and Cdc42 in the striatum and 
nucleus accumbens respectively following chronic MPH treatment raises the possibility that 
prolonged MPH exposure enhances dendritic spine density in these brain areas. In support of this 
hypothesis, an immunohistochemistry study has shown that chronic exposure to MPH and 
another psychostimulant (i.e. cocaine) increased dendritic spine density in medium spiny neurons 
(i.e. GABAergic neurons) in the nucleus accumbens and striatum, respectively (Kim et al. 2009). 
Dendritic spine density or spine plasticity is implicated in learning, long-term memory and 
motivation (Roberts et al. 2010; Xu et al. 2009). In particular, the growth of new dendritic spines 
is thought to partly mediate long-term memory (Roberts et al. 2010; Xu et al. 2009). 
As previously mentioned, the effects of IRSp53/58 and Cdc42 converge on the Arp2/3 complex. 
Interestingly, in line with the findings on Cdc42, the present study also shows that chronic MPH 
treatment significantly increased the expression of both the mRNA and protein of Arp2 in the 
nucleus accumbens, while the acute treatment elevated the expression in the hippocampus 
(Figures 7.8 and 7.9). Indeed, as mentioned earlier, an activation of the Arp2/3 complex induces 
polymerisation of new actin filaments that can cause extension of dendritic spine heads (Higgs 
and Pollard 2001). The hippocampus and nucleus accumbens are key areas in learning/memory 
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and drug-induced behaviours (Kasai et al. 2003). An overexpression of these plasticity-associated 
proteins in these brain regions might therefore prove critical for memory and learning. However, 
without microscopic analyses, it is difficult to establish with certainty that increased Arp2, Cdc42 
and Arc in the nucleus accumbens may necessarily be accompanied by an increased number of 
dendritic spines and hence more synapses. Nevertheless, previous electron microscopic analyses 
have revealed that increases in protein expression and dendritic spines produced by several 
learning experiences are accompanied by increases in the number of synapses per neuron 
(Robinson and Kolb 2004). An increased Arp2 expression in the nucleus accumbens as shown in 
this study fits well with previous studies demonstrating that psychostimulants, such as 
amphetamine (a drug which similar to MPH increases extracellular levels of DA in the nucleus 
accumbens) elevates spine density and dendritic branching (Li et al. 2003). Further, this effect of 
amphetamine was shown to be confined to the dendrites of medium spiny neurons in the nucleus 
accumbens, a primary locus for dopaminergic and glutamatergic inputs into these cells (Robinson 
and Kolb 2004; Singer et al. 2009).  
In contrast to the increased IRSp53/58 density in the striatum, chronic MPH treatment decreased 
this protein in the parietal cortex and cerebellum in the present study (Figure 7.4). Interestingly, 
previous findings indicate that rodents lacking or having decreased IRSp53/58 display enhanced 
NMDA receptor function, which is accompanied by social and cognitive deficits and 
hyperactivity (Kim et al. 2009; Sawallisch et al. 2009; Chung et al. 2015). This suggests that in 
addition to its potential to dampen neurite growth and spine density, decreased (or lack of) 
IRSp53/58 could have adverse effects on learning and memory behaviours (Kim et al. 2009), 
particularly in the cortical and cerebellar areas that are known to be involved in cognition and 
motor activity. The cerebellum is interconnected with aspects of cerebral networks involved in 
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cognition, hence it sends and receives inputs to and from the cerebral areas making it an 
important regulator of cognition (Schmahmann and Caplan 2006; Buckner 2013). 
7.5 Conclusion 
The Arc protein and members of the insulin receptor (IRSp53/58) signalling pathway are all 
important in the regulation of actin filament, dendritic spine formation, and plastic changes that 
mediate memory, learning and drug-related behaviours in the maturing brain. In this study, we 
demonstrate that MPH alters the expression of Arc and other proteins involved in the IRSp53/58 
signalling pathway (i.e. Cdc42 and Arp2), as well as their corresponding mRNAs in the 
adolescent rat brain. Overall, the effects were more pronounced after chronic MPH treatment 
indicating that long-term treatment of the widely prescribed anti-ADHD drug, MPH, causes 
neuroadaptive changes in the maturing brain. This study investigated simultaneously the action of 
MPH in specific regions of the cerebrum, in addition to the cerebellum, a brain region suggested 
to be involved in the symptoms of ADHD but rarely explored regarding the action of 
psychostimulants. Interestingly, we found that MPH altered the cerebellum differently compared 
to most regions of the cerebrum including the action of the drug on the Arc protein, emphasising 
the distinct roles of these two large brain areas. In the cerebrum, particularly marked changes by 
chronic MPH were detected in the striatum and nucleus accumbens that are known targets for 
MPH. These marked changes included: up-regulation of Arc (protein and mRNA), IRSp53/58 
(protein and mRNA), Cdc42 (protein only) and Arp2 (protein and mRNA). No significant MPH 
induced changes of these proteins or their corresponding genes were recorded in frontal cortex (a 
region that has an increased noradrenergic function), possibly suggesting that NA does not 
mediate these neuroplasticity-related changes. An increase of these proteins in the striatum and 
nucleus accumbens could have implications in the formation of new dendritic spines in these 
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brain regions, and may also have implications on memory, learning, and drug-related behaviour 
(i.e. addiction). The functional consequence of the contrasting reduction of Arc and IRSp53/58 






























































The overall aim of this study was to examine the mechanisms of action of the commonly 
prescribed anti-ADHD drug MPH and the long-term consequences, if any, of chronic exposure to 
this drug on the maturing brain. It is worth noting that global consumption of MPH has increased 
rapidly (~269% between 1995 and 2006), with the estimates indicating that the amount of MPH 
consumed even exceeds the prescriptions of the drug per year (Gahr et al. 2014; Dietz et al. 
2013). Additional reports indicate that the drug is becoming increasingly popular among young 
people and students who use it as either a performance enhancer or study aid (Gahr et al. 2014; 
Dietz et al. 2013; Lakhan and Kirchgessner 2012; Swanson and Volkow 2003). This thesis has 
hopefully made a significant contribution to our understanding of the mechanisms of action of 
this drug in the adolescent brain. 
In general, abnormalities in monoaminergic systems such as the dopaminergic and noradrenergic 
systems, as well as alterations in metabolic pathways (including glutamatergic and GABAergic 
pathways) within the cortico-striato-cerebellar circuitry have been implicated in the 
pathophysiology of ADHD (Del Campo et al. 2011; Perlov et al. 2007; Volkow et al. 1998) and 
in the mechanism of several anti-ADHD drugs including MPH (Volkow et al. 1998; Del Campo 
et al. 2011). Dopaminergic function is believed to be impaired in ADHD due to an abnormal 
cortical and striatal DAT expression (Dougherty et al. 1999; Spencer et al. 2005). In addition, 
several studies have suggested that hemispheric abnormalities contribute to ADHD pathology. 
Indeed, observations from several neuroanatomical studies have suggested that ADHD may be 
associated with a right hemisphere dysfunction (Castellanos et al. 1996; Makris et al. 2007; 
Rubia et al. 1999). Therefore, to explore the possible existence of a lateralised MPH action, we 
investigated the effect of the drug on dopaminergic and metabolic markers in the left and right 
hemispheres of brain regions within the cortico-striato-cerebellar circuitry. Moreover, to study 
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the effect of MPH on the developing brain, we tested two MPH doses (2.0 and 5.0 mg/kg, i.p.). 
Both of these doses in different settings have previously been shown to achieve clinically 
relevant plasma concentrations (8-40 ng/ml) in rats, and have not been shown to cause any visible 
signs of acute toxicity (Balcioglu et al. 2009; Kuczenski and Segal 2002; Kuczenski and Segal 
2005). 
A major finding from Chapter 3 of this thesis is the significant up-regulation of the dopamine 
transporter (i.e. DAT) in the striatum and nucleus accumbens, particularly after chronic MPH 
administration. So far, findings on DAT expression in studies on ADHD patients have been 
inconsistent, with some initial studies suggesting upregulated striatal DAT density in people 
diagnosed with ADHD (Dougherty et al. 1999; Spencer et al. 2007), and others reporting either 
no significant changes or significant decreases of the transporter (Volkow et al. 2009; Volkow et 
al. 2007a; Volkow et al. 2007b). The data reported in this thesis suggest that it is chronic MPH 
exposure that upregulate DAT density in the striatum and accumbens. This finding is consistent 
with recent clinical study that also showed that chronic MPH treatment elevates DAT density 
significantly in the nucleus accumbens (Wang et al. 2013). Interestingly, this thesis shows that 
not only DAT density is increased by chronic MPH treatment in the accumbens, as noradrenaline 
transporter (i.e. NET) density, which is also targeted by MPH, was significantly upregulated in 
the nucleus accumbens, as well as in the parietal cortex, an effect which to our knowledge, is 
reported for the first time in this thesis. It is known that the levels of DAT (and perhaps NET) 
expressed on neuronal membranes are regulated by the extracellular concentrations of DA 
(and/or NA), with DAT levels decreasing when extracellular DA levels are low and increasing 
when extracellular DA levels are high (Wang et al. 2013). From the findings reported in this 
study and the evidence in literature, the increased DAT and NET densities in the nucleus 
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accumbens, striatum and parietal cortex following prolonged exposure to MPH, appear to be 
consistent with an adaptational response in order to compensate for the prolonged increases in 
extracellular DA (and/or NA). Such upregulation of DAT and NET levels following chronic 
MPH treatment may limit the long-term efficacy of the drug and could increase drug-seeking 
behaviour as larger doses of the drug may be required by individuals taking the medication to 
obtain clinical efficacy (Hazell 2011; Wang et al. 2013).  
Another significant finding from Chapter 3 is that MPH increases whole tissue levels of DA in 
the frontal cortex, as well as both whole tissue and extracellular levels of DA in the striatum. The 
increased whole tissue levels of DA in the frontal cortex, following both acute and chronic MPH 
administration, indicates enhanced vesicular storage of DA induced by the drug, and together 
with DAT blockade will contribute to the known effect of MPH, which has to do with the 
increase of extracellular levels of DA (Berridge et al. 2006; Kuczenski and Segal 2002). Such 
enhanced concentration of extracellular DA will increase stimulation of D1 receptors in the 
frontal cortex and ultimately improve working memory and help to sustain attention for longer 
periods. This finding in the frontal cortex could be of particular importance as previous functional 
imaging studies have found an under-activation of several areas of the cortex including the 
frontal and parietal areas in ADHD patients during tasks related to attention (Dickstein et al. 
2006; Rubia et al. 1999; Vance et al. 2007). This under-activation in ADHD is suggested to be 
more prominent in the right cortex, based on this ADHD has been tagged as a right hemisphere 
disorder (Vance et al. 2007; Rubia et al. 1999). Despite this, our findings indicate that the MPH-
induced upregulation of DA in the frontal cortex was more pronounced in the left frontal cortex, a 
finding that has not previously been reported. Further, following chronic administration, the 
MPH-induced increase of whole tissue DA levels in the frontal cortex, is unlikely to be driven by 
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enhanced expression of the rate-limiting enzyme for DA synthesis (i.e. TH), as the expression of 
this protein remained unaltered in the frontal cortex. Given that the expression of the vesicular 
protein VMAT2 was increased by chronic MPH in the frontal cortex, increased tissue levels of 
DA in this brain region is probably a reflection of increased DA vesicular storage capacity. In a 
similar vein, the increased whole tissue and extracellular DA levels in the striatum were more 
pronounced in the left side, further reinforcing the hypothesis that MPH exerts more pronounced 
effects on monoaminergic markers in the left side of the adolescent rat brain. Consistent with the 
present findings, a previous clinical study also showed that MPH may have a more pronounced 
effect on neurochemicals in the left frontal cortex and left striatum compared to the 
corresponding right sides of these brain areas (Ben Amor 2014). In contrast to the importance of 
the right frontal cortex in ADHD, a dysfunction of the left striatum is considered to be a core 
abnormality in ADHD, as some studies have reported that individuals suffering from left striatal 
lesions have deficits in attention and executive function (Vaidya et al. 2005; Benke et al. 2003). 
Therefore, an MPH-induced increase of whole tissue and extracellular DA levels in the left 
striatum may be critical to the normalisation of striatal functions in those suffering from ADHD.  
 
Results from Chapters 4 and 5 depict, perhaps, the most novel aspect of the work presented in 
this thesis. The findings in Chapters 4 and 5 show that the MPH alters the LNAAs, tyrosine and 
phenylalanine, as well as several metabolic pathways in the cerebrum. Given that the MPH-
induced increase of whole tissue and extracellular DA levels in the striatum and frontal cortex 
reported in Chapter 3 of this thesis did not correspond with increased TH densities, we sought to 
determine alternative mechanisms by which MPH elevates DA levels in these brain regions. 
Currently, increased extracellular DA levels (in the frontal cortex and striatum as well as other 
brain regions) following MPH administration is attributed to the blockade of DAT (and NET) by 
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MPH and very few studies, if any, have examined other possible mechanisms that may mediate 
this effect of MPH on DA levels. The data presented in this thesis indicate that along with 
blocking DAT and NET, MPH may increase DA and NA by increasing the levels of tyrosine and 
phenylalanine (that act as substrates for catecholamine synthesis) in the cerebrum. This finding 
resulted in our novel hypothesis that MPH may alleviate ADHD symptoms in two ways: (1) by a 
blockade of DAT and NET, and (2) by enhancing the brain pool of tyrosine and phenylalanine. 
To further confirm this finding and to also determine in which specific cerebral areas that MPH 
alters these LNAAs, we examined the effects of the drug in three brain areas, including the 
frontal cortex, hippocampus and striatum in Chapter 5. The data suggested that indeed MPH 
increases the brain pool of tyrosine and phenylalanine and that the effect was restricted to the 
frontal cortex and the hippocampus but not the striatum of adolescent rats (region-specific effect) 
after either acute or chronic drug treatment. With the finding on these LNAAs confirmed, there 
was still the question of the source and mechanism by which MPH increases tyrosine and 
phenylalanine in the frontal cortex and the hippocampus. Thus, we further examined the the 
effect of MPH on plasma levels (Chapter 5). In this regard, this thesis reveals that chronic but not 
acute MPH treatment (treatment duration-dependent effect) alters the balance of these LNAAs in 
the plasma, possibly favouring the competitive uptake of plasma tyrosine and phenylalanine and 
their subsequent transport across the blood-brain-barrier into the frontal cortex and hippocampus 
via the LAT-1 transport system (Fernström 2013), which for example, resulted in decreased 
plasma levels of tyrosine and phenylalanine in the chronically treated rats compared to the 
corresponding controls. Although increased levels of tyrosine and phenylalanine do not directly 
imply an enhanced DA synthesis as TH is a rate-limiting enzyme that can get saturated at high 
brain levels of tyrosine, there are studies demonstrating that administration of a tyrosine-rich 
amino acid mixture effectively reduces ADHD symptoms in some children (Hinz et al. 2011), 
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and also that tyrosine potentiates MPH-induced increase of extracellular DA in rats when co-
administered (Woods and Meyer 1991). Given the present findings, therefore, this thesis offers an 
additional explanation beyond what currently exist in literature and may shape our understanding 
of the therapeutic action of MPH in the treatment of ADHD and possibly initiate an enhanced use 
of dietary supplement with high levels of tyrosine and phenylalanine for the treatment of ADHD 
symptoms. 
Results from Chapters 4, 5 and 6, further demonstrate that MPH alters a number of metabolic 
pathways. In particular, data from this thesis reveals that metabolites related to the 
glutamatergic/GABAergic pathway (including glutamate, glutamine and GABA) and those 
related to brain energy metabolism (e.g. lactate, acetate, creatine and NAD) may contribute to the 
mechanism of action of MPH. These metabolites are altered by MPH treatment in both the 
cerebral and cerebellar areas. Over the years, the dopaminergic and noradrenergic systems have 
received much attention in studies examining ADHD pathology and stimulant treatment (Del 
Campo et al. 2011). However, while these two catecholaminergic systems may be very important 
systems in ADHD, together with the findings presented in this thesis, a number of recent reports 
suggest that the glutamatergic/GABAergic system and brain energy metabolites are also critical. 
Indeed, converging evidence shows that glutamate, glutamine and GABA, as well as lactate, 
acetate and creatine have abnormal concentrations in multiple brain regions of both young and 
adult drug naïve ADHD patients (Carrey et al. 2007; Jin et al. 2001; Maltezos et al. 2014; Perlov 
et al. 2007; Perlov et al. 2010), and data from this thesis suggests that some of these brain 
metabolic abnormalities could indeed be normalised following MPH therapy. Like tyrosine and 
phenylalanine, this thesis also shows that chronic MPH treatment alters the balance of plasma 
lactate and acetate, favouring the competitive uptake of these energy-related metabolites by the 
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monocarboxylate transport system, which transports them across the blood-brain barrier into 
brain areas such as the frontal cortex (Cremer et al. 1976; Deelchand et al. 2009; Waniewski and 
Martin 1998). Thus, the findings on the metabolites presented in this thesis indicate that more 
attention needs to be paid to the brain energy-related and the glutamatergic/GABAergic pathways 
in research on ADHD.  
Further research is required to understand the role of the L-type amino acid transporter (LAT) 
system in the mechanism of action of psychostimulants, particularly following chronic MPH 
therapy. LATs are responsible for the transport of LNAAs such as tyrosine and phenylalanine. 
Most of these transporters possess two subunits, a light chain, which includes LAT1 and LAT2 
and a heavy chain (CD98/4F2hc), and are located in the cell membrane (Ohtsuki et al. 2010). 
Given its expression within the BBB, LAT-1 is particularly important in studies on brain 
disorders, as abnormalities in its density or activity may influence amino acid transport, with far-
reaching effects on dopaminergic neuronal function and drug therapy (Ohtsuki et al. 2010). For 
instance, LAT-1 has been shown to participate in L-DOPA (a medication for Parkinson’s disease) 
transport across the BBB (Pinho et al. 2004). Unfortunately, time constraints did not permit us to 
investigate the effect of MPH treatment on the mRNA and protein expression of this transport 
system, although we put forward the hypothesis that the LAT-1 system may facilitate an 
increased transport of LNAAs (e.g. tyrosine and phenylalanine) across the BBB, based on the 
previous observation that substrate availability influences the uptake of these LNAAs by this 
transport system into the brain (Fernström 2013). It is, however, uncertain whether MPH only 
alters the physiological balance of tyrosine and phenylalanine in the plasma favouring their 
uptake into the brain or whether MPH treatment also alters the protein expression and the activity 
of the LAT-1 system. As already mentioned, we also found that MPH treatment alters the 
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physiological balance of lactate and acetate in the plasma, which are also transported across the 
BBB by another transport system, the monocarboxylate transport system. In particular, in 
young/adolescent animals, lactate and acetate are suggested to have a high affinity for and high 
permeability to the monocarboxylate transport system (Cremer et al. 1976; Deelchand et al. 
2009; Waniewski and Martin 1998). Thus, the examination of possible MPH induced changes of 
the mRNA and protein expression patterns for the monocarboxylate transport system, as well as 
the LAT-1, and the LAT-2 transport systems deserve future investigations. 
Our in-depth investigation regarding the mechanism of action of MPH in the cerebellum is also 
of interest and reported in Chapter 6. In recent times, the cerebellum and its potential role in 
ADHD and cognition is the subject of intense research (Schmahmann and Caplan 2006; Buckner 
2013; Ivanov et al. 2014). Indeed, recent studies have demonstrated that along with its traditional 
role in motor activity, the cerebellum plays important roles in cognition, mostly due to its dense 
connection with the cerebral cortex and the previously unknown presence of dopaminergic and 
noradrenergic markers in this region (Schmahmann and Caplan 2006; Buckner 2013). In this 
thesis, contrasting findings were recorded following acute and chronic MPH treatment. Here, 
acute MPH treatment decreased some examined biomarkers (e.g. VMAT2, as well as glutamate, 
glutamine, NAA and NAD) but increased other biomarkers (e.g. GABA, glycine, aspartate, 
acetate and hypoxanthine) in a dose-dependent manner. In contrast, chronic treatment generally 
enhanced several biomarkers (e.g. VMAT2, glutamate, glutamine, phenylalanine, tyrosine, 
lactate, glycine, taurine, and creatine), suggesting treatment duration-dependent effects of MPH 
on the cerebellum. The increased VMAT2 following chronic MPH treatment corresponded with 
increased tyrosine and phenylalanine. However, this did not correlate with increased cerebellar 
DA, which would suggest that perhaps in the cerebellum, the increased LNAAs may elevate the 
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synthesis of NA rather than DA (i.e. whole tissue DA in the cerebellum serves mostly as a 
substrate for NA synthesis), as previously suggested (Glaser et al. 2006). Further, although the 
mechanisms underlying the MPH-induced contrasting findings in the cerebellum after acute and 
chronic treatment are not yet clear, the findings following acute treatment are consistent with 
previous studies that found decreased NAA levels compared to corresponding controls, as well as 
decreased glutamate and glutamine levels in young ADHD patients that had received MPH 
treatment (Ben Amor 2014; Soliva et al. 2010). Interestingly, the MPH-induced decrease of some 
cerebellar metabolites (e.g. glutamate and glutamine) following acute treatment are in sharp 
contrast to the MPH-induced increase of these metabolites in the cerebrum following acute 
treatment. However, similar to our findings, reports from both human and rodent studies have 
also indicated contrasting findings between the MPH-induced metabolic changes in the cerebral 
areas and the cerebellum (Michaelides et al. 2010; Volkow et al. 1997).   
Chronic exposure to psychostimulants such as MPH has been previously suggested to cause 
complex structural and plastic modifications in the reward circuitry of the developing brain, 
involving changes to actin cytoskeleton and dendritic spine morphology (Berman et al. 2008; 
Haydon et al. 2009). Dendritic spines are crucial for synaptic strength and help to transmit signals 
to the cell body of the post-synaptic neurons (Kasai et al. 2003). Structural and functional 
changes in spines and synapses are known to be important processes mediating memory and 
learning, as well as drug-related behaviour (Soria Fregozo and Pérez Vega 2012; Kang et al. 
2016). Interestingly, a recent study has shown that chronic exposure to MPH and cocaine alter 
dendritic spine density (Kim et al. 2009). Therefore, we sought to determine the mechanisms 
underlying the MPH-induced alterations to dendritic spines by evaluating signalling pathways 
(including Arc and IRSp53 pathways) that are associated with spine formation. Indeed, the Arc 
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and insulin receptor (IRSp53/58) pathways have been been implicated in the pathophysiology of 
ADHD and in the modulation of human memory strength (Liu et al. 2013; Ribasés et al. 2009). 
We found that while acute MPH treatment has minimal effects on plasticity-related proteins 
within the Arc and IRSp53 pathways, chronic MPH treatment has a much more pronounced 
effect. For instance, chronic MPH treatment induced an increase of Arc gene in the striatum and 
the Arc protein in the parietal cortex and hippocampus. The MPH-induced increase of Arc may 
be linked to glutamate and lactate levels as well as D1 receptor density, since glutamate and 
lactate stimulate Arc mRNA expression via NMDA receptor mediated Ca2+ influx (Bramham et 
al. 2010) and Arc gene expression is also stimulated by D1 receptor-induced increase of cAMP. 
Interestingly, this thesis has demonstrated that chronic MPH increases the levels of glutamate and 
its precursor glutamine in the hippocampus, striatum and  frontal cortex, as well as increased D1 
receptor in the accumbens and parietal cortex. The Arc protein increases the proportion of the so-
called “learning spines” (Peebles et al. 2010). Therefore, the increased Arc protein expression 
following the chronic MPH treatment, particularly in the hippocampus may be essential for 
learning. On the other hand, chronic but not acute MPH treatment also enhanced the densities of 
IRSp53/58, Cdc42, and Arp2 in the striatum and the nucleus accumbens. Reports indicate that 
IRSp53/58 localises at synapses and mediate filopodia (a precursor of dendritic spine) formation, 
and that increasing IRSp53/58 expression in most cell types often induces extensive actin-
containing cell protrusions, which may be Cdc42 dependent (Krugmann et al. 2001). Similarly, 
higher expressions of Cdc42 and its downstream signalling molecules including the Arp2/3 
complex promotes F-actin polymerisation, a process that is essential for a filopodia to become 
long enough to develop into a mature spine (Soria Fregozo and Pérez Vega 2012). Therefore, the 
observed increase of IRSp53/58, Cdc42 and Arp2 in the striatum and nucleus accumbens 
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following chronic MPH treatment (as shown in Chapter 7 of this thesis) raises the possibility that 
prolonged MPH exposure enhances dendritic spine density in these brain areas. Consistent with 
this finding, MPH and cocaine have both been shown to increase dendritic spine density in the 
striatum and nucleus accumbens (Kim et al. 2009). The MPH-induced changes in dendritic spine 
density and these plasticity-associated genes and proteins could be related to learning and 
memory consolidation, as well as drug-seeking behaviour (Everitt and Robbins 2005; Kalivas and 
O’Brien 2008). In addition, given that IRSp53 co-localises with insulin receptors at the synapse 
and insulin has been detected in the brain (although the source still remains unknown), it cannot 
be excluded that the IRSp53 pathway may be involved in insulin signalling that mediates glucose 
homeostasis, feeding behaviour and cognitive processes (Blázquez et al. 2014).  
In summary, this thesis will contribute to an enhanced understanding of the mechanism of action 
of MPH in the developing brain. The data presented in this thesis show an upregulation of both 
DAT and NET following chronic MPH treatment, which could potentially limit the long-term 
efficacy of the drug. In addition, the data also show a potential new mechanism of action of MPH 
involving enhanced transport of plasma LNAAs such as tyrosine and phenylalanine into the 
brain, beside the already established DAT blocking mechanism of the drug. This finding could be 
instrumental for the development of new treatment paradigms for ADHD management including 
modified diets that are rich in phenylalanine and tyrosine and therapeutic drugs targeting 










APPENDIX 1  
Principal Component Analysis (PCA) was conducted on the cerebral datasets (see Chapter 4). 
This demonstrated a clear separation between the acute 5.0 mg/kg MPH-treated and the control 
groups (Figure A1). 
                        
Figure A1: PCA scores plot showing a clear separation between the acute 5.0 mg/kg MPH-
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